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 Bovine respiratory coronavirus (BRCoV) is a group 2a coronavirus expressing both 
hemagglutinin-esterase and spike (S) envelope glycoproteins. The S glycoprotein is a primary 
coronavirus virulence factor responsible for both receptor specificity and membrane fusion-
mediated entry into host cells. In addition, the S glycoprotein serves as a major antigen targeted 
by both the cellular and humoral immune responses and, as such, is an important target for 
antibody-facilitated virus neutralization.  The objective of this research was the design of a safe 
and effective vaccine against BRCoV using a “prime-boost” vaccination approach. This method 
utilized an initial DNA vaccine encoding either the soluble portion of the spike glycoprotein, or 
the soluble portion of the spike glycoprotein fused in-frame to bovine CD154, administered 
intramuscularly. The initial priming was followed 14 days later by vaccination with purified 
immunogenic extracellular portion of S glycoprotein alone or this portion fused in-frame to the 
soluble portion of the bovine CD40 ligand (CD40L; CD154). The bovine CD40L was included 
to enhance the immunogenicity of the S glycoprotein and elicit protective immune response 
against BRCoV infection. Both of the recombinant proteins were expressed in insect Sf9 cells 
via recombinant baculovirus expression and purified using affinity chromatography. The efficacy 
of these vaccine approaches in eliciting neutralizing antibody responses, preventing virus 
replication and spread and the onset of respiratory disease in cattle was then investigated in 
animal experimental infections. An ELISA was developed and utilized to screen 129 cattle for 
animals that did not have appreciable antibody titers to BRCoV. In addition, BRCoV-specific 
serum was obtained from one cow immunized with commercially available vaccine and high-
titer anti BRCoV S-specific serum was obtained by immunization of rabbits  with the S-CD154-
fusion protein. As expected, animals responded to vaccination with the soluble portion of spike. 
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Furthermore, fusion of CD154 to the soluble portion of the spike glycoprotein resulted in a 
pronounced increase in circulating and neutralizing serum antibody specific for the BRCoV 




Bovine respiratory disease complex 
The greatest health-associated impact on beef cattle profitability is Bovine 
Respiratory Disease (BRD), commonly known as “shipping fever”, a disease complex 
typically associated with multiple etiologies (Smith, 1998). Predisposing factors 
commonly associated with the risk of BRD development include stress associated with 
fasting and transport, introduction of microbial pathogens via stressful comingling of 
calves, rapid environmental and weather changes, age, and sudden nutritional alterations 
(Callan and Garry, 2002; reviewed by Cusack et al., 2003). Additionally, while overall 
feed intake by stressed calves is low (Galyean and Hubbart, 1995; Cole, 1996), more 
specifically, nutritional antioxidant status has been suggested to play a role as a 
predisposing factor in the development of BRD (McDowell et al., 1996), although the 
validity of this claim has yet to be fully substantiated (Hill, 1987). Chirase et al. reported 
in 2004 a relationship between serum malondialdehyde (MDA) concentrations, 
considered a biomarker of lipid peroxidation in non-ruminants and humans, although it 
has not been previously established as an indicator of lipid peroxidation in ruminants, and 
risk of BRD. In their study, calves subjected to marketing and transport stressors showed 
a 3-fold increase in serum MDA concentration from pre-transit levels. In addition, calves 
that later died as a result of BRD complications were found to have had a 1.44-fold 
increase in serum MDA concentration over surviving calves before they were ever even 
subjected to transport stressors. Thus, it was concluded that there was, indeed, a positive 
correlation between pre- and post-transit antioxidant status and risk of developing BRD 
(Chirase et al., 2004).  
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The BRD complex is responsible for considerable economic losses, particularly 
within the feedlot industry, and is considered the most significant disease affecting young 
feedlot cattle after arrival to North American feedlots (Martin et al., 1998). A study 
performed by Snowder et al. reported that BRD was responsible for considerable 
economic losses to feedlots, especially when factors such as decreased weight gain and 
incurred treatment costs associated with BRD incidence where also factored in (2006). In 
fact, Snowder et al. reported that, at the time, this cost could be estimated to be 
approximately $13.90 per animal within a 1,000 head feedlot, excluding the costs 
associated with labor for increased handling of these of these animals (2006). In addition, 
development of BRD while in the feedlot has been reported to negatively impact carcass 
value at slaughter by not only decreasing weight gain of affected animals, but also be 
decreasing the value of carcass composition and associated yield traits (Montgomery et 
al., 1984; Roeber et al., 2001; Garcia et al., 2010). 
Of the numerous microbial agents known to contribute to the development of 
BRD, one of the most consistently isolated is Bovine Respiratory Coronavirus (BRCoV; 
Storz et al., 1996; Storz et al., 2000). However, this virus alone is not solely responsible 
for development of BRD, as a number of other viruses have also been implicated in the 
development of the disease complex. Some of the most commonly associated viruses 
include Bovine viral diarrhea virus (BVDV), Bovine Herpes virus-1 (BHV-1), Bovine 
respiratory syncytial virus (BRSV), and Parainfluenza virus-3 (PI-3). Furthermore, 
previous research has strongly suggested that respiratory virus infection alone is 
insufficient for the development of BRD (Martin et al., 1988), although these infections 
are generally thought to play a pivotal role in potentiating development of the complex 
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(Dunn et al., 1991). Calves experimentally infected with either BHV-1 or PI-3 alone, or 
with both viruses simultaneously developed more conspicuous clinical disease, marked 
by a delayed and depressed antibody response, lower lymphocyte proliferative response, 
and higher increased serum cortisol levels when compared with animals infected with a 
single virus type (Ghram et al). The development of BRD is generally thought to follow a 
common progression involving viral-bacterial synergism (Jericho and Langford, 1978), 
starting with immune suppression due to stress or other causes and followed by exposure 
to respiratory viral pathogen. These viral pathogens most likely spread during the 
comingling of animals from different farms during shipping to feedlots (Lathrop et al., 
2000). The exacerbated viral infection is thought to be followed by opportunistic 
overgrowth of commensal bacterial species (Lopez et al., 1976) commonly inhabiting the 
nasopharynx of healthy animals, some of the most commonly isolated being Mannheimia 
haemolytica and Pasteurella multocida (Allen et al., 1991). 
Bovine respiratory disease and bovine respiratory coronavirus 
Of the viruses typically thought to contribute to the development of BRD, the role 
of BRCoV may be one of the most controversial. This virus is an RNA virus belonging to 
the Coronaviridae family of viruses, which consists of a number of host-species specific 
RNA viruses, the most well known of these being the human coronavirus commonly 
known as the Severe Acute Respiratory Syndrome coronavirus, or SARS. Although 
SARS virus infection in humans results in severe respiratory distress, BRCoV infection 
in cattle is not generally considered to cause severe disease, with many animals actively 
infected and shedding virus showing no clinical indicators of disease (McNulty et al, 
1982; Reynolds et al., 1984; Hasoksuz et al., 2002). The primary sites of infection are 
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generally the epithelial cells lining the nasal cavity and trachea, resulting in development 
of mild clinical symptoms, including nasal discharge, rhinitis, sneezing, and coughing, 
which are commonly accompanied by a mild elevation in body temperature (Reynolds et 
al., 1984). Lower respiratory tract involvement may also occur, resulting in the 
development of minor lung lesions that are subclinical in nature, although more severe 
lower respiratory tract involvement has been previously reported (Kapil et al., 1991). In 
spite of the fact that BRCoV infection does not generally result in the presentation of 
symptoms usually associated with the clinical representation of severe pneumonia, 
considerable evidence seems to support the view that infection with BRCoV serves to 
further the immunosuppression that was incurred as a result of the stresses of shipping by 
promoting infection by opportunistic flora and fauna typically associated with the 
respiratory tract, including the bacteria, Mannheimia haemolytica and Pasteurella 
multocida (Cusack et al., 2003).  
Since its initial isolation from lung washes and nasopharyngeal swabs of calves 
involved in two pneumonic outbreaks in 1982 (Thomas et al., 1982), various strains of 
bovine coronavirus (BCoV) have been isolated from and implicated in cases of BRD in 
feedlot calves after shipping (Storz et al., 1996; Hasoksuz et al., 1999; Silva et al., 1999; 
Storz et al., 2000a; Storz et al., 2000b; Cho et al., 2001). Many of these same researchers 
suggest in their reports that BCoV infection can be considered a general indicator for 
increased risk of BRD development after arrival to feedlots, especially in animals 
actively shedding BCoV via nasal secretions (Carman and Hazlett, 1992; Storz et al., 
1996; Lathrop et al., 2000), and that these animals typically show high rates of BRD-
related mortality (Storz, 2000). However, findings by other researchers have challenged 
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this claim, reporting a failure to find any association between increase in antibody titer to 
BCoV after arrival to the feedlot and subsequent development of BRD (Martin et al., 
1998; O’ Conner et al., 2001). Previous work has shown that high antibody titers to 
BCoV upon arrival in the feedlot were statistically associated with decreased risk for 
development of BRD (Martin et al., 1998). Although O’Conner et al. report in their 2001 
study that animals having higher antibody titer to BCoV upon arrival to the feedlot had 
significant decrease in the risk of being treated for BRD with an unconditional odds ratio 
of 0.3, they interpret this to mean that these animals possessed more robust immune 
responsiveness rather than pathogen-specific protection conferring BRD resistance via 
BCoV resistance, as they found that seroconversion to positive BCoV antibody titer 
during the time at the feedlot was not associated with increased risk of developing BRD. 
However, although the findings of O’Conner et al. (2001) seem to suggest differently, at 
present, infection with BCoV immediately following arrival to feedlot, as signified by 
seroconversion during time at the feedlot, continues to be considered a predisposing 
factor for development of BRD in feedlot cattle (Fulton et al., 2011). 
Prevention of bovine respiratory disease 
There is a considerable economic toll associated not only with the treatment of 
animals in the feedlot for BRD, but also with losses associated with decreased gains and 
yield scores for those animals, one estimate having been calculated as a $40.64 decrease 
in return per animal treated only once and as high as a $291.33 loss in return for animals 
treated up to three times (Fulton et al., 2002). Therefore the key to reducing or potentially 
eliminating BRD-associated losses may lie in development of an effective prevention 
strategy before animals are ever marketed, as opposed to treatment for it after animals 
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have arrived at the feedlot. The best means by which to achieve this would be the 
development of a safe and effective vaccination protocol for pre- or newly-weaned 
calves, and indeed a number of vaccines targeting some of the most common pathogens 
associated with BRD are already widely utilized in the United States. Duff and Galyean, 
in their discussion of management strategies for the prevention of BRD, suggest that 
animals undergo preconditioning programs prior to marketing to feedlots, meaning that 
calves have been weaned for some time, typically 30 to 45 d, vaccinated, treated for 
intestinal parasites, castrated, dehorned, and habituated to feed bunks and watering 
troughs (2007). These investigators recommend that calves be vaccinated 4 to 6 wk prior 
to weaning, followed by booster vaccinations at the time the animals are weaned, 
although, if not feasible, calves should at the very least be vaccinated at weaning 
followed by booster vaccination 21 d later (Duff and Galyean, 2007). Unfortunately, in 
addition to the non-compliance of numerous small-herd and hobby farmers to in regards 
to these recommendations, approximately 40% of those surveyed in 2007 (USDA, 2007), 
there are a number of other factors that may play a significant role in the efficacy of 
vaccines against the pathogens associated with BRD. Vaccine effectiveness may be 
considerably influenced by the nutritional status, age, immune status, and other 
environment factors affecting the overall health of the intended recipient (Larson and 
Bradley, 1996). 
The general goal of a successful vaccine is the ability to induce both a humoral 
and cellular immune response closely mimicking that typically associated with natural 
infection by the pathogen against which the vaccine has been administered (Meeusen et 
al., 2007). An effective vaccine protocol should, then, target the most optimal antigen and 
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deliver it to the intended recipient at the most advantageous time and physiological 
location to ensure the best immune response capable of providing protection to the 
recipient. The term “vaccine” originates from the Latin word “vacca”, meaning “cow”, 
and was originally coined by Edward Jenner, responsible for discovering that humans 
could be protected from the deadly smallpox virus by inoculation with the closely-related 
but far less pathogenic cowpox virus. Although human pathogen vaccinology and animal 
pathogen vaccinology are closely related sciences, the criteria by which successful 
vaccination is judged may be vastly different, based on the ultimate goal of the vaccine 
itself. While development of most human and companion animal vaccines is focused 
primarily on the health and ultimately the well-being of the recipient, the development of 
most livestock vaccines is more economically driven. Considerations such as cost-to-
benefit ratio must be made in the livestock industry, whereas in human and modern 
companion animal medicine cost-to-benefit is less of a concern, so long as the vaccine is 
effective and provides, preferably, safe, long-term protection. Even the exact definition of 
“efficacy” may differ between the two industries, with the goal of human and modern 
animal vaccines typically being complete protection from infection by and even 
eradication of a pathogen, while that of livestock vaccines is often more oriented around 
a vaccine’s ability to reduce the overall infection or treatment rate associated with a 
particular pathogen. In fact, in some cases livestock vaccine efficacy is merely associated 
with the ability to reduce or eliminate clinical symptoms of infection, but not to 
necessarily eliminate or eradicate the infectious organism itself (Martin, 1983). The end 
goal of the vast majority of livestock vaccines revolves around the so-called “bottom 
line”, that is, the ability of the vaccine to improve economic and financial return. In 
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addition, considerations such as ease of use as well as public perception must also be 
made. For instance, vaccination of livestock with every available vaccine against any and 
all pathogens would be financially irresponsible, as not all vaccines are equally effective 
or even equally applicable to a specific geographic location.  
 Therefore, a key aspect of BRD prevention by way of vaccination programs is 
determining which vaccines or combinations of vaccines produce the most beneficial 
protection from pathogens implicated in the development of BRD. Unfortunately, the fact 
of the matter is that the answer to this question is not a straightforward one. As 
previously discussed, bovine respiratory disease has a multi-factorial etiology, for which 
a number of pathogens, both viral and bacterial, have been implicated. Virus isolation and 
serological findings have commonly suggested that BHV-1, BVD, and PI-3 are the viral 
entities generally implicated in the development of BRD (Potgieter, 1977), although 
BRSV has also been suggested to participate in the development of the disease complex 
(Baker and Frey, 1985). These viruses, therefore, have been the targets of considerable 
effort to design effective vaccines for the prevention of BRD. In addition, development 
and implementation of effective bacterin-toxoid vaccines against the bacterial pathogens 
and their toxins most commonly associated with the development of BRD, namely M. 
haemolytica and P. multocida, has also been of considerable interest. The choice as to 
which vaccines to administer in order to optimize economic returns may vary 
considerably from feedlot to feedlot and depends on factors such as age class, body 
weight, procurement method, extent of commingling before and after arrival at the 
feedlot, and previous vaccination and management history, when available (Wildman et 
al., 2008). In addition, the geographic location of the feedlot in question my also play a 
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role in determining important pathogens against which cattle should be vaccinated (Hoare 
et al., 1994). In a 2008 study of vaccination protocols for feedlot calves upon arrival to 
the feedlot facility, Wildman et al. compared two vaccination strategies for their ability to 
decrease development of BRD in calves at high risk for development of the disease 
complex (2008). The first consisted of a multivalent modified-live vaccine (MLV) 
containing BHV-1 (for IBRV) and BVD types I and II as well as M. haemolytica and P. 
multocida bacterin-toxid, while the second protocol consisted of a multivalent MLV 
containing BHV-1, BVD type I, PI-3, and BRSV, as well as M. haemolytica bacterin-
toxid. Wildman and colleagues reported that, surprisingly, calves vaccinated with the 
BHV-1/BVDV vaccine had a significantly (p<0.05) lower BRD treatment rate as well as 
a lower incidence of BRD mortality as compared with calves receiving the vaccine 
containing a wider range of BRD-associated pathogens. In addition, calves receiving the 
BHV-1/BVDV vaccine had significantly (p<0.05) higher average daily gain and final 
carcass value than did calves receiving the vaccine containing a wider range of BRD-
associated pathogens. The authors concluded that on an economic basis, the BHV-
1/BVDV vaccine was considerably more cost-effective than the more expensive vaccine, 
even though it, in theory, should confer resistance to a wider range of BRD-associate 
pathogens. Unfortunately, these studies underline the difficulties associated with 
selecting a vaccination program for implementation within cattle operations, as, at least in 
the latter study, contrary to what might be expected, more does not always seem to be 
better. 
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Taxonomy of coronaviruses 
Coronaviruses belong to the Coronaviridae family of viruses (Cavanagh et al., 
1994, 1995) within a relatively newly established order, Nidovirales, viruses producing 3’ 
nested subgenomic RNAs. The Nidoviruses also possess additional distinguishing 
features that further set them apart from other positive-sense RNA viruses: expression of 
the replicase polyprotein by way of a unique ribosomal frameshifting technique, unique 
enzymatic activities among the replicase protein products, and a multi-spanning integral 
membrane protein. Until 1993, Coronaviridae was completely monogeneric, composed 
solely of Coronavirus, of which there were considered to be three antigenic groups 
defined primarily by monoclonal antibody analysis and nucleotide sequencing (Siddell, 
1995), although, originally, the genus was divided into four antigenic groups based on 
serological analyses (Holmes, 1990). Refinement of the antigenic groupings was 
proposed based on the results of monoclonal antibody testing and nucleotide sequencing 
suggesting that turkey coronavirus (TCV) and BCoV were actually more closely related 
than originally thought (Siddell, 1995). While the members of groups I and II are closely 
related, not only within their respective groups, but in some respect across groups, the 
sole member of group III, avian infectious bronchitis virus (IBV), notably the first 
coronavirus to be isolated and propagated (Shalk and Hawn, 1931), is dramatically 
different from groups I and II, even showing a considerable amount of within-species 
variation.  In 1993 the International Committee for the Taxonomy of Viruses (ICTV) 
officially included a second genus into the Coronaviridae family, based on previous 
observations that the genus Torovirus, which had not yet at that time officially been 
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included in a virus family, displayed many of the same characteristics generally 
associated with coronaviruses (Cavanagh et al., 1994, 1995). More recently, the ICTV 
once again modified the Coronaviridae classification, separating it into three distinct 
groupings, essentially divergent enough to be considered genera: the alpha-,  
beta-, and gammacoronaviruses, corresponding to the original groupings 1, 2, and 3, 
within the subfamily Coronavirinae, within the family Coronaviridae (2009). Virtually 
all of the group 1 and 2 coronaviruses have mammalian hosts, and the human 
coronaviruses are represented in each of these groups, including the newly discovered 
human coronaviruses (HCV) HCV-NL63 (van der Hoek et al., 2004) and HCV-HKU1 
(Woo et al., 2005). A number of additional coronaviruses have also been added to groups 
1 and 2, their discovery sparked by the emergence of the previously unknown SARS-
CoV. These are the bat coronaviruses, three of which have been reported. Two of these 
belong to group 1 and the third, identified as the likely precursor to the SARS-CoV, is 
within group 2 (Lau et al., 2005; Li et al., 2005; Poon et al., 2005). The group 3 
coronaviruses, on the other hand, have been isolated solely from avian hosts, and, much 
like as has occurred in groups 1 and 2, a number of new IBV-like species have been 
identified, including those that infect geese, ducks, and pigeons (Jonassen et al., 2005).  
Coronavirus architecture 
Coronaviruses are large, approximately 120 nm in diameter pleomorphic virions 
possessing a cell membrane-derived bi-layer lipid envelope which reflects the lipid 
content of the host cell membrane (Pike and Garwes, 1977). Projecting from this lipid 
envelope are numerous prominent, 17-20 nm petal-shaped spikes (McIntosh, 1974), 
glycoproteins (gp) composed of heavily glycosylated type I proteins anchored within the 
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lipid envelope of the virion (Fig. 2.1). These projections are easily recognizable on 
electron micrograph as projections with a thin base topped by a globular structure of 
approximately 10 nm in width at the distal extremity (Sugiyama and Amano, 1981), and 
it is from this “crown” of gps that coronaviruses derive their name. In addition to the 
large “Spike” gp (S), which is required for infection, a subset of the coronaviruses, all of 
those classified within the betacoronaviruses, also possess a second set of shorter, far less 
prominent, 5-10 nm long gps projecting from the lipid envelope (Caul and Egglestone, 
1977; King and Brian, 1982; Dea and Tijssen, 1988). Unlike S, however, this type I gp, 
the hemagglutinin-esterase (HE) protein, is not essential for virus infectivity. An 
additional protein associated with the lipid envelope of the virion is the small type III 
membrane protein known as M or matrix protein, the integral membrane gp, formerly 
known as the E1 gp, and not only spans the lipid envelope three times, but is also 
associated at its carboxyl (C) terminus with the nucleocapsid (N) protein. The N protein 
is non-glycosylated and interacts with the linear viral genomic RNA in a “beads on a 
string” fashion (Laude and Masters, 1995) to form the 14 to 16 nm helical viral 
ribonucleoprotein (RNP) known as the nucleocapsid (McNaughton et al., 1978; Sturman 
and Holmes, 1983), located at the internal periphery of the virion, adjacent to the viral 
envelope as a result of its interaction with the M gp during virion assembly (Hurst et al., 
2005). Interestingly, coronaviruses are generally considered to contain a helically 
symmetric nucleocapsid, a distinguishingly unusual characteristic for positive-sense RNA 
viruses but considered the norm for RNA viruses having a negative-sense genome. More 
recently, what was previously held as the prototypical coronavirus architecture has been 
challenged. Risco et al, by way of negative staining, ultra-thin sectioning, freeze-fracture, 
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immunogold mapping, and cryoelectron microscopy of detergent-treated transmissible 
gastroenteritis virus (TGEV) particles observed a previously unreported icosahedral core 
within the virion encompassing not only the RNP but also the M gp. Only after treatment 
with Triton-X did the nucleocapsid further dissociate into the expected helical 
arrangement (1996). However, this odd coronavirus nucleocapsid arrangement has thus 
far only been reported for TGEV. 
Nucleocapsid protein  
The nucleocapsid protein of coronavirus is a 50 to 52 kDa non-glycosylated, 
phosphoprotein (Calvo et al., 2005; King and Brian, 1982) capable of forming disulfide-
linked trimers with an average molecular weight (MW) of 160 kDa under non-reducing 
conditions. The N proteins are concentrated along the internal periphery of the lipid 
envelope, interacting with the integral membrane protein (M). The N proteins have been 
reported to range anywhere from 9 to 16 nm in diameter and vary from 377 to 455 amino 
acids in length. These proteins are highly basic in nature and contain numerous serine 
residues; in fact the proteins may contain as much as 7 to 11% serine, and it is these 
residues that are targets for phosphorylation (Stohlman and Lai, 1979; Siddell et al., 
1981). This phosphorylation is proposed to have regulatory significance, and Chen et al. 
have reported that, for IBV, phosphorylated N protein is better able to differentiate viral 
from non-viral substrates when compared with unphosphorylated N protein in vitro 
(2005). Furthermore, in studies of BRCoV N protein, researchers have reported that only 
a small subset of phosphorylated forms of the intracellular N protein are incorporated into 
virions, leading these researchers to postulate that N protein phosphorylation may be 
linked to virion assembly and maturation (Hogue, 1995).  
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In addition to its numerous serine residues, the N protein is also rich basic amino 
acids, which are generally concentrated in RNA-binding domains (Masters et al., 1992; 
Nelson and Stohlman, 1993) associated with both coronavirus and non-viral RNA 
binding (Robbins et al., 1986; Stohlman et al., 1988; Masters, 1992). Specifically, the 
murine hepatitis virus (MHV) N protein has been reported to bind to the RNA leader 
sequence, particularly at nucleotides 56-67, under specific binding conditions (Stohlman 
et al., 1988; Nelson et al., 2000; Chen et al., 2005). In addition, the N protein of IBV has 
been reported to bind to the 3’ untranslated region (UTR) of the IBV genomic RNA in 
vitro (Zhou et al., 1996). Other proposed sites of viral genomic RNA binding include the 
N gene within the viral genome (Cologna et al., 2000) and the genomic RNA packaging 
signal (Molenkamp and Spaan, 1997; Cologna et al. 2000). This RNA binding ability is 
vital to the formation of viral particles, as N proteins interacts with the viral genomic 
RNA to form the viral nucleocapsid (Hurst et al., 2005); viral genomic RNA cannot be  
incorporated into the viral particle without this essential interaction (Bos et al., 1996; 
Vennema et al., 1996). Furthermore, it has been suggested that N protein may actually 
participate as a part of the viral RNA synthesis machinery, since it is able to both bind 
viral RNA and interact with the membrane (Anderson and Wong, 1993), which has been 
shown to be the primary site of viral RNA synthesis in infected cells (Brayton et al., 
1982; Dennis and Brian, 1982). In support of this hypothesis is the report by Compton et 
al. in which monoclonal antibodies against the N protein added to an in vitro RNA 




demonstrated that N protein is, indeed, associated with replication-transcription 
complexes in infected cells (Verheije et al., 2010). 
Membrane protein 
 The M gp of coronavirus, formerly known in the literature as gp E1, is a 
glycosylated, multi-spanning membrane protein that gives the viral envelope its shape. 
As such, it is the most abundant constituent of the virus (Sturman et al., 1980; Sturman, 
1977). The protein is thought to originate as an unglycosylated polyprotein, and prior to 
glycosylation, the protein can be identified as a 25 to 30 kDa polypeptide, although 
numerous higher MW products possessing varying levels of glycosylation can be 
Figure 2.1. Coronavirus virion architecture. The viral ribonucleocapsid is encased within a bi-layer 
lipid envelope containing three viral proteins: Spike, HE, and M, from Finlay and Hancock, 2004). 
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identified by SDS-PAGE analysis (Krijnse Locker et al., 1992). The glycosidic residues 
are, in the vast majority of betacoronaviruses, O-linked to the polypeptide backbone, the 
exceptions to this being MHV-2 (Yamada et al., 2000) and the SARS coronavirus (Nal et 
al., 2005), both of which contain N-linked glycosidic residues. All members of the other 
two coronavirus groups posses M proteins with strictly N-linked glycosylation (Stern and 
Sefton, 1982; Jacobs et al., 1986; Cavanaugh and Davis, 1988). Interestingly, viral O-
linked glycosylation had not previously been described before its discovery in the MHV-
2 coronavirus (Holmes et al., 1981). 
 The first polytopic membrane protein to be described was the coronavirus M 
protein (Armstrong et al., 1984; Rottier et al., 1984), which contains a short, 5 kDa 
hydrophilic amino-terminal tail as its ectodomain, followed by three hydrophobic, -
helical transmembrane segments. The transmembrane domain is then followed by a large 
amphipathic carboxyl-terminus that makes up the majority of the molecule and which is 
situated within the interior of the virion (Rottier, 1995). Only the ectodomain of the M 
protein is glycosylated, and has been shown to be translocated to the lumen of the 
endoplasmic reticulum (ER) following its translation by microsomes in vitro (Rottier et 
al, 1986; Rottier et al., 1984; Cavanagh and Davis, 1988). While the ectodomain of M 
protein has bee shown to be particularly protease-sensitive, the C-terminus of the protein 
is quite resistant to proteolytic cleavage, suggesting that the endodomain is tightly 
associated with the surface of the viral envelope or that it has a particularly tight 
configuration that protects it from proteolysis (Rottier, 1995).  
The M protein plays a crucial role in virion assembly and budding and has been 
shown to interact with each other (deHaan et al., 2000), as well as with other viral 
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proteins, including N protein (Kuo and Masters, 2002; Fang et al., 2005), S (deHaan et 
al., 1999), envelope protein (Nguyen and Hogue, 1997), and, in some betacoronaviruses, 
HE (Opstelten et al., 1995). In addition to these interactions, MHV N protein has also 
been reported to interact directly with the MHV genomic RNA packaging signal in the 
direction of genomic RNA packaging during virion assembly (Narayanan et al., 2003).  
Small membrane protein E 
 The coronavirus small membrane protein, E, is a small polypeptide ranging from 
8.4 to 12 kDa and makes up the smallest percentage of viral protein within the virion (Liu 
and Inglis, 1991; Godet et al., 1992; Yu et al., 1994; Raamsman et al., 2000). It is an 
integral membrane protein and, owing to its small size, one of the last coronavirus 
structural proteins to be discovered. The E protein was first discovered in IBV (Liu and 
Inglis, 1991), followed soon after in TGEV (Godet et al., 1992), and finally was reported 
in the MHV coronavirus (Yu et al., 1994), representing all three genre of the 
Coronavirinae. The E protein is an unusual coronaviral protein in that it is not translated 
from its own individual subgenomic mRNA; instead, it has been reported to be translated 
in a bi- or tri-cistronic manner from an open reading frame (ORF) downstream of, in the 
case of MHV, one (Leibowitz et al., 1988) or, in the case of IBV, two (Liu et al., 1991), 
ORFs that encode viral accessory genes which are also expressed from the same mRNA. 
Furthermore, IBV M protein is also unusual for the coronaviral proteins in that its 
translation from mRNA has been shown to be facilitated by an internal ribosomal entry 
site (IRES; Liu and Inglis, 1992). However, it is currently unknown whether or not other 
coronaviruses utilize this mechanism for translation of the E protein.  
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 The E protein gene of the coronaviruses is not well conserved across the three 
coronavirus genre, even showing considerable variation between members within a single 
genre. However, in spite of this considerable divergence, the E protein maintains the 
same general architecture amongst all three genres, having three distinct domains: a short 
hydrophilic N-terminus consisting of approximately 8 to 12 amino acid residues followed 
by an unusually long hydrophobic region representing the transmembrane domain 
containing two to four cystine residues which are important for the function of the 
protein. This intermembrane region is followed then by a considerable hydrophilic C-
terminal tail consisting of 39 to 76 amino acid residues. Additionally, the C-terminal 
domain of the protein has been reported to be both palmitoylated (Yu et al., 1994; Liao et 
al., 2006; Boscarino et al., 2008) and ubiquinated (Alvarez et al., 2010).  
The topology of the E protein has only been partially elucidated. Studies of the 
MHV and IBV E proteins strongly suggest that the C-terminal tail of the protein is 
situated within the virion (Corse and Machamer, 2000; Raamsman et al., 2000), while 
less extensive analysis of the TGEV E protein suggested it was oriented with the C-
terminus exterior to the virion, while the amino (N)-terminus was within (Godet et al., 
1992). Corse and Machamer also reported that the C-terminal domain of the IBV E 
protein, in the absence of its membrane-bound domain, is sufficient to specify targeting 
to the budding compartment (2002). Elucidation of the N-terminus orientation has been 
less straightforward, however. While molecular dynamics simulations have previously 
suggested that the E protein should be a single-transit transmembrane protein (Torres et 
al., 2005), results of studies with MHV using an E protein expressing an N-terminus 
epitope tag have revealed that this domain may very well be buried within the membrane 
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near the cytoplasmic face, suggesting that the protein is oriented in a hairpin fashion 
within the viral membrane (Maeda et al., 2001). In support of this finding is the report by 
Raasmsman and colleagues that none of the E protein in purified MHV virions is 
accessible to degradation by protease treatment (2000). Furthermore, these findings 
together are in agreement with those predicted for SARS-CoV E protein (Arbely et al., 
2004). Thus, additional work remains to be done to fully determine the orientation of this 
protein. 
The E protein plays a vital role in virion assembly (Bos et al., 1996; Corse and 
Machamer, 2000), and palmitoylation of one or both of its cystine residues on the C-
terminal tail has been shown to be required for this function (Alvarez et al., 2010). 
Additionally, complete palmitoylation of the protein has been shown to be important for 
protein stability (Lopez et al., 2008). Fischer et al. (1998) reported that E protein plays a 
significant role in the assembly of viral particles, and co-expression of the E and M 
proteins has previously been shown to be sufficient for assembly of virus-like particles of 
most of the coronaviruses that have been examined to-date (Bos et al., 1996; Baudoux et 
al., 1998; Corse and Machamer, 2000). However, the E protein does not appear to be 
absolutely essential for the assembly of all coronaviruses. In their 2003 study, Kuo and 
Masters constructed an E-deleted MHV mutant via targeted recombination that was 
shown to be viable through several passages in cell culture, in spite of the production of 
tiny plaques and significantly decreased viral replication. Likewise, DeDiego et al. (2007) 
constructed an E-deleted SARS-CoV in similar fashion, which they reported was also 
viable, in fact only reaching titers that were approximately 1-2 log lower than that 
observed for wild-type virus in culture. 
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Hemagglutinin-esterase 
 The hemagglutinin-esterase gp (HE) is an unusual viral gp protein in that it is not 
possessed by all coronaviruses. Rather, only a specific subset of coronaviruses, those 
belonging to group 2a, including HEV, MHV, HCV-OC43, BCoV, and TCV, contain the 
gene for expression of this membrane gp, which possesses both receptor binding 
(hemagglutinin) and receptor destroying (acetylesterase) activities. Even more interesting 
is the observation that not all of the viral strains within the group 2a coronaviruses 
express the HE gene, as the MHV strain A59 possesses an untranscribed HE pseudogene 
lacking the initiation codon in the open reading frame (orf; Lutjes et al., 1988). Other 
group 2a coronavirus strains have also been reported to possess truncated versions of the 
HE gene that also remain unexpressed (Yokomori et al., 1991). In fact, despite the fact 
that HE was first reported in BCoV in 1985 (King et al., 1985), it was not accepted as a 
true viral gp for quite some time due to the fact that MHV-A59, one of the most 
thoroughly-studied coronaviruses, did not possess HE.  
 The HE gp is an approximately 65 kDa glycoprotein that exists as a homodimer 
anchored by its C-terminus within the viral membrane (Caul and Egglestone, 1977; Dea 
and Tijssen, 1988; Zeng et al., 2008), a conformation achieved via interaction of the 
receptor and membrane-proximal domains of the protein (Zeng et al., 2008). It is believed 
that the HE of the group 2a coronaviruses was obtained as a result of a non-homologous 
recombination event between an ancestral coronavirus and an influenza C virus (Luytjes 
et al., 1988), and, indeed, the two share approximately 30% homology in the gene 
encoding their respective HE/hemagglutinin-esterase-fusion proteins (HEF, influenza C 
virus; Kienzle et al., 1990). Additionally, the putative esterase-active site, FGDS, is 
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conserved between the two viruses (Parker et al., 1989; Kienzle et al., 1990), as are a 
number of cystine residues (Zhang et al., 1991). Interestingly, the membrane proximal 
domain is formed from the remnant of the F1 fusion domain and the F2 domain of the 
closely related HA protein from influenza A and B viruses and the HEF protein of 
influenza C viruses (reviewed in Mesecar and Ratia, 2008). The dimerization of the HE 
protein of coronavirus is thus accomplished by a unique arrangement for this family of 
proteins, as both the HA and HEF proteins exist in their respective viruses as trimeric 
structures resulting from significant interaction of the entire fusion domain of these 
viruses, inclusive of F1, F2, and F3, as well as the membrane-proximal domain (Wilson 
et al., 1981; Rosenthal et al., 1998; Ha et al., 2002). The coronavirus HE, in the course of 
evolution, has, in contrast, lost most of its F1 domain, as well as its F2 and F3 domains in 
their entirety, most likely as a result of decreased selection pressure to retain these 
domains, as coronaviruses depend largely on the fusogenic function of the S gp for 
receptor binding and membrane fusion, unlike the influenza viruses, which rely on the 
action of the HA or HEF proteins for this function (Zeng et al., 2008). 
 The HE of coronaviruses possesses both hemagglutination and hemadsorption 
properties, the latter being the ability to adsorb erythrocytes to the membranes of infected 
cells (Sharpee et al., 1976; King et al., 1985; Kienzle et al, 1990; Payne and Stortz, 
1990). The cellular receptor target for the HE protein is the cell membrane carbohydrate 
moiety 9-O-acetylated neuraminic acid (Vlasak et al., 1988; Schultze et al., 1991), which 
it is also able to hydrolyze via its neuraminate-O-acetylesterase activity, an enzyme 
activity that releases the protein from its receptor, effectively reversing hemagglutination 
induced by it or the S gp (Vlasak et al., 1988; Yokomori et al., 1989; Parker et al., 1990). 
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For this reason HE is also considered to be a receptor destroying enzyme. Interestingly, 
however, like the newly described orthomyxovirus, infectious salmon anemia virus 
(Hellbeo et al., 2004), the MHV-S strain of coronavirus has been reported to instead bind 
4-O-acetylated neuraminic acid (Regl et al., 1999). 
 The functional significance of the coronavirus HE gp is not currently fully 
understood. It has been previously reported that HE contains multiple important 
neutralizing epitopes (Deregt et al., 1989) mapping primarily to one of three epitope 
locations on the protein (Deregt and Babiuk, 1987; Parker et al., 1989, 1990; Vautherot et 
al., 1990) and that antibodies directed against these epitopes were neutralizing both in 
vitro and in vivo (Deregt et al., 1989). This research has suggested that specific 
monoclonal antibodies against the HE of the enteropathic strain of BCOV are capable of 
inhibiting virus infectivity (Deregt and Babiuk, 1987; Deregt et al., 1989; Hussain et al., 
1991), and that development of antibodies against both the S and HE gps play significant 
roles in clearing viral infection (Lin et al., 2000). Given this apparent antigenicity, a 
feature typically reserved for epitopes on pathogens mapping to highly conserved and 
necessary proteins, it was originally thought, at least with respect to BCoV infectivity, 
that HE was necessary for infectivity (Yokomori et al, 1992, 1995); however, this was 
disproven by Popova et al. (2002) utilizing chimeric MHV virions expressing either 
BCoV S or BCoV HE gps. When these chimeric viruses were used to inoculate cultures 
of the 18G clone of human-derived rectal tumor cells (HRT-18G), an immortalized cell 
line known to support infection and replication by BCoV (Thompkins et al., 1974; Storz 
et al., 1996), only those viruses expressing the functional BCoV S gp, and not the 
chimeric MHV virions expressing the functional BCoV HE gp, were able to enter HRT-
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18G cells. Thus the group concluded that the BCoV S gp alone is necessary and sufficient 
for infection of HRT-18G cells. Alternatively, based on studies utilizing monoclonal 
antibody (Mab) against the MHV HE which suggested that MHV with the functional HE 
may have altered neuropathogenicity when compared with MHV lacking functional HE 
(Yokomuri et al., 1992, 1995), it was proposed that HE may allow coronaviruses bearing 
this protein to utilize alternative receptors independent of the S gp. However, this, too, 
was shown to not be the case, based on a report in which the use of Mab against the 
major receptor for the MHV S inhibited infection of cells by an MHV expressing the HE 
gp (Gagneten et al., 1995). Thus, although the coronavirus HE seems to bear some 
importance with respect to infectivity based on the presence of strongly neutralizing viral 
epitopes, the function of this protein with respect to viral infectivity and replication has 
yet to be fully understood. 
Spike 
 The spike gp (S) of coronaviruses is arguably the most distinctive coronaviral 
protein, as it projects some 17 to 20 nm out from the surface of the viral envelope, giving 
the virus the appearance of a crown. Responsible for facilitating not only host receptor 
recognition and binding (Collins et al., 1982; Godet et a., 1994; Kubo et al., 1994), but 
also virus-host and host-host membrane fusion and viral entry (Gallagher et al., 1991; 
Qiu et al., 2006), S plays a vital role in promoting infection and has been implicated as a 
significant factor influencing virulence (Navas et al., 2001) as well as both tissue (Navas 
et al., 2001; Phillips et al., 2001; Navas and Weiss, 2003) and host tropism (Li et al, 
2006). The protein exists on the virion surface as a trimer (Delmas and Laude, 1990), 
with the S1 subunits, the approximately N-terminal one-half of the polypeptide, 
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interacting to form the globular head and the S2 subunits, comprised of the approximately 
C-terminal one-half of the polypeptide, interacting to form the transmembrane stalk (de 
Groot et al., 1987; Figure 2.2).  
Spike is a large gp, ranging anywhere from 1160 amino acids in the IBV S to 
1452 in feline coronavirus (FCV). The protein contains an N-terminal cleaved signal 
sequence that directs its cotranslational insertion into the endoplasmic reticulum 
(Cavanagh et al., 1986) and a transmembrane sequence near the C-terminus, with the N-
terminal ectodomain making up the vast majority of the protein, while the C-terminal 
transmembrane and ectodomains are, by comparison, significantly shorter, consisting of 
only 71 or fewer amino acids. The S ectodomain contains between 30 and 50 cystine 
residues, the positions of which have been shown to be well-conserved within each of the 
coronavirus groups (Abraham et al., 1990; Eickmann et al., 2003), although 
comprehensive mapping of resulting potential disulfide linkages has yet to be performed 
for any of the coronaviruses. Some of these cystine-rich domains have been shown to be 
critical in the expression of S gp on the surface of host cell membranes (Petit et al., 
2005). The protein also contains numerous glycosylation sites, ranging in number 
anywhere from 21 to 35, all of which are exclusively N-linked (Holmes et al., 1981; 
Rottier et al., 1981). The ectodomain of the coronavirus S proteins contains an assortment 
of potential conserved glycosylation sites, but comprehensive mapping of these sites has 
yet to be reported for any coronavirus to date. However, mass spectrometric studies of the 
SARS-CoV have shown that at least 12 of the 23 potential sites are glycosylated in this 




cotranslational manner, although it has been reported in TGEV that terminal 
glycosylation is in fact preceded by trimerization of the protein, an event that can also be 
rate-limiting in S protein maturation (Delmas and Laude, 1990). Furthermore, monomer 
folding may also be assisted by proper glycosylation of the TGEV S protein, as it has 
been reported that treatment with tunicamyacin, which inhibits high-mannose transfer, 
was shown to block trimerization of the S monomers (Delmas and Laude, 1990). 
 Spike can be divided into two approximately 90 kDa subunits, the S1 and S2 
domains of the protein, which can be cleaved from one another in the presence of trypsin 
(Hogue and Brian, 1986), the latter of the two being acylated (Sturman et al., 1985). Most 
of the MHV S proteins, with the exception of those belonging to MHV-2, are cleaved 
postranslationally by a cellular furan-like protease into the S1 and S2, which remain 
bound via a non-covalent linkage (Frana et al., 1985; Sturman et al., 1985). Interestingly, 
trypsin treatment of MHV S proteins causes cleavage of all S gps without disruption of 
Figure 2.2. The primary structure and functional domains of the S glycoprotein, from 
Masters, 2006. 
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the spikes (Sturman et al., 1985), but treatment with mild alkali or urea will release S1 
from the virion (Cavanagh and Davis, 1986; Sturman et al., 1990; Weismiller et al., 
1990). Peptide sequencing of the cleavage products for a number of coronaviruses has 
determined that cleavage occurs following the last residue in a highly basic motif, which 
varies between coronavirus species. In the IBV S protein the sequence of this motif has 
been shown to be RRFRR (Cavanagh et al., 1986), while in MHV-A59 it has been 
reported to be RRAHR (Luytjes et al., 1987), and KRRSRR in BCoV (Abraham et al., 
1990). Amongst the coronaviruses as a whole, S2 is considered to be far more conserved 
as compared with S1 (de Groot et al., 1987), in which there is virtually no sequence 
conservation, even among strains and isolates within a single coronavirus species (Parker 
et al., 1989; Gallagher et al., 1990; Wang et al., 1994). Additionally, comparison of the 
S1 sequences amongst strains within a species or between species of a given group have 
shown that the S1 contains a number of hypervariable regions denoted by frequent 
deletions, mutations, or even areas of recombination (Cavanagh et al, 1988; Parker et al., 
1989; banner et al., 1990; Gallagher et al., 1990).  
 The S gp, a class I fusion protein (Bosch et al., 2003), alone is sufficient to cause 
membrane fusion, an observation supported by the formation of syncytia in the presence 
of recombinant S (de Groot et al., 1989; Pfleiderer et al., 1990; Yoo et al., 1991; Taguchi, 
1993), and posttranslational cleavage of the S gp following its synthesis in the 
endoplasmic reticulum has been implicated in induction of the membrane fusion process 
for a number of coronavirus species (Sturman et al., 1985). The binding of the MHV S S1 
subunit to its cellular receptor results in a conformational change accompanied by 
separation of the S1 and S2 subunits, a change which may be involved in triggering 
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membrane fusion and that can be mimicked in the absence of a cellular receptor by 
exposure of the S gp to 37°C and an elevated pH of 8 (Gallagher, 1997; Holmes et al., 
2001; Sturman et al., 1990). However, cleavage of the S protein is not necessary in all 
cases to facilitate the fusogenic activity of S, as shown via studies utilizing MHV S 
proteins containing mutated S1-S2 connecting peptides (Stauber et al., 1993; Taguchi, 
1993, Bos et al., 1995), although the process has been shown to enhance the fusogenicity 
of S (Gombold et al., 1993; Taguchi, 1993). Naturally occurring MHV mutants defective 
in S cleavage recovered from persistently infected murine cells remain infective but have 
delayed fusion activity (Gombold et al., 1993). Furthermore, neither the feline infectious 
peritonitis virus (FIPV) (de Groot et al., 1989) nor the SARS-CoV (Simmons et al., 2011) 
S gp are cleaved during synthesis, but still enter host cells and result in cell-cell fusion 
and syncytia formation. For these cleavage-deficient viruses, it is thought that, rather than 
entering the host cell at the level of the cell membrane via fusion of the viral and cellular 
lipid membranes, the virus may employ an endosomal route of entry. In this scenario, the 
virus, following attachment to the cellular receptor, is taken up by into cellular 
endosomes, at which point cathepsin or another cellular trypsin-like protease dependent 
upon decreasing endosomal pH is responsible for cleavage of the S1 and S2 subunits, 
triggering fusion of the viral and endosomal membranes, in turn resulting in release of the 
viral from the endosomal compartment (Qiu et al., 2006; Simmons et al., 2011). 
 The S2 subunit contains two 4,3-hydrophobic heptad repeat sequences (Delmas 
and Laude, 1990) termed HR1 and HR2, which together form a six helix bundle 
structure, a motif characteristic of coiled coils. Specifically, the helices of HR1 form a 
homotrimeric coiled coil into the hydrophobic grooves of which are tightly packed the 
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coils of HR2, in an antiparallel manner, a conformation that brings the fusion peptide into 
close proximity with the transmembrane anchor (reviewed by Eckert and Kim, 2001). 
When the fusion peptide is inserted into the host cell membrane, this conformation brings 
the two membranes into close apposition, facilitating their fusion (Melikyan et al., 2000; 
Russell et al, 2001). Like many features of the S2 subunit, these HRs are highly 
conserved in both sequence and position across the members of the three groups of 
coronaviruses. A combination of predictions and observations have led to the supposition 
that the HR1 and HR2 motifs of the S S2 subunit are directly involved in mediating viral 
envelope fusion with the cell membrane. The first of these predictions is that a fusion 
peptide may lie near (Chambers et al., 1990) or within (Luo and Weiss, 1998) the HR1 
region, and, secondly, that viruses containing mutations in the HR2 region are defective 
with regard to oligomerization and fusogenicity (Luo et al., 1999). In fact, mutations 
within HR1 or HR2 of the MHV S gp have been shown to abolish the fusogenic 
properties of the protein (Luo and Weiss, 1998; Luo et al., 1999). Thirdly, the JHM strain 
of MHV has been shown to be capable of host entry via the endosomal pathway, but does 
not require low pH for release from the endosomal compartment (Nash and Buchmeier, 
1997); however, for those viruses utilizing the same pathway but requiring acidic 
endosomal pH for release, the defect has generally mapped to HR1 (Gallagher et al., 
1991). Further underlining the importance of the S heptad repeats in viral-mediated 
membrane fusion are the observations that, 1) three site-directed mutations in or near the 
HR1 region were responsible for conveying the low pH requirement of some MHV-JHM 
mutant strains isolated from persistently infected cells (Gallagher et al., 1991), and 2) a 
significant reduction in cell-cell fusion exhibited by some MHV-JHM mutant strains was 
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attributed to two mutations in the gene encoding the S protein, one of which, again, 
mapped to HR1 and could be overcome by acidification (Krueger et al., 2001). 
Additionally, codon mutations in HR2 have also been reported to severely inhibit 
fusogenicity and oligomerization of the S gp, in spite of the fact that the mutations did 
not hinder their expression on the membrane surface (Luo et al., 1999). 
 The highly variable S1 subunit, on the other hand, has been implicated in receptor 
binding, a function that has been mapped to the N-terminal 330 amino acids for MHV 
(Williams et al., 1991; Taguchi, 1995). In fact, previous researchers have reported that 
changes in the residues located at positions 62, 212, 214, and 216 via site-directed 
mutagenesis were able to completely abolish the binding of S to its receptor (Suzuki and 
Taguchi, 1996). Receptor binding sites have also been mapped for the TGEV S gp, and 
reside within a 223-residue region at amino acids 506-729 of the S1 subunit (Godet et al., 
1994). Perhaps interestingly, but not surprisingly, this region overlaps with and epitope 
for a neutralizing Mab, which was reported as capable of blocking binding by the 223 
amino acid polypeptide to its receptor. A finding, however, that was somewhat surprising 
was that, conversely, the receptor did not in turn block binding of the Mab to the 223 
amino acid polypeptide, suggesting that the epitope and receptor binding domain were, 
although overlapping, distinct and possibly conformation-dependent (Godet et al, 1994). 
 Being the primary viral protein involved in host cell binding, and, ultimately, the 
determinant of host cell infectivity, it is perhaps no surprise that the S gp is also the 
primary target of the host adaptive immune response (Collins et al. 1982; Stohlman, 
1985; Williams et al., 1991; Compton et al., 1992), with antibodies developed against this 
protein generally associated with strong protection against viral infection (Buchmeier et 
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al., 1984; Nakanaga, 1986). A considerable body of work has been done in the past in an 
attempt to delineate both the continuous and discontinuous epitopes of the S gp 
associated with development of neutralizing antibodies. In a1984 study performed by 
Wege et al., the group characterized a set of MHV-JHM S gp-specific Mab, which were 
used to identify six antigenic sites, A through F. Of these, they found that two sites were 
associated with strong binding with neutralizing antibodies, and were noted to define 
discontinuous epitopes, epitopes encompassing sections of the protein only close together 
in the secondary structure of the protein, on the S gp. On the other hand, antigenic sites C 
through F were noted to be associated with continuous epitopes, not dependent on protein 
secondary structure for recognition (Wege et al., 1988). The discontinuous antigenic site 
A was found to be contained within the S1 subunit, considered to be the 
immunodominant B-cell determinant of the S gp (Stuhler et al., 1991), a finding 
supported by previous work utilizing Mab-selected neutralization-resistant MHV mutants 
having extensive deletions in the S1 subunit (Parker et al., 1989), suggesting that this 
portion of the S gp is a major target for the induction of neutralizing antibody (Gallagher 
et al., 1990). Additional work performed with Mab produced against the S gp of IBV also 
showed that strongly neutralizing antibody formation was associated primarily with the 
S1 subunit of S (Mockett et al., 1984), and, in fact, research utilizing IBV in which the S1 
portion of the S gp had been removed via treatment with urea, while the S2 portion was 
retained, failed to induce production of protective antibody (Cavanagh et al., 1986). 
However, neutralizing antibodies mapping to the S2 subunit of the S gp have been 
reported (Collins et al., 1982; Taguchi and Shimazaki, 2000); these antibodies, in the case 
of MHV, have been mapped to domains within S2 involved in membrane fusion, 
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although the authors do allow that the neutralizing activity of the anti-S2 antibodies are 
not as strongly neutralizing as those associated with binding of the S1 subunit, especially 
those domains on S1 associated directly with receptor binding (Taguchi and Shimazaki, 
2000). It is worth mentioning, however, that the S2 subunit of the S gp may play a vital 
role in the induction of a strong neutralizing antibody response unrelated to the 
production of anti-S2 antibody. Recent research in the development of a SARS DNA 
vaccine has shown that truncation of portions of the S2 subunit, namely the 
transmembrane domain, result in the production of only poorly virus neutralizing 
antibody. The authors suggest that this may be a result of the involvement of the 
transmembrane domain in supporting proper tertiary structure development, or that 
anchoring in the membrane may give rise to a more stable, physiologically relevant form 
of the protein, in turn preserving conformational determinants important for epitope 
formation (Yang et al., 2004).  
Accessory proteins 
In addition to the five structural proteins encoded within the coronavirus genome, 
there are also additional accessory proteins encoded, in some cases within their own 
ORF, but in many cases within or overlapping the ORFs encoding the structural proteins. 
Analysis of numerous coronavirus genomes has revealed the presence of at least 10 
ORFs, some of these corresponding to a distinct mRNA product, but others being less 
conventional in the method of their processing and translation. These proteins were 
originally described as the nonstructural (ns) proteins, but this may turn out to be 
somewhat of a misnomer, since the function of some of these proteins has been elusive 
and remains to be described; however, description of function for some of these proteins 
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has been at least partially determined, although there remains some disagreement about 
the complete function even of many of these proteins, necessitating further research in the 
future. 
The first polyproteins to be translated following viral entry into the host cells are 
encoded within ORF1a, which encodes the approximately 450 kDa pp1a, and ORF1b, 
encoding the approximately 750 kDa pp1ab, also known jointly as the coronavirus 
replicase locus, encompassing an impressive 20 kb, or almost two-thirds of the 
coronavirus genome. The protein product of this locus is cotranslationally processed into 
16 nonstructural proteins (nsp1 through nsp16), which are thought to assemble into a 
cytoplasmic, membrane-associated replication complex involved in both replication of 
the genome and production of the 3’ nested subgenomic RNAs (Snijder et al., 2003; 
Stadler et al., 2003). Cotranslational processing of these polyproteins is accomplished by 
either one or two papain-like proteases (PLP) encoded within ORF1a, the most 
commonly identified of these being nsp3. ORF1a has been predicted to encode at least 
one PLP (nsp3) and a 3C-like protease (3CLpro) similar to those observed in 
picornaviruses, as well as a number of putative nsps of unknown function. ORF1b is 
located downstream of ORF 1a and is transcribed as a fusion protein via a -1 ribosomal 
frameshift (Herold and Siddell, 1993), resulting in the production of pp1ab, which 
includes the core RNA polymerase nsp12, a helicase domain (nsp13), and a predicted 
primase, nsp8. Additional nsps are also contained within this large polyprotein, including 
the N7-capping enzyme, an exonuclease (Minskaia et al., 2006; Chen et al., 2007) and 
proposed proofreading enzyme (Denison et al., 2011), nsp14, the endoribonuclease nsp15 
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(Bhardwaj et al., 2004; Ivanov et al., 2004; Bhardwaj et al., 2006), and a 2’-O-
methyltransferase, nsp16 (Snijder et al., 2003; Decroly et al., 2008). 
 The proteins Nsp12 and Nsp8 are encoded within orf1b and are involved in viral 
genome replication. Nsp12 contains the RNA-dependent RNA polymerase core activity 
associated with both replication of the genomic RNA via a negative stranded RNA 
intermediate (te Velthuis et al., 2010) as well as transcription of the multiple nested 
subgenomic mRNAs, while Nsp8 has similar activity but preferentially initiates synthesis 
of short oligonucleotides containing fewer than six residues (reviewed in Weiss and 
Leibowitz, 2011). It has been proposed that, at least for the SARS-CoV, Nsp8 may in fact 
act as a primase in concert with nsp7 and be responsible for synthesizing the short oligo 
primers that are then utilized by Nsp12 for RNA synthesis (Imbert et al., 2006; te 
Velthuis et al., 2009; te Velthuis et al., 2012).  
The helicase activity associated with the coronavirus replicase belongs to a 66 
kDa protein known as Nsp13. This protein contains an N-terminal binuclear zinc finger 
structure linked to a C-terminal superfamily 1 helicase domain, unusual for positive-
stranded RNA viruses but commonly seen in other nidoviruses (Gorbalenya et al., 1989; 
Heusipp et al., 1997; Van Dinton et al., 2000) and has been shown to, as a recombinant 
protein expressed via baculovirus in infected insect cells (Ivanov and Ziebuhr, 2004) and 
as a fusion protein expressed in E. coli (Ivanov et al., 2004), possess both RNA and DNA 
duplex 5’ to 3’ unwinding capabilities (Seybert et al., 2000). The directionality of this 
helicase has been proposed to be a result of the necessity of synthesizing multiple 
subgenomic coronavirus mRNAs from their templates, which have negative polarity. In 
addition to its helicase activity, the nsp13 of the human coronavirus, HCV-229E, has also 
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been shown to have nucleoside triphosphatase and RNA 5’ triphosphatase activities 
(Heusipp et al., 1997; Ivanov and Ziebuhr, 2004).  
The mature nsp14, an approximately 60 kDa protein, is cleaved from pp1ab by 
the CL3pro (Xu et al., 2001). Nsp14 contains within its N-terminal half a domain 
predicted to belong to an exonuclease family belonging to the DEDD superfamily of 
proteins (Snijder et al., 2003), and has been shown to be essential to RNA synthesis in 
MHV-A59 infected cells (Sawicki et al., 2005). The 3’ to 5’ exonuclease activity of 
nsp14 has previously been confirmed (Minskaia et al., 2006; Chen et al., 2007), and, 
interestingly, observations that the protein both shares considerable similarities with 
DNA polymerase-associated 3’ to 5’ exonuclease domains and prefers dsRNA substrates 
to ssRNA has led to the supposition that nsp14 may, in fact, act as a proofreading 
exonuclease during coronavirus RNA synthesis (Snijder et al., 203; Minskaia et al., 
2006). Further evidence of this activity has also been reported by Denison et al. (2011), 
via genetic inactivation of the DEDD exonuclease active site, which resulted in viruses 
having 15- to 20-fold increases in mutation rates when compared with virus containing 
nsp14 with a functional DEDD site. If this postulate holds true, the discovery of an RNA 
virus encoding a proofreading enzyme will be a substantial one, as this type of enzymatic 
activity has never before been described for an RNA virus. 
 Yet another protein synthesized as the pp1ab precursor, the mature nsp15 is 
protealytically cleaved by the C3Lpro into an approximately 38 kDa protein product (Xu 
et al., 2001) containing an NendoU (Nidoviral endonuclease specific for U) domain 
sharing considerable similarity to the Xenopus laevis U-specific endonuclease, XendoU, 
that has been implicated in small nucleolar RNA processing (Snijder et al., 2003). 
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Interestingly, this is another example of protein unique to viruses within the Nidovirus 
order, and is present not only in the coronaviruses, but also in the arteriviruses as well 
(Nedialkova et al., 2009). Like the X. laevis endonuclease (Laneve et a., 2003), nsp15 
cleaves uridylate stretches in a Mn 2+ dependent manner to release 2’-3’ cyclic 
phosphodiester products (Bhardwaj et al., 2004; Ivanov et al., 2004; Xu et al., 2006). 
Previous studies utilizing either site-directed mutagenesis or reverse genetic approaches 
have suggested that nsp15 plays a significant role in maximizing viral RNA synthesis, 
although, based on results of these studies, it does not appear to be essential for 
coronaviral replication (Ivanov et al., 2004; Posthuma et al., 2006; Ricagno et al., 2006; 
Kang et al., 2007). However, it is notable that induced mutations resulting in the inability 
of the protein to form hexameric structures, the only form of the protein that is 
catalytically active (Joseph et al., 2007), were lethal (Ivanov et al., 2004; Almazan et al., 
2006), in turn suggesting that nsp15 may actually have an essential role in virus 
replication that has yet to be described. 
Organization of the viral genome 
The coronavirus genome consists of a single, nonsegmented RNA of positive 
polarity with an estimated molecular weight of 6 x 106 to 8 x 106 Da (Lomniczi and 
Kennedy, 1977; Lai and Stohlman, 1978) and averages on the order of 27 to 32 kb, the 
largest viral RNA genomes known (Lai, et al., 2001), a surprising fact given the high 
error rates associated with RNA-dependent RNA synthesis (Holland et al., 1982). The 
genome of coronaviruses is both 5’ capped (Lai and Stohlman, 1981) and 3’ 
polyadenylated (Yogo et al., 1977), and, in the manner of most RNA viruses, replicates 
within the cytoplasm of host cells (Masters, 2006). As a result of its positive polarity, the 
 40
naked RNA itself is infectious and can instigate infection upon transfection or entry into a 
permissive cell, as the genomic RNA itself serves as an initial template for translation of 
the viral RNA-dependent RNA polymerase and other viral proteins involved in the 
replication-transcription complex (Leibowitz et al., 1982; Siddell, 1983).  
At least 10 ORFs have been identified in the genomic RNA of coronaviruses, some of 
which encode a single mRNA species, while others are polycistronic, containing multiple 
ORFs that may or may not overlap. The 5’ UTR is comprised of approximately 200 to 
500 nucleotides, the terminal 60 to 70 nucleotides of which make up the leader sequence 
that is transposed to the 5’ end of each nested mRNA that is produced via discontinuous 
transcription (Lai et al., 1981; Lai et al., 1983; Spaan et al., 1983; Sawicki and Sawicki, 
1990). Additionally, at each intergenic region is a small stretch of consensus sequence, 
termed an acceptor “hotspot”, the donor sequence responsible for internal template 
switching (Zuniga et al., 2004; Sola et al., 2005). Comparison of multiple coronavirus 
genomes has revealed that the gene arrangement is surprisingly conserved, exceptions 
being the genes 3a and 3b and 5 for IBV, which do not have homologues in the group 
1and 2 coronaviruses (Boursnell et al., 1985; Liu et al., 1991; Enjuanes et al., 2000), and 
TGEV, which possibly contains an additional gene at its 3’ end (Kapke and Brian, 1986). 
In addition, many of the group 2 coronaviruses, including MHV and BCoV, contain two 
additional genes encoding the HE protein and a nonstructural protein, p30 (Zhang et al., 
1992). 
The coronavirus lifecycle 
Host cell infection by the coronaviruses is initiated when a virion interacts with 
specific host cell receptors. This interaction is typically virus species-specific, with most  
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coronaviruses exhibiting a very particular and narrow host range, although, as previously 
discussed, there are exceptions to this rule, including BCoV (Zhang et al., 1994; 
Tsunemitsu et al., 1995; Erles et al., 2003; Saif, 2004) and, more recently, SARS-CoV 
(Holmes, 2005). In spite of this, the coronavirus S gp remains recognized as the primary, 
if not sole, determinant of host range and tissue tropism (Kuo et al., 2000), a phenomenon 
that has been demonstrated multiple times for multiple coronavirus species. For example, 
when a usually non-permissive cell line is made to express an identified host receptor 
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protein of a heterologous species, it has been shown that the cell line is then rendered 
permissive to the corresponding coronavirus (Delmas et al., 1992; Yeager et al., 1992; 
Tresnan et al., 1996; Li et al., 2003; 2004; Mossel et al., 2005). Additionally, construction 
of chimeric S proteins has been reported to alter host range in vitro. Specifically, 
transferring the ectodomain of the FIPV S gp to that of MHV rendered the new, chimeric 
virus specific to infection of normally FIPV, but not MHV, permissive cells Kuo et al., 
2000). The reverse of this observation also holds true (Haijema et al., 2003). Likewise, 
replacement of the S gp ectodomain of MHV strain A59 with that of the highly 
neurotropic MHV-JHM strain rendered the otherwise hepatotropic A59 strain highly 
neurotropic (Philips et al., 1999). 
The receptors for many group 1 and group 2 coronaviruses have been identified, 
including the first cellular receptor identified for any virus, that of the widely-studied 
MHV, the murine carcinoembryonic antigen cell adhesion molecule-1 (mCEACAM-1), a 
member of the carcinoembryonic family within the immunoglobulin superfamily 
(Williams et al., 1990; 1991; Compton et al., 1992). However, not all coronaviruses 
utilize the same cellular receptors for entry, as demonstrated by studies with a 
coronavirus infecting a very closely related species, rats. Rat coronavirus (RCoV) and 
Sialodacryoadenitis virus (SDAV) have both been studied for their ability to bind 
mCEACAM-1, as these viruses are capable of growing in some of the same cells lines as 
MHV. Interestingly, what researchers found when using a Mab against mCEACAM-1 
capable of completely blocking infection by MHV was that infection by the rat 
coronaviruses was not hindered at all (Gagneten et al., 1996). This evidence of a 
completely separate cellular receptor for the rat coronaviruses was further supported 
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when BHK cells, which are non-permissive to MHV infection, were transfected with a 
plasmid for the expression of mCEACAM-1. While MHV was now able to infect the 
transfected BHK cells, the rat coronaviruses remained unable to infect this cell line 
(Gagneten et al., 1996). The S and HE glycoproteins of BCoV virus bind 9-O-acetyl 
sialic acid, as demonstrated by the potent ability of both glycoproteins to aggregate 
erythrocytes (Schultze et al., 1991), as well as by the ability to block BCoV infection of 
MDCK cells via pretreatment with neuraminidase or acetylesterase (Schultze and Herrler, 
1992). However, there is a considerable amount of uncertainty as to whether or not the 
BCoV S gp has an additional, more specific, cellular receptor associated with its entry 
into host cells. 
Interestingly, while SARS-CoV is considered to be a member of the group 2 
coronaviruses, it is one of the most phylogenetically distant members of the group. Thus, 
it is perhaps not surprising that this virus utilizes receptors wholly unrelated to the 
CEACAMs. The SARS-CoV S gp recognizes as its cognate receptor the cellular 
metallopeptidase, angiotensin-converting enzyme-2 (ACE-2), a zinc-binding 
carboxypeptidase involved in the regulation of heart function. This receptor was 
identified as the SARS-CoV receptor via development of a SARS-CoV S1-IgG fusion 
protein, which was then used to immunoprecipitate cellular membrane proteins of Vero 
E6 cells, the cell type found to be most permissive to SARS-CoV infection. The binding 
of the SARS S1 fusion protein to Vero E6 cells was then found to be blocked by soluble 
ACE-2, but not by a closely related membrane protein, ACE-1 (Li et al., 2003), evidence 
yet further supported when cloned ACE-2 was expressed in cell lines otherwise non-
permissive to SARS-CoV infection rendered the virus capable of producing syncytia 
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within the transfected cell line (Li et al., 2003; Mossel et al., 2005). Furthermore, studies 
into the neuronal involvement of SARS-CoV in human hosts with transgenic mice 
engineered to express hACE-2 showed that these mice, usually unaffected by SARS-
CoV, were able to support SARS-CoV infection resulting in extensive neuronal cell death 
when inoculated intracranially with the virus, while non-transgenic mice did not succumb 
to lethal infection (Netland et al., 2008). 
Finally, a discussion of CoV cellular receptors would be incomplete without a 
mention of the group 1 coronaviruses, many of which utilize the aminopeptidase N 
(APN) of their respective species to facilitate fusion (Delmas et al., 1992; Yeager et al., 
1992; Tresnan et al., 1992). This protein is a membrane-bound cell surface, zinc-binding 
protease that participates in the proteolysis of small peptides within the respiratory and 
enteric epithelia. It is also located within some human neural tissues, rendering them 
susceptible to infection by the HCoV-229E (Lachance et al., 1998). Although it seems 
that a number of the group 1 coronaviruses utilize this receptor, interestingly, the receptor 
activities of APN homologues are generally not interchangeable across species, that is, 
the hAPN cannot serve as a receptor for TGEV and vice versa (Delmas et al., 1994). 
However, there is a curious exception to this generalization: fAPN has been shown to 
serve as a receptor not only for the very closely related FIPV type II, but also for canine 
coronavirus (CCoV), TGEV, and HCoV-229E (Tresnan et al., 1996). Furthering this 
curiosity is the observation that, while FIPV type II can utilize fAPN as a cellular 
receptor, FIPV type I seemingly cannot, since antibody to fAPN effectively blocks FIPV 
type II infection but not FIPV type I infection (Hohdatsu et al., 1998).  
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The interaction of the coronavirus S gp with its cognate cellular receptor leads 
then to either the pH-independent fusion of host and viral membranes (Gallagher et al., 
1991; Nash and Buchmeier, 1997) or, in the case of virus lacking proper S fusion 
function, the uptake of virus into endocytic vesicles followed by pH-dependent uncoating 
of the virus (Qiu et al., 2006; Simmons et al., 2011); in both scenarios the end result of 
the pathways is the release of the viral nucleocapsid into the cytoplasm of the cell, where 
the positive sense viral genome is then available for translation by host cell ribosomes. 
As a class I fusion protein (Bosch et al., 2003), both virus-cell and cell-cell membrane 
fusion are facilitated by conformational changes of the fusion protein, in this case, the S 
gp, that trigger first the formation of intermediate conformations, followed by the final 
formation of the six-helix bundle conformation (Coleman and Lawrence, 2003; Earp et 
al., 2005). These conformational changes result in exposure of a hydrophobic fusion 
peptide, predicted to reside at the N-terminus of S2 (Sainz et al., 2005), which, when 
inserted into the host cell membrane, brings the two membranes into close apposition as a 
result of the overall changes in conformation, facilitating their fusion (Melikyan et al., 
2000; Russell et al, 2001), events similar to those observed for other class I fusion 
peptides (Baker et al., 1999; Melikyan et al., 2000; Russell et al., 2001). The 
conformational changes are mediated, at least in part, by a region of the protein termed 
the juxtamembrane domain (JMD), an area located in the ectodomain between the 
previously discussed HR2 and the beginning of the transmembrane domain (Coleman and 
Lawrence, 2003). In addition, this JMD may also interact directly with host membranes 
and/or induce membrane destabilization (Guillen et al., 2005; Broer et al., 2006). In fact, 
several synthetic peptides derived from the SARS-CoV S gp JMD have previously been 
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shown to interact directly with synthetic lipid bilayers, resulting in destabilization of the 
liposomes, supporting the hypothesis that the JMD may interact directly with host 
membranes (Sainz et al., 2005; Guillen et al., 2005). Interestingly, the JMDs of other 
enveloped virus families, including the Lentiviruses, Filoviruses, Rhabdoviruses, 
Orthomyxoviruses, and Paramyxoviruses, have been shown to highly variable within 
family in regards to amino acid sequence; in contrast, this domain seems to be highly 
conserved across all three genre of Coronaviruses (Howard et al., 2008). In particular, the 
Coronavirus S gp JMDs contain six highly conserved aromatic amino acids that have 
been shown in SARS-CoV to be of critical importance to the membrane fusion activity 
leading both to virus-cell as well as cell-cell fusion (Howard et al., 2008). It is worth 
noting that, although fusion for many coronaviruses is mediated in a pH-independent 
manner, there are coronaviruses, primarily within group 1, that appear to rely solely on 
acidification within endosomal compartments for membrane fusion, including TGEV 
(Hansen et al., 1998) and HCoV-229E (Nomura et al., 2004). In addition, subtle changes 
in the amino acid residues of the S gp can also have a dramatic effect on the ability of the 
virus to enter host cells via membrane fusion; for instance, studies with MHV S gp have 
shown that changes in as few as 3 amino acids within one of the HRs within S2 were 
capable of rendering the virus unable to enter via membrane fusion, resulting in reliance 
of the virus on receptor-mediated uptake into endocytic vesicles in order to enter host 
cells (Gallagher et al., 1991; Nash and Buchmeier, 1997). 
 Following viral entry into the host cell, ORF1a and 1b are translated to produce 
the enormous polyproteins pp1a and pp1ab, which are co-translationally processed into 
the individual components of the replicase complex by one or more proteases situated in 
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syn within the developing polyprotein (Snijder, 2005). Following translation and 
processing, the viral replicase proteins assemble into membrane-bound replication-
transcription complexes, accumulating at perinuclear regions within the cell and 
associating with double-membrane vesicles (DMV; Gosert et al., 2002; Brockway et al., 
2003; Snijder et al., 2006). These DMVs are thought to be generated via cellular 
autophagy-related processes (Prentice et al., 2004) and may be derived from either late 
endosomal membranes (van der Meer et al., 1999) or the endoplasmic reticulum (Shi et 
al., 1999; Prentice et al., 2004). The assembled replication-transcription complexes then 
serve to synthesize the negative strand intermediates of both progeny genomes as well as 
a set of 3’ coterminal nested subgenomic mRNAs, each of the latter possessing a 5’ 
leader sequence derived from the 5’ end of the genomic RNA template via a process of 
discontinuous transcription (Sawicki and Sawicki, 1995; 1998), joined to the main 
mRNA transcripts at regions termed transcription-regulation sequences (Zuniga et al., 
2004; Sola et al., 2005). The template switch that occurs during the process of 
discontinuous transcription has been likened to the process of copy-choice recombination 
(Jarvis and Kirkegaard, 1991; Lai, 1992; Brian et al., 1997; Nagy and Simon, 1997), as it, 
too, occurs during RNA synthesis and typically requires the pairing of bases between the 
core donor and acceptor sites, the transcription-regulation sequences (Ozdarendeli et al., 
2001; Alonso et al., 2002; Sola et al., 2005). This 5’-proximal genomic “acceptor 
hotspot” has been shown in BCoV to be a surprisingly large 65 nucleotides wide and 
may, in fact, actually be part of a larger yet-to-be-determined 5’-proximal multifunctional 
structure (Wu et al., 2006).   
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As translation of the viral mRNA progresses, resulting membrane-bound proteins 
are co-translationally inserted into the ER, from which they traverse the ER to the ER-
Golgi intermediate compartment (reviewed by Spaan et al., 1988). Of all of the structural 
proteins, M was the first to be shown to play a central role in the coordination of the other 
structural proteins in virion assembly (Holmes et al., 1981; Rottier et al., 1981; Holmes et 
al., 1987), and it, too, travels the secretory pathway as far as the trans-golgi network 
(Swift and Machamer, 1991). In spite of its importance in directing virion assembly, M 
protein is insufficient for the assembly of viral particles, as expression of M proteins 
alone results in its accumulation in the trans-golgi compartment, from whence it is not 
transported to the plasma membrane (Rottier and Rose, 1987; Krijnse-Locker et al., 
1992). By contrast, MHV, IBV, TGEV, and FIPV have all been shown to bud into the 
proximal compartment, the ERGIC (Klumperman et al., 1994; Krijnse-Locker et al., 
1994; Tooze et al., 1984, 1988). This was a curious observation until the role of E was 
better understood, as it plays the second critical part in directing virion assembly and is 
necessary and sufficient for the assembly of virus particles lacking both N and S proteins 
(Bos et al., 1996).   
On the other hand, internal viral structural proteins, namely nucleocapsid protein, 
interact with the newly synthesized, positive strand progeny genomic RNAs, 
encapsidating the genomes and resulting in the assembly of the nucleocapsid (van der 
Most et al., 1991; Fosmire et al., 1992), which then coalesce with the membrane-bound 
viral components at the ERGIC (Anderson and Wong, 1993). As the nucleocapsids bud 
through into this compartment, they obtain a lipid envelope and intact virions are thus 
formed (Krijnse-Locker, 1994). In what is the last step of the infective lifecycle, progeny 
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virions are exported from infected cells by transport in smooth-walled vesicles, also 
known as Golgi sacs, to the plasma membrane, to be released into the extracellular 
environment. In some cases however, for those coronaviruses capable of mediating cell-
cell fusion, a fraction of the processed S gp is not included in virion assembly, but 
eventually makes its way to the plasma membrane, where it facilitates fusion of adjacent 
cell membranes, resulting in the formation of large, multinucleate syncytia (Lontok et al., 
2004). Curiously, a 2004 study of the IBV and other coronavirus S gps has shown that the 
group 1 and 3 coronavirus S gps contain within their cytoplasmic domains an 
intracellular retention signal, responsible for recovering S that has escaped from the 
ERGIC (Lontok et al., 2004). This recognition of this signal results in endocytosis of 
escaped S that has traversed to the plasma membrane, a finding that is in direct apposition 
to the idea that S gps expressed on the surface of host cells result in the formation of 
syncytia (Lontok et al., 2004). Conversely, the researchers report that S gps of the group 
2 coronaviruses, including BCoV, lack this intracellular retention signal within their 
cytoplasmic domain, suggesting that these viruses may then be more adept at cellular 
syncytia formation, in turn allowing progeny virions to spread from cell to cell with 
minimal exposure to extracellular viral surveillance systems. 
Recognition of viruses by the innate immune system 
During the course of evolution, viral pathogens have successfully found a way to 
infect an incredibly diverse range of living organisms, and science has discovered viruses 
that infect species as simple as the single-celled amoeba to those that infect the most 
complex of mammalian hosts. In this context, living organisms have thus, too, evolved to 
protect themselves from these invading pathogens. Evolutionarily speaking, the innate 
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immune system is the oldest system for the detection of and protection against viral 
infection, and, as such, is the first line of defense against invading organisms, including 
viruses. This system consists of a network of germline-encoded “nonspecific” receptors 
called pattern recognition receptors (PRRs; Janeway, 1989) as well as phagocytes such as 
macrophages and dendritic cells responsible for engulfing invading organisms. These 
PRRs all share a few common characteristics: 1) PRRs recognize microbial components, 
pathogen-associated molecular patterns (PAMPs) that are typically highly conserved and 
essential to the lifecycle of that microbe within the host cell. This, in turn, makes it 
difficult for the microbes to alter these components in a effort to evade immune 
surveillance; 2) PRRs are germ-line encoded proteins constitutively expressed within the 
host and are expressed regardless of lifecycle stage; and lastly, 3) PRRs are non-clonal 
and expressed independent of immunologic memory. The PRRs vary with regard to the 
PAMPs that they detect, as not all PRRs interact with all PAMPs, and different PRRs 
activate different signaling pathways, giving what was originally thought to be a non-
specific immune system a certain degree of specificity.  
 There are 3 classes of PRRs that have been described to date: the retinoic acid-
inducible gene-I (RIG-I)-like receptors (RLRs), the Toll-like receptors (TLRs), and the 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs). These 
receptors each have differing signaling pathways with varying downstream targets, 
although for most of those that detect viral PAMPs, the most common end result is the 
expression of genes encoding the type I interferons (IFN), IFN-  and - , an essential step 
in the antiviral response (Medzhitov, 2007). These type I IFNs induce intracellular 
signaling pathways via a type-I IFN receptor, to which IFN-  and  bind, in turn 
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regulating the expression of the IFN-inducible genes. These genes encode antiviral 
products such as protein kinase R (PKR) and 2’5’-oligoadenylate synthase, responsible 
for eliminating viral components from infected cells, as well as eliminating infected cells 
themselves by inducing apoptosis. Furthermore, these products also act on uninfected 
cells to confer resistance to infection by viral pathogens. Additionally, expression of the 
very receptors responsible for inducing downstream IFN production are also, in turn, 
themselves induced by IFN, resulting in a positive feedback loop that creates a local 
cellular response (Stetson and Medzhitov, 2006). Interferon is also responsible in some 
ways for linking the innate and adaptive immune systems (Tough, 2005), as IFN acts to 
directly activate dendritic cells and natural killer cells (Theofilopoulos et al., 2006), as 
well as promotes the survival of T and B cells (Marrack et al., 1999; Braun et al., 2002). 
The NLRs, however, are slightly different in their antiviral mechanism, as these receptors 
are known to induce not IFN production, but instead regulate interleukin 1  (IL-1 ) 
maturation (Kanneganti et al., 2007). 
 The RLRs are a class of PRRs responsible for the detection of cytosolic viruses 
and viral products.  This family of membrane-bound receptors currently consists of three 
members: RIG-I (Yoneyama, et al., 2004) melanoma differentiation-associated factor 5 
(MDA5; Kang et al., 2002) and laboratory of genetics and physiology-2 (LPG-2; 
Takeuchi et al., 2007). The RLRs RIG-I and MDA5 share considerable homology, as 
both contain a DExD/H box helicase domain capable of binding dsRNA and responsible 
for the binding of these RNAs (Kang et al., 2002; Yoneyama et al., 2004), and two N-
terminal caspase recruitment (CARD) domains, which are responsible for initiating 
downstream signaling (Kovacsovics et al., 2002) via CARD-CARD interactions with 
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IFN-  promoter stimulator 1 (IPS-1) located on the outer mitochondrial membrane 
(Kawai et al., 2005; Xu et al., 2005; Kumar et al., 2006 ). In addition, both RIG-I and 
MDA5 also contain repressor domains within their C-terminus responsible for blocking 
signal transduction in the absence of bound ligand (Saito et al., 2007). The RLR LPG-2, 
on the other hand, contains the helicase domain, but lacks the CARD domains seen in its 
fellow RLR family members; thus, it is thought that LPG-2 may play a role as a negative 
regulator (Rothenfusser et al., 2005; Venkataraman et al., 2007). 
 Differences in ligand recognition by PRRs results in a certain amount of 
specificity for the recognition of specific viruses or virus families. Infection of cells with 
RNA viruses results in the production of viral products not typically found in the 
cytoplasm of uninfected cells. For instance, replication of RNA viral genomes, both ds 
and ss by RDRP within the cytoplasm results in long dsRNAs and RNAs containing 5’ 
triphosphates; long dsRNAs are not normal constituents of the cytoplasm of healthy cells 
and most cytoplasmic RNAs of cellular origin are 5’-capped mRNAs. Thus, the immune 
system uses the discrimination of dsRNA versus ssRNA as a means by which to detect 
viral infection. RIG-I has been implicated in the preferential binding of ssRNAs 
containing homopolyuridine or homopolyriboadenine motifs (Saito et al., 2008; Kato et 
al., 2008; Saito et al., 2008) and phosphorylated at the 5’ end (Hornung et al., 2006; 
Pichlmair et al., 2006), while MDA5 has been shown to recognize long dsRNAs that may 
or may not also have 5’ phosphorylation (Gitlin et al., 2006; Kato et al., 2006, 2008). The 
recognition of viral products by these PRRs results in a downstream signaling cascade via 
the adaptor IPS-1 that eventually results in the production of type 1 IFN. In addition, the 
expression of proinflammatory genes is also activated by this pathway, as another 
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downstream target of RLR signaling is the nuclear transcription factor NF- B (Takahashi 
et al., 2006). 
 In addition to the RLR family of PRRs, the TLRs are vital participants in antiviral 
surveillance and signaling by the innate immune system. These proteins are membrane-
bound and contain luminal leucine-rich repeats responsible for detection of PAMPs, as 
well as a cytoplasmic domain designated the Toll/IL-1 receptor homology (TIR) domain, 
responsible for signaling through downstream adaptors (Akira et al., 2006). While RLRs 
are solely intracytoplasmic viral product detectors, the TLRs are capable of detecting 
viral components both outside of cells as well as within cytoplasmic vacuoles following 
phagocytosis or endocytosis (Iwasaki and Medzhitov, 2004). All TLRs, with the notable 
exception of TLR3, activate a common signaling pathway responsible for the production 
of both pro-inflammatory cytokines as well as type I IFN via the signaling adaptor 
protein myeloid differentiation factor 88 (MyD88; Medzhitov et al., 1998).  
 There are currently 10 members of the TLR family that have been identified in 
humans, and 13 that have been identified in mice, although not all of these receptors are 
involved in detection of viral components. Specifically, the TLRs 3, 7, 8, and 9 are 
localized on the luminal membranes of cytoplasmic vesicles such as endosomes and 
within the ER, and are involved in detection of various viral components within cellular 
endosomal compartments (Iwasaki et al., 2004). On the other hand, TLR2, which is 
known to detect a variety of bacterial lipoproteins as well as yeast-associated zymosan, 
and TLR4, traditionally known as a sensor of LPS, are situated on the extracellular 
surface of the plasma membrane and have been implicated in the detection of viral 
envelope proteins expressed on the outer plasma membrane of infected cells (Morrison, 
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2004; Zhang et al., 2007). The TLRs 3, 7, and 8 have been shown to be important in the 
detection of viruses containing genomic RNA: TLR3 recognizes dsRNA (Alexopoulou et 
al., 2001), while TLR7 and 8 are responsible for the detection of ssRNA and 
imidazolequinilone compounds (Diebold et al., 2004; Heil et al., 2004; Lund et al., 2004; 
Beignon et al., 2005). TLR9, on the other hand, is implicated in detection of DNA 
viruses, as it recognizes unmethylated CpG-containing DNA, a common component of 
DNA virus genomes (Bauer et al., 2001). 
Linking the innate and adaptive immune systems 
Although the innate immune system has and continues to serve as an effective 
method of surveillance for would-be pathogenic intruders, its lack of true specificity and, 
arguably more importantly, immunological memory, has necessitated the need for a more 
robust system for recognition of pathogens that have previously been encountered. This is 
especially true in the context of pathogenic microorganisms that provide an almost 
constant onslaught of attack, including the ubiquitous viral pathogens to which exposure 
occurs on virtually a daily basis. Thus, over the course of evolution, more highly evolved 
life forms, namely mammals and cartilaginous fishes, have evolved an immunological 
system capable of, in some cases, extreme specificity as well as memory, conveying the 
ability to very quickly recognize and respond to pathogenic organisms, especially those 
that have already been eliminated once by the immune system some time in the past 
(reviewed by Cooper and Alder, 2006). 
 Although it seems clear that this “adaptive immune system” evolved 
independently of the ancient innate immune system, the adaptive system relies heavily on 
instruction from the innate system for identification of invading microorganisms as well 
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as activation of adaptive responses (Janeway, 1989). One essential link between these 
two systems is the antigen presenting cell (APC), including macrophages and especially 
dendritic cells (DC), the professional APCs of the immune system (Banchereau and 
Steinman, 1998). The uniquely shaped DCs are responsible for “sampling” the 
extracellular milieu via receptor-mediated endocytosis, macropinocytosis, and even 
uptake of apoptotic cell bodies (Sallusto and Lanzavaecchia, 1994; Sallusto et al., 1995), 
actively differentiating self from non-self via a variety of PRRs (Fearon et al., 1996; 
Medzhitov and Janeway, 1997; Muzio et al., 1998).  
First observed in 1868 as Langerhans cells present in the epidermis, DC make up 
a heterogeneous family of leukocytes capable of integrating innate information and 
effectively conveying it to lymphocytes of the adaptive immune system. These cells 
encompass multiple subsets, including Langerhans cells, interstitial DCs, and 
plasmacytoid DCs; it is thought that these subsets may have distinct biological functions 
within the immune system (Ibrahim et al., 1995; Fearon et al., 1996; Banchereau et al., 
1998). For this reason, DC are commonly delineated by their stage of maturation: 
precursor DC patrol the blood and lymphatics, while immature DC reside in the tissues 
where they survey the interstitial spaces for both self and non-self peptide antigens. 
Finally, mature DC can be found within the lymphoid organs where they interact with B 
and T lymphocytes to direct the maturation of these cells (reviewed by Palucka and 
Banchereau, 1999). Tissue resident immature DC are exceptional at capturing antigen, 
which is then directed towards MHC class II-rich late endosomal compartments within 
the cell. Here antigen is loaded onto MHC class II molecules, which subsequently 
relocalize to the cell surface to be displayed for T cell receptor (TCR) recognition. These 
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cell surface complexes can remain stable for days, helping to ensure that CD4+ T cells 
bearing cognate TCRs will come into contact with the DC (Cella et al., 1997; Pierre et al., 
1997; Pierre et al., 1998). While presentation of antigen to CD4+ T cells is vital to 
eventual development of a B cell-mediated antibody response, CD8+ cytotoxic T cells 
are also important in eliminating virus-infected cells. In order to “communicate” with 
CD8+ T cells, however, antigen must be presented by DCs in the context of MHC class I 
(Watts, 1997). This may occur via two potential routes: 1) the DC itself may be infected 
with the virus, in which case viral peptides may be processed in the DC proteosome and 
translocated to the ER, where they are loaded via TAP onto MHC class I molecules for 
presentation at the cell surface (Watts, 1997), or, conversely, 2) viral peptides may 
become available to the DC when they take up apoptotic cell bodies and process the 
resulting self and non-self peptides in a poorly-understood process commonly referred to 
as “cross-priming” (Bhardwaj et al., 1994; Albert et al., 1998; Ridge et al., 1998). 
T lymphocyte priming and activation  
One of the primary and essential functions of DCs is the priming and activation of 
T cells within lymphoid tissues. After the uptake of antigen, DCs undergo migration to 
the lymph nodes under the direction of homing signals, the receptors for which are 
upregulated in DCs that have taken up antigen (Tang et al., 1993; Roake et al., 1995; 
Sozzani et al., 1995; Rubbert et al., 1998; Dieu et al., 1998). While en route to the lymph 
nodes, DCs undergo further maturation from immature antigen-capture cells to cells fully 
capable of antigen presentation and activation of alloreactive T cells (reviewed by Bell et 
al., 1998). This maturation process includes the upregulation of a number of co-
stimulatory molecules required for formation of an effective immunological synapse 
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between the DC and its alloreactive T cell, including adhesion molecules such as the 1 
and 2 integrins, as well as several members of the immunoglobulin superfamily. In 
addition, several receptors, present only in low number on the surface of immature DCs, 
undergo intense upregulation. Amongst these are CD80/86 and CD40, a 50 kDa integral 
membrane protein and member of the TNF-receptor family (Stamenkovic et al., 1989) 
also present on the surface of macrophages (Alderson et al., 1993), and B cells 
(Stamenkovic et al., 1989), as well as on the surface of endothelial cells (Karmann et al., 
1995), the thymic epithelium (Ruggerio et al., 1996), and fibroblasts (Yellin et al., 1995). 
These molecules act as the “second signal” following MHC class II-TCR interaction, 
signals required to avoid induction of T cell anergy following TCR recognition of peptide 
in the context of MHC class II (Caux et al., 1994; Fanslow et al., 1994; Inaba et al., 1994, 
1995). The interaction of the B7 and CD40 co-stimulatory molecules found on mature 
DCs with CD28 and CD154, respectively, found on the surface of T cells, results in the 
activation of the T cell. This in turn induces the upregulation of these receptors on the 
surface of both cell types in a positive feedback loop, an important occurrence, as the 
strength of the immune response is dependent on the density and duration of the 
immunological synapse (Pinchuk et al., 1996). In fact, previous research has shown that a 
minimum of ten peptide-MHC interactions are required in order for an immunological 
synapse to form, and in vivo induction of T cell proliferation has been shown to require 
DCs with at least 2 x 104 peptide-MHC complexes (Henrickson et al., 2008). In addition 
to the activation of T cells that occurs when these cells interact with DCs presenting 
alloantigen, the DCs themselves also undergo further activation, primarily thorough 
signaling resulting from the interaction of CD40 on the surface of the DC with CD154 on 
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the surface of the T cell. The ligation of CD40 on the DC results in further upregulation 
in the expression of CD80, CD83, and CD86 on the surface of the DC, as well as in the 
production and release of cytokines, including IL-1, tumor necrosis factor (TNF), IL-12, 
and various chemokines. The upregulation of these genes results in DCs with even further 
improved ability to interact with, prime, and activate additional alloreactive T cells (Bell 
et al., 1998; Banchereau and Steinman, 1998). 
B lymphocyte regulation and activation 
 Dendritic cells are indirectly responsible for influencing the activation of B cell 
effector functions by activating the CD4+ T cells responsible for providing the T cell help 
that eventually leads to B cell activation and class switching (Banchereau and Steinman, 
1998). In fact, the activation and differentiation of both B and T cells is dependent on the 
cognate interaction of these two lymphocyte classes, with the specificity of the 
interaction determined via interaction of the TCR/CD3 complex on the surface of the T 
cell (Weissman et al., 1989; Cleavers et al., 1998) with peptide presented by B cells in the 
context of MHC class II (Allen, 1987). This is because B cells are capable of acting, in 
some capacity, as APCs, binding specific soluble antigen with high affinity via their B 
cell receptor (BCR), a membrane-bound Ig molecule, and taking it into the cell via either 
pinocytosis or BCR-mediated endocytosis. In fact, B cell antigen affinity has been shown 
to be directly related to the ability of the B cell to effectively present antigen to CD4+ T 
cells (Batista and Neuberger, 1998). However, much like the activation of naïve T cells 
by DC ligand binding, activation of B and T cells as a result of their interaction requires 
the involvement of additional co-receptors, although resting B cells circulating in the 
blood or localized within the lymph nodes do not express the co-stimulatory molecules 
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necessary to accomplish this. The activation required for B cell expression of co-
stimulatory molecules is initiated by signaling as a result of two distinct events: binding 
by the BCR of cognate antigen and ligation of CD40 on the B cell surface by its cognate 
T cell receptor, CD154, expressed on the surface of activated T cells (reviewed by 
Rodriguez-Pinto, 2005). Unlike T cells, in which the ligation of co-stimulatory molecules 
acts primarily to regulate activation of the antigen receptor complex, the BCR and B cell 
co-stimulatory molecules serve, to a greater extent, to help maintain viability of the 
mature and activated B cell. Recognition and binding of antigen by the BCR results in 
extensive crosslinking of neighboring BCRs, required for the initiation of B cell 
activation. This crosslinking induces growth and proliferation of the B cell and ensures its 
survival; in addition, signals resulting from the crosslinking of numerous BCRs also 
result in the expression of a vital co-stimulatory molecule, CD86, important for naïve T 
cell activation (Lenschow et al., 1994; Nashar and Drake, 2005). The ligation of CD40 is 
vital for sustaining B cell activation as well as for promoting enhancement of B cell 
antigen processing (Faassen et al., 1995), upregulation of the expression of MHC class II 
molecules, increased expression of CD86, and induction of the expression of yet another 
co-stimulatory molecule, CD80 (Ranheim and Kipps, 1983; Kennedy et al., 1994; Roy et 
al., 1995; Wu et al., 1995; Mackey et al., 1998; Evans et al., 2000). Thus, although B 
cells are capable of antigen presentation, they require interaction with previously 
activated CD4+ T cells, both in order to engage in this role as well as to become activated 




B lymphocyte and humoral immunity: Affinity maturation and class switching 
Although mature B lymphocytes are capable of binding and presenting antigen, in 
the naïve state they are only capable of doing so with relatively low affinity, binding 
antigen with what is commonly termed “natural IgM”, the BCR (Jerne, 1955; Boyden, 
1966). The specific humoral response that follows this initial recognition of cognate 
antigen is not immediate, requiring a number of days to develop. Furthermore, the Ig 
produced from this initial response is still not of high affinity, but activation of the B cell 
triggers the maturation of the antibody response from relatively low affinity Ig to that of a 
highly specific, high affinity Ig response, maturation that occurs within a somewhat brief 
period of B cell development. Generally late within the humoral response following the 
primary exposure to antigen, the production of antigen-specific antibodies has improved 
dramatically, with resulting Ig not only having marked higher affinity, but also being of a 
different class other than the IgM involved in the initial antibody response. This increase 
in antigen affinity is the result of a process known as “affinity maturation”, in which 
specific “hotspots” within the BCR undergo hypermutation, carried out by the enzyme 
activation-induced cytidine deaminase (AID; Muramatsu et al., 2000).Thus, as antigen 
become increasingly limiting, those clones expressing BCRs with higher affinity will 
have a selective advantage and preferentially be selected for survival and proliferation 
(reviewed by Wabl and Steinberg, 1996). In addition to the somatic hypermutation that 
results in the production of B cells capable of expressing Ig receptors having high 
affinity, a second set of molecular modifications occur that result in the production of 
soluble Ig versus the membrane-bound IgM responsible for the initial antigen 
recognition. In the process of class switching, the segments that make up the gene 
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encoding the Ig itself undergo rearrangement, such that the Ig heavy chain constant 
region (CH) is rearranged for expression from other CH regions such as C , C , C , or C , 
instead of from the Cμ, which encodes IgM (reviewed by Zhang et al, 1995). This results 
in the production of soluble, highly specific antibody that can be targeted to specific sites 
or biologic functions within organism.  
Development of immunological memory: Memory B cells and plasma cells 
While the development of a robust primary antibody response marked by affinity 
maturation and class switching is vital to eventual clearance of infectious pathogens, as 
evidenced in individuals with hyper M syndrome (Levy et al., 1997), it is the 
establishment of immunological memory that sets the adaptive immune response apart as 
an effective and efficient protector from these would be invaders. While the initial 
antibody response is quite slow, requiring as many as 10 to 12 d post-exposure in most 
cases to develop, and composed primarily of IgM having a relatively low affinity for 
antigen, secondary exposure to antigen results in a response that is markedly quicker and 
exhibits the secretion of primarily IgG antibody with a considerably increased affinity for 
cognate antigen. This improvement in response time is explained in part by the clonal 
selection theory (Burnet, 1957), which simply states that an initial exposure to antigen 
leads to the clonal expansion of those B cells possessing a specific cognate BCR capable 
of recognizing said antigen. Thus, at the time of secondary of exposure, there are simply 
an increased number of circulating B cells possessing the same BCR and capable of now 
recognizing and binding antigen. That being said, clonal selection is insufficient to fully 
explain the quality of the secondary antibody response, a function of the affinity 
maturation discussed in the previous section. A strong memory response, then, is incurred 
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when B cell clones not only divide and expand in response to antigen, but when the 
mature with respect to both the affinity for antigen of the antibodies they produce as well 
as the type of antibody being secreted, thus resulting their maturation to and selection as 
memory B cells (reviewed by Neuberger et al., 2000, Gass et al., 2004). Interestingly, 
maturation to memory B cells results in cells that do not secrete antibody (McHeyzer-
Williams and Ahmed, 1999), but that are surprisingly long-lived even in the absence of 
antigen (Maruyama et al., 2000) and capable of undergoing rapid and massive expansion 
in response to secondary exposure to antigen, in some cases generating an 8- to 10-fold 
increase in the population (McHeyzer-Williams and Ahmed, 1999). 
 There is, however, a second part to this phenomenon of immunological memory: 
the development of a circulating population of cells with the sole responsibility of 
producing significant levels of high-affinity secretory antibody. These cells are known as 
plasma cells, and are essentially B-cells that have terminally differentiated and exist in a 
post-mitotic state, as these end-stage cells do not divide. Although no plasma cells are 
produced following a primary antigen encounter, memory B cells in the bone marrow and 
spleen are biased to develop into plasma cells following a secondary encounter of antigen 
(Arpin et al., 1997). The lifespan of these cells can vary from only a few days to 
numerous months, a span of time that appears to be determined in some regard by their 
developmental history and the ability of the spleen to support them (Sze et al., 2000). 
Plasma cells are essentially cellular factories whose sole purpose is high-level secretion 
of soluble antibody. As such, these cells have high rates of transcription and translation, 
supported by significantly increased cytoplasmic to nuclear ratio and a pronounced 
increase in the amount of ER and secretory vesicles (reviewed by Gass et al., 2004). 
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Following the secondary antigen stimulation resulting in their differentiation, plasma 
cells, especially those that home to the bone marrow, are capable of secreting antibody 
for many months, resulting in the levels of circulating antibody that may persist long after 
the secondary exposure event. Interestingly however, these cells do not respond to further 
antigenic stimulation (Slifka, 1998). 
CD154 as an immunomodulator in vaccination  
 As discussed previously, the role of the CD40-CD154 interaction in development 
of the adaptive immune response has been clearly established. Present primarily on the 
surface of activated CD4+ T cells (Roy et al., 1993), but also found on the surface of 
CD8+ T cells (Hermann et al., 1995; Sad et al., 1997), eosinophils (Gauchatet al., 1995), 
mast cells (Gauchat et al., 1993), and natural killer (NK) cells (Carbone et al., 1997), 
CD154 is a 39 kDa type II integral membrane protein and a member of the TNF 
superfamily (reviewed by Grewal and Flavell, 1998; van Kooten and Banchereau, 2000). 
CD154 ligation with CD40 on DCs results in production of signals required for the 
activation and survival of both DC and T cells (Banchereau et al., 1998), while ligation of 
CD154 with CD40 on the surface of B cells influences the maturation of B cells, inducing 
the secretion of various cytokines as well as the process of class switching (Burden et al., 
1996), processes vital to the induction of a robust humoral immune response. The use of 
CD154 as an immunomodulator, or adjuvant, in vaccine therapy has its roots in the 
observation that antigens linked to or administered in conjunction with molecules 
targeting them to APCs generally increases the response of the immune system versus 
administration of the antigen alone (Chaplin et al., 1999; Deliyannis et al., 2000). 
Examples include the use of CTLA-4 and L-selectin (Drew et al., 2001), as well as 
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plasmids expressing cytokines such as IL-18 (Reddy et al., 2010). The development of 
methods for production and expression of recombinant fusion proteins and cDNA 
vaccines for the expression of these proteins has paved the way for the use of CD154 
fusion to a plethora of antigens as potential vaccines. The idea is that CD154 fused to the 
expressed recombinant protein will target the relatively small quantities of expressed 
antigen specifically to APCs within the tissues in which they are expressed, resulting in 
significantly more efficient antigen uptake and presentation, in turn eliciting a faster and 
potentially more robust immune response (Manoj et al., 2004). Although there have been 
some reports that this method for immunomodualtion is ineffective (Manoj et al., 2004; 
Maue et al., 2004), Zhang and colleagues reported that incorporation of human CD154 
into simian immunodeficiency virus (SIV)-human immunodeficiency virus (HIV) 
chimeric (SHIV) virus-like particles (VLP) enhanced SHIV-VLP induced dendritic cell 
activation, effectively boosting immune responses against HIV (2010). Likewise, Manoj 
and colleagues reported that fusion of the gene encoding bovine CD154 to that encoding 
a truncated version of BHV-1 gD and inserted into a plasmid for use as a cDNA vaccine 
effectively targeted the expressed fusion protein to APCs, eliciting a significantly 
enhanced antibody response versus animals vaccinated with a cDNA plasmid expressing 
only the truncated portion of BHV-1 gD (2003). In another set of studies in the design of 
a vaccines for use in domestic waterfowl, immunotargeting via the duck homologue of 
CD154 effectively enhanced humoral immune responses to both duck hepatitis V core 
antigen in pekin ducks (Gares et al., 2006) as well as a cDNA vaccine against avian 
influenza virus using the HA subtype H5 protein (Yao et al., 2010), providing evidence 
that the use of CD154 as an immunomodulator is not limited to use only in mammalian 
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species, but may be extended to application within a wide range of species for which the 
gene encoding CD154 has been identified. 
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The greatest health-associated impact on beef cattle profitability is Bovine 
Respiratory Disease (BRD), commonly known as “shipping fever”, a disease complex 
typically associated with multiple etiologies (Smith, 1998). Predisposing factors 
commonly associated with the risk of BRD development include stress associated with 
fasting and transport, introduction of microbial pathogens via stressful comingling of 
calves, rapid environmental and weather changes, age, and sudden nutritional alterations 
(Callan and Garry, 2002; reviewed by Cusack et al., 2003).  
Of the numerous microbial agents known to contribute to the development of 
BRD, one of the most consistently isolated is Bovine Respiratory Coronavirus (BRCoV; 
Storz et al., 1996; Storz et al., 2000a,b), although this virus is not solely responsible for 
development of BRD, as a number of other viruses have also been implicated in the 
development of the disease complex, including BVDV, BHV-1, BRSV, and PI-3. 
Furthermore, previous research has strongly suggested that respiratory virus infection 
alone is insufficient for the development of BRD (Martin et al., 1998), although these 
infections are generally thought to play a pivotal role in potentiating development of the 
complex (Dunn et al., 1991). The development of BRD is generally thought to follow a 
common progression involving viral-bacterial synergism (Jericho and Langford, 1978), 
starting with some form of immune suppression and followed by exposure to respiratory 
viral pathogen, either in the environment, or, most commonly, carried by other animals 
and spread during the comingling of animals from different farms during shipping to 
feedlots (Lathrop et al., 2000). The viral infections are typically followed by 
 94
opportunistic overgrowth of commensal bacterial species (Lopez et al., 1976) commonly 
inhabiting the nasopharynx of healthy animals, some of the most commonly isolated 
being Mannheimia haemolytica and Pasteurella multocida (Allen et al., 1991). 
Coronaviruses belong to the Coronaviridae family of viruses (Cavanagh et al., 
1994, 1995) within a relatively newly established order, Nidovirales. Coronaviruses are 
large, approximately 120 nm in diameter pleomorphic virions possessing a cell 
membrane-derived bi-layer lipid envelope (Pike and Garwes, 1977), from which project 
numerous prominent, 17-20 nm petal-shaped spikes (McIntosh, 1974), glycoproteins (gp) 
composed of heavily glycosylated class I fusion proteins anchored within the lipid 
envelope of the virion. These viruses contain linear, non-segmented, positive sense, 
single stranded genomic RNA, and possess the largest genomes of the RNA viruses, up to 
30 kb for some coronavirus species. Coronaviruses have an impressive host range, 
infecting a wide variety of mammalian and avian hosts, although host range for each 
species of virus is typically narrow and well defined, although exceptions to this general 
rule do exist. For instance, BCoV has been well-documented in its ability sporadically 
engage in cross-species transmission (Saif, 2004), as viruses very closely related to 
BCoV have been isolated from wild ruminants (Tsunemitsu et al., 1995), domestic dogs 
(Erles et al., 2003), and, in one case, a human child (Zhang et al., 1994). One would be 
remiss in failing to mention the species jump made by the SARS-CoV from its unknown 
natural reservoir to the palm civet, and from the palm civet to humans (Li et al., 2006).   
Although it has been identified as an important factor in the development and 
progression of the BRD complex, there is currently no effective vaccine for protection 
against BRCoV infection or the development of BRD, as this disease complex continues 
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to be a major threat in feedlot environments, in spite of considerable use of various 
vaccines against other viral agents of BRD (Van Donkersgoed, 1992). There are, 
however, vaccines commercially available for the prevention of infection by the 
enteropathic strain of the virus, bovine enteric coronavirus (BECoV), and some research 
purports that the two strains of BCoV are, in fact, antigenically related and cross-reactive 
(Hasoksuz et al., 1999), suggesting that a single vaccine developed against BECoV, if 
administered nasally, may be protective against the respiratory strain of the virus (Decaro 
et al., 2009; Plummer et al., 2004; Cho et al., 2001). However, additional research needs 
to be performed to this end, as other researchers have reported that, although BECoV and 
BRCoV are almost genetically indistinguishable, the two strains have distinct differences 
in the amino acid sequences, especially for the gene encoding the spike glycoprotein (S; 
Chouljenko et al, 2001), which is a major antigenic site containing important epitopes for 
recognition of neutralizing antibody (Deregt et al., 1989). Furthermore, the majority of 
vaccines commonly used in feedlots for the prevention of BRD have proven to be 
ineffective against the development of respiratory disease in feedlot animals (Martin, 
1983). In addition, IgA-associated mucosal immunity, which would be the primary 
response to a vaccine administered via the intranasal (IN) route, is in most cases not 
associated with effective long-term protection from viral infection (reviewed by 
Holmgren and Czerkinsky, 2005), thus necessitating the need for the development of a 
BRCoV-specific vaccine that results in the development of, preferably, a long-lasting 
IgG-associated immune response.  
The concept of using DNA for vaccine purposes is not a new one, and in many 
cases it is thought that DNA may be superior in this capacity to both killed virus and live, 
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attenuated virus vaccines. Firstly, DNA poses no risk of infection as long as infectious 
viral DNA genomes are not used for vaccination. This is especially important when 
considering the use of live, attenuated RNA viruses for vaccination purposes. As a result 
of the use of virus-encoded RDRP for replication purposes, these viruses are notoriously 
unstable, as this polymerase lacks for the most part any proofreading capability. This is 
especially true of RNA viruses with particularly large genomes, such as coronaviruses, 
although some evidence exists suggesting that the coronavirus-encoded RDRP may 
possess some proofreading capability (Denison et al., 2011), providing the virus some 
degree of fidelity during genome replication. However, as a result of RDRP-directed 
replication, even these viruses still undergo a considerable amount of mutation while 
replicating within even a single host (Holland et al., 1992; Duarte et al., 1994; Lauring 
and Andino, 2010). In fact, within one host exist a variable mélange of viral quasispecies, 
rather than a single virus strain. Thus, attenuated RNA viruses are inherently capable of 
reverting to wild type, as has been shown with the live, attenuated oral Sabin vaccine 
strain of poliomyelitis (Dunn et al., 1990; Abraham et al., 1993). Secondly, because they 
contain no viral replicative component, DNA vaccines pose no risk of persistence or the 
establishment of latency. Although they have shown to be effective, the use of 
adenoviruses as vaccine vectors has been questioned due to the fact that these DNA 
viruses are capable of undergoing additional rounds of replication following the initial 
infection within the host (Imler, 1995). As such, these viral vaccine vectors have the 
potential to recrudesce, resulting in infection of the host. Additionally, DNA vaccines are 
relatively easy to construct, and can be designed and manufactured with considerable 
ease, requiring the use of common cloning techniques, essentially every day molecular 
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laboratory applications. Furthermore, these DNA vaccines are fairly inexpensive to 
design and produce and remain stable during transport and storage. Finally, contributing 
to their overall efficacy is the ability of DNA to essentially self-adjuvant. Recognition of 
foreign DNA by Toll-like receptors of the innate immune results in interferon release and 
recruitment of antigen presenting cells such as dendritic cell and macrophages, which are 
then available for capture of recombinant viral antigen resulting from expression of the 
DNA vaccine plasmid taken up by cells surrounding the vaccination site. 
CD154, also known as CD40 ligand (CD40L) is present primarily on the surface 
of activated CD4+ T cells (Roy et al., 1993), but also found on the surface of CD8+ T 
cells (Hermann et al., 1995; Sad et al., 1997), eosinophils (Gauchatet al., 1995), mast 
cells (Gauchat et al., 1993), and natural killer (NK) cells (Carbone et al., 1997). This 
integral membrane protein is a 39 kDa type II integral membrane protein and a member 
of the TNF superfamily (reviewed by Grewal and Flavell, 1998; van Kooten and 
Banchereau, 2000). CD154 ligation with CD40 on DCs results in production of signals 
required for the activation and survival of both DC and T cells (Banchereau et al., 1998), 
while ligation of CD154 with CD40 on the surface of B cells influences the maturation of 
B cells, inducing the secretion of various cytokines as well as the process of class 
switching (Burden et al., 1996), processes vital to the induction of a robust humoral 
immune response. The use of CD154 as an immunomodulator in vaccine therapy has its 
roots in the observation that antigens linked to or administered in conjunction with 
molecules targeting them to APCs generally increases the response of the immune system 
versus administration of the antigen alone (Deliyannis et al., 2000). The development of 
methods for production and expression of recombinant fusion proteins and cDNA 
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vaccines for the in vivo expression of their protein products has paved the way for the use 
of CD154 fusion to a plethora of antigens as potential vaccines, the idea being that 
CD154 fused to the expressed recombinant protein will target the relatively small 
quantities of expressed antigen specifically to APCs within the tissues in which they are 
expressed. This in turn should result in significantly more efficient antigen uptake and 
presentation, in turn eliciting a faster and potentially more robust immune response 
(Manoj et al., 2004). Furthermore, by not only increasing the potential number of 
secondary signals available for both T and B cell stimulation, but by also mimicking the 
development of the immunological synapse by clustering both the primary MHC-TCR or 
TCR-BCR signals and secondary CD40-CD154 signals together in one location, the 
likelihood that all signals necessary for DC, T cell, and B cell activation will be received 
may be increased. 
Our goal in this study was to develop an effective, robust IgG-stimulating vaccine 
against BRCoV. In addition, we wanted to compare the ability of soluble antigens alone 
in eliciting a strong, protective neutralizing antibody response to that of the 
immunostimulatory effects that have been previously reported for antigens fused to 
CD154. To this end we chose to compare two prime-boost vaccination strategies: one 
using DNA expressing either the soluble portion of the BRCoV S gp either alone and 
boosted with the same purified recombinant protein expressed in a baculovirus system 
compared with a DNA vaccine expressing the same portion of the S gp fused to the 
soluble portion of bovine CD154 boosted with its respective purified protein, also 
expressed via a baculovirus system. 
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Materials and methods 
Construction of a plasmid vector for transient expression of the extracellular 
domain of the BRCoV S glycoprotein (Sopt) 
The DNAworks program (Hoover and Lubkowski, 2002) was used to design 
synthetic oligonucleotides to be utilized in a PCR-based system for the generation of a 
codon-optimized BRCoV S glycoprotein (Sopt) corresponding to the S sequence of 
isolates obtained from a calf having succumbed to fatal pneumonia during a bovine 
shipping fever epizootic (Chouljenko et al., 2001). Since the S gps  differ between the 
pneumopathogenic and enteropathogenic strains by only seven amino acids, the codon 
optimized respiratory and enteropathic S gps were first constructed via PCR-assisted 
overlap extension (Aiyar, Xiang, and Leis, 1996). The BCoV-Lun Sopt 3xFL and BCoV-
Ent Sopt 3xFL plasmids were then generated by cloning the respective codon-optimized 
BCoV S gene, either BCoV-Lun Sopt or BCoV-Ent Sopt, lacking the DNA sequence 
coding for the signal peptide, into the p3XFLAG-CMV-9 plasmid vector (Sigma, St. 
Louis, MO).  
Cells 
African green monkey kidney (Vero) cells were obtained from the American 
Type Culture Collection (Rockville, MD) and were propagated and maintained in 
Dulbecco’s Modified Eagle Media (DMEM; Invitrogen, Carlsbad, CA) containing 
sodium bicarbonate, 25 mM HEPES (Invitrogen, Carlsbad, CA), and 10% heat-
inactivated fetal bovine serum (FBS). 
Cells of the 18-G clone of a human rectal tumor cell line (HRT-18G) were 
obtained from the American Type Culture Collection (Rockville, MD) and propagated 
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and maintained in Dulbecco’s Modified Eagle Media (DMEM; Invitrogen, Carlsbad, CA) 
containing sodium bicarbonate, 25 mM HEPES (Invitrogen, Carlsbad, CA), and 10% 
heat-inactivated FBS. Cells were maintained at 37° C in a 5% CO2 atmosphere. 
SF9 cells, derived from Spodoptera frugiperda (Fall Armyworm) IPLB-Sf21-AE 
cells, were obtained from Invitrogen (Carlsbad, CA). Cells were propagated and 
maintained in serum-free SF900-II SFM (Invitrogen, Carlsbad, CA) containing 1% 
penacillin-streptomyacin solution (Invitrogen, Carlsbad, CA), either as attached cells in a 
monolayer or as a suspension culture. Cells were maintained at 29° C in a 0% CO2 
atmosphere. 
Virus 
A respiratory coronavirus isolate, BCoV-Lun, was obtained from a calf having 
succumbed to fatal pneumonia during a bovine shipping fever epizootic (Chouljenko et 
al., 2001). A viral stock was propagated from virus stored at -80°C by inoculation onto 
the G clone of an HRT-18 cell line, derived from human rectal tumor cells (Thompkins et 
al., 1974; Storz et al., 1996). The viral stock was maintained for a low number of 
passages through HRT-18G cells in culture. Passage 6 viral stock, 0.5 mL, was 
inoculated onto a tightly confluent monolayer of HRT-18G cells in 2 x T150 flasks and 
rocked at room temperature for 1h to permit virus adsorption onto monolayer. Cells were 
then incubated at 37°C for the remainder of the infection period. Approximately 48 h 
following initial infection, cytopathic effects were evident as numerous clumps of dead 
and dying cells were observed in the cell culture supernatant, indicative of successful 
infection for this strain of BCoV. Cells were harvested by submitting cell cultures in T150 
flasks to single freeze-thaw cycle at -80° C. The resulting cell suspension was then 
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sonicated to further release any remaining cell-associated viral particles and clarified via 
low-speed centrifugation at 1,000 rpm for 10 min. The resulting supernatant was then 
separated from the debris pellet, and the viral stock was then aliquoted and stored at  
-80°C.  
Recombinant protein production 
The Bac-to-Bac Baculovirus protein expression system (Invitrogen, Carlsbad, 
CA) was used to produce two versions of the truncated, soluble portion of the Bovine 
Respiratory coronavirus (BRCoV) codon-optimized spike glycoprotein (Sopt): the 
soluble portion of Sopt, from amino acid 19 through amino acid 1296 (an EcoRV site; 
Sol-Sopt), and the second consisting of the same fragment fused after amino acid 1296 to 
the soluble portion of bovine CD154 (Sopt-CD154). These proteins were designed to 
contain a 5’ 3X Flag sequence and a 3’ 9-histidine tag for detection and purification 
purposes, respectively, and were over-expressed in SF9 insect cells infected with 
recombinant baculovirus carrying the appropriate expression cassette, either that of Sol-
Sopt or Sopt-CD154. Briefly, SF9 cells were seeded into SF900-II cell culture media 
(Invitrogen, Carlsbad, CA) at a density of 2x106 cells/ mL and infected with recombinant 
baculovirus carrying the expression cassette for either Sol-Sopt or Sopt-CD154 at an 
MOI of 5. Cell suspension cultures were maintained at 27°C in an orbital incubator. Cell 
supernatants were harvested approximately 72 h post-infection, and soluble protein 
present in the supernatant was isolated and purified via two rounds of cobalt-based 
immobilized metal affinity chromatography (IMAC) using the Talon Metal Affinity resin 
(ClonTech Laboratories, Inc., Mountainview, CA). Briefly, SF9 cell cultures were 
decanted into 50 mL centrifuge tubes and centrifuged at 3000 rpm for 10 min at 27°C. 
 102
The resulting supernatant was then decanted into clean 50 mL centrifuge tubes and 
placed on ice, while the cell pellets were stored at -80°C. A 20% Igepal  CA-630 
(Sigma, St. Louis, MO) solution was then added to each supernatant for a final 
concentration of 1% Igepal (v/v) and inverted to gently mix. Supernatants were then 
centrifuged for 30 min at 8,000 rpm at 4°C. The resulting supernatants were then 
decanted into new 50 mL centrifuge tubes and Talon Metal Affinity resin (ClonTech 
Laboratories, Inc., Mountainview, CA) was added 1:100 (v/v) to each aliquot. 
Supernatants were then rocked overnight at 4°C to allow binding of His-tagged proteins. 
Following overnight incubation, supernatants were centrifuged at 4,000 rpm at 4°C. The 
resulting supernatant was decanted from the pellet, which consisted of the affinity resin 
bound to His-tagged proteins. Beads were then washed 4 times with native wash buffer 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, pH 7.4). Bound proteins were then 
eluted twice with 0.5 mL each of native elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
250 mM Imidazole, pH 7.4) and stored at -80°C until further analysis. The purified 
proteins were verified via expected size using western immunoblot analysis, using mouse 
anti-flag antibody (Sigma, St. Louis, MO) as the primary detection antibody. The purified 
protein concentration was then determined using the Pierce BCA protein quantification 
assay (Thermo Fisher Scientific, Inc., Rockford, IL), according to manufacturer’s 
instructions. 
Immunofluorescence assay 
In order to determine viral titer, an immunofluorescence assay (IFA) was 
performed. Briefly, HRT-18G cells were cultured overnight in 6-well tissue culture plates 
to obtain a confluent monolayer. Serial 10-fold dilutions of virus from 10-2 to 10-6 were 
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prepared in DMEM and 1 mL of these dilutions used to infect individual wells. Plates 
were then rocked at room temperature for 1h to permit virus adsorption onto monolayer. 
The cell culture medium was then removed from each well, and wells washed twice with 
PBS. Fresh cell culture medium was then added to each well and plates incubated at 
37°C. After 12h culture medium was removed and cells washed with two volumes of 
PBS, followed by 1mL ice-cold methanol to fix cells. Cells were incubated in methanol 
for 15 minutes, followed by washing with ice-cold PBS containing 2% bovine serum 
albumin (BSA). Wells were then blocked for 1h with PBS containing 2% BSA. To each 
well was then added the anti-BCoV spike hyperimmune rabbit serum, obtained as 
discussed previously, diluted 1:2500 in PBS containing 2% BSA and incubated 2h at 
room temperature with rocking. Cells were then washed twice with PBS containing 2% 
BSA. Alexafluor 488-conjugated goat anti-rabbit secondary antibody (Invitrogen, 
Carlsbad, CA) diluted 1:500 in PBS containing 2% BSA was added to each well and 
incubated at room temperature for 1h with rocking. Infected cells were then visualized 
and counted via an Olympus fluorescence microscope at an excitation of 488 nm in order 
to determine the number of infectious virus particles per mL.  
Screening of BCoV-negative calves 
Veinipuncture was performed on 128 crossbred calves ranging from 7 to 5 mo of 
age using red top Vacutainer tubes. Blood was allowed to stand for a minimum of 1h, 
followed by centrifugation at 4,000 rpm for 20 min. The resulting serum supernatant was 
removed from the red blood cell pellet and aliquoted into 1 mL and 4 mL aliquots. Sera 
were then centrifuged a second time at 10,000 rpm for 10 min to remove any remaining 
erythrocytes. Sera samples were then stored at  
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-80° C until analysis. 
To perform the ELISA screening assays, BCoV-Lun virus grown in HRT-18G 
cells and HRT-18G cell lysates were prepared by submitting cell cultures in T75 flasks to 
two freeze-thaw cycles at -80° C. The resulting cell suspension was then clarified via 
centrifugation at 4,000 rpm for 30 min., followed by filtering through a 0.45 nm filter. 
BCoV-Lun and HRT-18G cell lysates were then adsorbed onto 96-well NUNC plates 
overnight at 4° C as follows: wells A1 through D12 were each coated with 100 μL 
BCoV-Lun stock diluted 1:10 in ELISA coating buffer, pH 9.6, while wells E1 through 
H12 were coated with HRT-18G cell lysate diluted 1:10 in ELISA coating buffer (100 
mM Na2CO3, 100 mM NaHCO3, pH 9.6).  Wells were then washed 4 times with ELISA 
wash buffer (25 mM Tris, 0.15 M NaCl.0.05% Tween-20) and each well blocked with 
100 μL PBS containing 5% goat serum for 1h at room temperature. Wells were then 
washed 4 times with ELISA wash buffer. Serum samples were diluted 1:500 in PBS 
containing 5% goat serum and 100 μL added to wells in duplicate. Serum samples taken 
from cows previously vaccinated and boosted with a commercially available BCoV 
vaccine were used as high and low positive controls, while gamma-irradiated FBS ( i-
FBS) was used a negative control. Following overnight incubation with rocking at 4° C, 
wells were washed 4 times with ELISA wash buffer. Secondary rabbit anti-cow IgG 
heavy and light chain antibody conjugated to alkaline phosphatase (ALP; AbCam, 
Cambridge, MA) was diluted 1:1000 in PBS containing 5% goat serum and 100 μL 
added to each well. Following 2 h incubation at room temperature with rocking, wells 
were again washed 4 times with ELISA wash buffer. To each well was then added 50 μL 
p-nitrophenyl phosphate (p-NPP) and wells incubated bench top for 45 min, followed by 
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the addition of 50 μL 0.75 M NaOH to stop the reaction. Absorbances were read at 405 
nm on a SpectraMax M2 Multimode Plate reader (Molecular Devices, LLC, Sunnyvale, 
CA). Based on OD405 values obtained for the positive and negative controls, a cut-off 
value of 0.2 was set, and all calves with an OD405  0.2 were selected for a second round 
of screening. 
In an attempt to increase the sensitivity of the assay, a second round of screening 
was designed. As described previously, plates were coated with both BCoV and HRT-
18G cell lysates, each diluted 1:10 in ELISA coating buffer, pH 9.6. Serum samples were 
diluted 1:10, 1:250, and 1:500 in PBS containing 5% goat serum and 100 μL of each 
added to wells in duplicate per dilution. The assays were then completed as described 
previously, including treatment with the same secondary antibody. Absorbances were 
then again read at 405 nm on a SpectraMax M2 Multimode Plate reader (Molecular 
Devices, LLC, Sunnyvale, CA). Absorbance values obtained for serum on wells coated 
with HRT-18G cell lysate alone were then subtracted from those obtained for serum on 
wells coated with BVC-Lun, and seronegative animals were designated as those animals 
with an OD405 for the 1:10 serum dilution < 0.2, as the negative control for each plate 
read was < 0.1, while the positive control was  0.55.  
Experimental vaccine protocol 
Crossbred calves (n=18) weighing, on average, 283.5 kg, previously screened and 
found to be seronegative for anti-BCoV antibodies were obtained from the LSU 
AgCenter Reproductive Biology Center in St. Gabriel, LA and delivered to the LSU 
AgCenter Infectious Disease Isolation Facility (IDIF). Upon arrival on d -7, calves were 
weighed and blood collected using 10 mL Vacutainer tubes (BD, Franklin Lakes, NJ), 
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then allotted by sex, 2 steers and 1 heifer per treatment, to one of the following treatment 
groups: Sol-Sopt vaccinated/uninfected (n=3), Sol-Sopt vaccinated/BCoV-Lun infected 
(n=3), Sopt-CD154 vaccinated/uninfected (n=3), Sopt-CD154 vaccinated/BCoV-Lun 
infected (n=3), Mock vaccinated/uninfected (n=3), or Mock vaccinated/BCoV-Lun 
infected (n=3). Calves were housed 3 per room in negative-pressure, temperature 
controlled isolation rooms with rubber-coated concrete flooring and fed a formulated, 
commercially available complete ration once daily. Blood was collected from each 
animal on d -7, d 0, and every 7 d afterwards for a total of 49 d. Rectal temperatures were 
obtained for each animal on d 0 and every 7 d afterwards until trial termination on d 49. 
Nasal swabs were collected for each animal on d 28, 35, and 42 of the experiment and 
stored in DMEM containing 0.2% Primocin (InvivoGen, San Diego, CA) and Nystatin 
(24,000 U/mL; Sigma, St. Louis, MO) stored at -80°C until analysis. Likewise, fecal 
samples were collected on d 28, 35, and 42 and stored at -80°C until analysis. All animal 
protocols and procedures were approved by the Louisiana State University Agricultural 
Center Animal Care and Use Committee (IACUC approval no. A2011-09) and all 
recombinant DNA and infectious agent procedures were approved by the Louisiana State 
University Inter-Institutional Biological and Recombinant DNA Safety Committee. 
DNA vaccine production 
The codon-optimized BRCoV spike glycoprotein (Sopt) truncated at nucleotide 
3888 and cloned into the pFastBac Dual shuttle vector (Invitrogen, Carlsbad, CA) was 
used to generate two versions of a DNA vaccine: one encoding only the soluble portion 
of the S gp (Sol-Sopt), and one encoding the same soluble portion of the S gp fused in 
frame with the soluble portion of the bovine CD154 molecule (Sopt-CD154; GenBank 
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accession Z48469.1). Polymerase chain reaction utilizing primers specific for each of the 
two cDNA fragments, Sol-Sopt and Sopt-CD154, and Taq Polymerase (Invitrogen, 
Carlsbad, CA) were then used to amplify the respective cDNA, resulting in cDNA 
fragments with overhanging adenosine residues. These overhanging adenosine residues 
were then used for TOPO TA ligation to clone the resulting PCR fragments into the 
mammalian expression vector pcDNA3.1 using the pcDNA™3.1/V5-His® TOPO® TA 
Expression Kit (Invitrogen, Carlsbad, CA). The resulting plasmids were designated 
pcDNA-Sol-Sopt and pcDNA-Sopt-CD154. Plasmid sequences and correct insert 
orientation were then verified via sequencing on an ABI Prism 377 DNA sequencer (PE 
Applied Biosystems). To verify expression of the Sol-Sopt and SoptCD154 recombinant 
proteins by the mammalian expression vector in mammalian cells, Vero cells were 
cultured overnight in 6-well tissue culture plates to approximately 95% confluence. Cells 
were then transfected in duplicate with 4 μg of either pcDNA-Sol-Sopt or pcDNA-Sopt-
CD154 per well via Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) 
according to manufacturer’s specifications. A mock transfection was also performed in 
which cells received PBS containing no plasmid DNA. After 72 h incubation at 37°C, 
transfected Vero cells were harvested to verify expression of recombinant proteins. 
Briefly, culture media was removed and cells washed once with PBS. Cells were then 
removed from each well via gentle mechanical scraping and contents of duplicate wells 
combined in the same microcentrifuge tube. Following centrifugation and removal of 
resulting supernatant, cell pellet was lysed using NP-40 containing proteolytic inhibitors 
for 30 min on ice with intermittent agitation. Following centrifugation at 10,000 rpm for 
10 min, the resulting pellet and supernatant were separated and equal volume of Laemmli 
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sample buffer (Bio-Rad, Hercules, CA) containing 5% -mercaptoethanol added to each 
for separate analyses via SDS-PAGE gel electrophoresis and western immunoblot. 
DNA and recombinant protein immunization 
Plasmids pcDNA-Sol-Sopt and pcDNA-SoptCD154 were amplified in E. coli 
Max Efficiency  DH5 -T1R competent cells (Invitrogen, Carlsbad, CA), extracted, 
purified on Qiagen columns (QIAGEN, Inc., Mississauga, ON, Canada), quantified via 
spectrophotometry, and stored at -20°C until use. On d 0 of the trial, each calf was 
vaccinated with the DNA vaccine for its respective treatment group, with Sol-Sopt and 
SoptCD154 vaccinated calves receiving 500 μg plasmid DNA containing the construct of 
interest in two injections, each containing 250 μg DNA in PBS in a 1 mL volume, while 
mock-vaccinated calves received 1 mL PBS. Injections were given intramuscularly (IM) 
on each side of the neck, in the trapezius, pars cervicalis muscle. The initial priming 
vaccination was then followed 14 days later, on d 14 of the trial, by a booster vaccination 
containing the purified protein product, either Sol-Sopt or Sopt-CD154, expressed in SF9 
insect cells and purified from SF9 insect cell culture supernatant. Calves were inoculated 
with 20 μg of the respective purified protein in native elution buffer emulsified with 
TiterMax Gold (TiterMax, Norcross, GA) for a total volume of 1 mL per calf. Injections 
were given intramuscularly (IM) on the left side of the neck, in the trapezius, pars 
cervicalis muscle. On this day, in addition to the purified protein product booster vaccine, 
calves were also administered a second 500 μg dose of the plasmid DNA vaccine 
containing the appropriate construct of interest, either Sol-Sopt or Sopt-CD154, in two 
injections, each containing 250 μg of plasmid DNA in PBS in a 1 mL volume, again 
administered IM on each side of the neck, in the trapezius, pars cervicalis muscle. 
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Animal challenge protocol 
Prior to inoculation with p8 BCoV-Lun on d 28 of the trial, animals were 
withheld feed for 24 h and water for 12 h, as fasting has long been understood, albeit 
usually in conjunction with transport, to predispose cattle to development of BRD 
(Draper et al., 1988; Cole et al., 1986). In addition, 12 h prior to exposure to BCoV-Lun, 
the previously segregated animals were moved out of their respective rooms and 
comingled in a common pen, as the stress of establishment of social hierarchy has been 
associated with increased risk for development of disease in cattle (Martin et al., 1982; 
Brakel and Leis, 1976). Animals were then first worked through a hydraulic squeeze 
chute, where pre-infection blood, fecal, and nasal swab samples were taken in an attempt 
to further stress the animals, as, again, stress has commonly been implicated in the 
development of respiratory illness in cattle (Filion et al., 1984). Following the sampling 
procedures, animals were then experimentally infected, with mock-infected animals first 
receiving an HRT-18 G cell lysate in DMEM intranasally in a 4 mL volume, 2 mL per 
nostril, via a modified sandblasting gun designed to effectively aerosolize droplets of 
liquid for introduction into the nasal passages. Animals allotted to groups to be infected 
with BCoV-Lun were then administered 107 infectious virus particles in a 4 mL volume 
of DMEM containing an HRT-18G cell lysate, with 2 mL administered into each nostril. 
This was also administered via use of the modified sandblasting gun in order to 
effectively aerosolize the liquid in which the virus was prepared. Following infection on 





 Bronchoalveolar lavage was performed on all calves at d 35 of the study as 
described previously (Brennan et al., 1998). Briefly, a specially designed speculum was 
used to gain access to the larynx of standing, restrained calves. Once in pace, a guarded 
culture tube was inserted into the speculum and down the trachea. A sterile, 4 mm outer 
diameter polyethylene tubing was then passed through the guarded culture tube and 
seated into a 4 mm diameter airway of the lung. Thirty milliliters of sterile PBS followed 
by 30 mL of air was then injected into the tube using a sterile 50 mL syringe. 
Approximately 10 to 20 mL of fluid was then drawn out and collected in 50 mL culture 
tubes. Lavage fluid was stored at -80°C until analysis. 
Virus isolation and real time PCR 
In an attempt to determine if animals were actively shedding infectious virus post-
infection, cell culture propagation for virus isolation was performed on d 28, 35, and 42 
nasal swab and fecal samples, as well as d 35 BAL samples from all calves sampled. 
Fecal samples were prepared as described previously (Kapil et al., 1991), with minor 
changes. Briefly, 20% (w/v) fecal samples were prepared in sterile PBS and homogenized 
via vortexing for 10 s. Samples were then centrifuged at 1000 rpm, 27°C for 15 m, and a 
1:10 dilution of the resulting supernatant was prepared in DMEM containing 0.2% 
Primocin (InvivoGen, San Diego, CA) and Nystatin (24,000 U/mL; Sigma, St. Louis, 
MO). Diluted fecal samples were then cleared via filtration through a 0.45 μm HT 
Tuffryn Acrodisc syringe filter (Pall Corp., Ann Arbor, MI), through which 500 μL 
DMEM containing 0.2% Primocin (InvivoGen, San Diego, CA) and Nystatin (24,000 
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U/mL; Sigma, St. Louis, MO) was first passed to limit virus adsorbance to the filter 
membrane.  
Nasal swab samples remained at -80°C until preparation for analysis. Briefly, 
swabs kept in DMEM containing 0.2 % Primocin and Nystatin (24,000 U/mL; Sigma, St. 
Louis, MO) were allowed to thaw on ice. Swabs were then homogenized in DMEM 
storage solution via vigorous vortexing for approximately 10 s, followed by 
centrifugation at 1000 rpm for 15 min at 27°C. Samples were then filtered through a 0.45 
μm HT Tuffryn Acrodisc syringe filter (Pall Corp., Ann Arbor, MI), having first passed 
approximately 500 μL DMEM containing 0.2% Primocin (InvivoGen, San Diego, CA) 
and Nystatin (24,000 U/mL; Sigma, St. Louis, MO) through the filter to limit virus 
adsorbance to the filter membrane. Lavage fluid samples were prepared in a similar 
fashion to the nasal swab samples, except that BAL samples were not diluted in DMEM 
prior to filtration through 0.45 μm HT Tuffryn Acrodisc syringe filters (Pall Corp., Ann 
Arbor, MI).  
Prepared clinical samples were then used to inoculate HRT-18G cells in culture. 
Briefly, HRT-18G cells were seeded onto 6-well plates overnight. The resulting tightly 
confluent monolayers were then washed once with PBS and infected with 500 μL nasal 
swab, BAL filtrate, or fecal sample filtrate in duplicate per sample and rocked for 30 min 
at 27°C. Culture plates were then placed into a 37°C incubator, under a 5% CO2 
atmosphere for an additional 30 min. Afterwards, 1 mL DMEM containing 0.2% 
Primocin (InvivoGen, San Diego, CA) and 2% -irradiated FBS ( -I FBS; Invitrogen, 
Carlsbad, CA) was added to each well and plates returned to 37°C incubator, under a 5% 
CO2 atmosphere.  Infection was allowed to proceed for approximately 72 hours, at which 
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time virus was passaged onto newly confluent monolayer of HRT-18G cells. Following 3 
such blind passages in which 1 mL cell culture supernatants were used to inoculate fresh 
HRT-18G monolayers, cultures were harvested via 3 cycles of freeze-thaw followed by 
storage at -80°C until analysis via PCR.  
Virus neutralization assay 
To determine BRCoV specific serum antibody titer in sera samples collected on d  
-7 and 28 of the study, a series of virus neutralization assays utilizing FACS were 
developed. The first experiments were designed to verify the positive and negative 
controls. To this end, HRT-18G cells were seeded to confluence in 24-well plates and 
allowed to attach at 37°C overnight. Positive control serum samples, those obtained from 
cows vaccinated and boosted with a commercially available BCoV vaccine and expected, 
based on ELISA results, to have titers of circulating anti-BCoV antibodies, and negative 
control samples, -i FBS and a serum-free positive infection control, were serially diluted 
5-fold, from 1:5 to 1:625 in DMEM containing 0.2% Primocin (InvivoGen, San Diego, 
CA) but no FBS. Diluted sera were then mixed 1:1 with the BVC-Lun virus stock and 
incubated on a BD Adams nutator rotational mixer (BD, Franklin Lakes, NJ) at 27°C for 
30 min. After the 30 min neutralization period, the serum-treated viruses were then used 
to infect HRT-18G cells in individual wells of the 24-well plates prepared the day before, 
0.15 mL per well, in triplicate per dilution per sample. Following 1 h rocking at 27°C to 
allow virus attachment, plates were washed once with PBS. Fresh DMEM containing 
0.2% Primocin (InvivoGen, San Diego, CA) but no FBS was then added to each well and 
cultures were then incubated 16 h at 37°C. Following the 16 h infection period, cells were 
washed once with 0.5 mL PBS and trypsinized with 0.2 mL TrypLE (Invitrogen, 
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Carlsbad, CA) per well at 37°C until approximately 90% of the cells were no longer 
attached. Goat serum was then added (Invitrogen, Carlsbad, CA), 50 μL per well, to 
quench the action of the TrypLE. Remaining attached cells were then dislodged and 
separated via pipetting, followed by the transfer of the entire contents of each well to a 
new well within a 96-well U-bottom plate. The 96-well plate containing the transferred 
cells was then centrifuged at 400 rcf, 4°C, for 7 min. Resulting supernatants were 
removed from each well and the remaining cell pellets were washed with 0.2 mL ice-cold 
FACS wash buffer (PBS containing 2.5 mM EDTA and 1% goat serum) and centrifuged 
again using the previously mentioned conditions. Supernatants were again discarded and 
cells were resuspended in 100 μL PBS containing 2% goat serum and primary antibody, 
rabbit serum containing polyclonal antibody against the Sopt-CD154 purified protein, 
diluted 1:2500 and incubated at 4°C for 30 min. Following a wash with 0.2 mL ice-cold 
FACS wash buffer, cells were then resuspended in 100 μL PBS containing 2% goat 
serum and secondary antibody, goat-anti rabbit IgG (heavy and light chains) conjugated 
to Alexafuor488 (2 mg/mL; Invitrogen, Carlsbad, CA), diluted 1:500 and incubated at 
4°C for 30 min. Cells were then washed in 0.2 mL ice-cold FACS wash buffer and 
centrifuged as outlined previously. Cells were then resuspended in 0.15 mL ice-cold 
FACS wash buffer and analyzed via the Accuri Flow Cytometer (Ann Arbor, MI). 
Following verification of the controls as outlined, serum samples were evaluated for 
ability to actively neutralize BRCoV using the same protocol as outlined above, using the 
same 5-fold serial dilution scheme. The percentage of cells positively staining for the 
presence of membrane-associated S gp was determined via flow cytometry and used to 
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calculate the 50% inhibitory concentration (IC50), the dilution of serum at which 
approximately 50% of the virus was neutralized. 
Results 
Construction and expression of gene constructs encoding Sol-Sopt and Sol-
Sopt-CD154 fusion protein 
 An alignment of the amino acid sequences of CD154 genes encoded by different 
animal species was performed using the COBALT Constraint-based Multiple Protein 
Alignment Tool available through the National Center for Biotechnology Information 
(NCBI).  The resulting alignment revealed a high degree of conservation among CD154 
proteins of rabbit (GenBank accession number AFA36650), bovine (GenBank accession 
number NP_777049.1), human (GenBank accession number CAA48077.1), mouse 
(GenBank accession number NP_035746.2), and rat (GenBank accession number 
NP_445805.1) origin, suggesting potential conservation of CD154 functions among 
different animal species (Fig. 3.1).   
Previous work has shown that the extracellular portion of the CD154 molecule 
retains the ability to bind its ligand CD40 and function as a adjuvant for the enhancement 
of immune responses against specific protein antigens (Mazzei et al., 1995).  Therefore, 
the extracellular portion of the CD154 protein spanning amino acids 1-216 were utilized 
as a potential adjuvant for the enhancement of immune responses against the BRCoV S 
glycoprotein.  A gene segment encoding amino acids 1-216 of the bovine CD154 was 
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1  MIETYSQPTPRSVATGPSVSMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNKGEGSLS  80 
1  MIETYSQPSPRSVATGPPVSMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNKGEGSLS  80 
1  MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRLDKIEDERNLHEDFVFMKTIQRCNTGERSLS  80 
1  MIETYSQPSPRSVATGLPASMKIFMYLLTVFLITQMIGSVLFAVYLHRRLDKVEEEVNLHEDFVFIKKLKRCNKGEGSLS  80 
1  MIETYSQPSPRSVATGLPASMKIFMYLLTVFLITQMIGSVPFAVYLHRRLDKVEEEASLHEDFVFVKKLKRCNKGEGSLS  80 
 
81 LLNCKEIRSQFEGFVKDIMLNKEEPKKEINFEMQKGDQDPQIAAHLISEASSKSSSVLQWAKKGYYTMSNTLVTLENGKQ 160 
81 LLNCEEIRSRFEDLVKDIMQNKEVKKKEKNFEMHKGDQEPQIAAHVISEASSKTTSVLQWAPKGYYTLSNNLVTLENGKQ 160 
81 LLNCEEIKSQFEGFVKDIMLNKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQ 160 
81 LLNCEEMRRQFEDLVKDITLNKEE-KKENSFEMQRGDEDPQIAAHVVSEANSNAASVLQWAKKGYYTMKSNLVMLENGKQ 159 
81 LLNCEEMRRQFEDLVKDISLNKEE-KKEKSFEMQRGDEDPQIAAHVVSEANSNAASVLQWAKKGYYTMKSNLVVLENGRQ 159 
 
161 LKVKRQGFYYIYAQVTFCSNQEPSSQAPFIASLCLKSSGGSERILLRAANARSSSKTCEQQSIHLGGVFELQADASVFVN 240 
161 LAVKRQGFYYIYTQVTFCSNRETLSQAPFIASLCLKSPSGSERILLRAANTHSSSKPCGQQSIHLGGVFELQSGASVFVN 240 
161 LTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVN 240 
160 LTVKREGLYYVYTQVTFCSNREPSSQRPFIVGLWLKPSSGSERILLKAANTHSSSQLCEQQSVHLGGVFELQAGASVFVN 239 
160 LTVKREGLYYVYTQVTFCSNREPLSQRPFIVSLWLKPSSGSERILLRAANTHSSSKLCEQQSIHLGGVFELQAGASVFVN 239 
 
241 VTDASQVNHGTGFTSFGLLKL 261 Rabbit (Oryctolagus cuniculus) CD154 
241 VTDPSQVSHGTGFTSFGLLKL 261 Bovine (Bos taurus) CD154 
241 VTDPSQVSHGTGFTSFGLLKL 261 Human (Homo sapiens) CD154 
240 VTEASQVIHRVGFSSFGLLKL 260 Mouse (Mus musculus) CD154 




Figure 3.1. Alignment of CD154 amino acid sequences encoded by multiple species 




cloned in-frame with the Sol-Sopt portion of the BRCoV S glycoprotein spanning amino 
acids 19-1296 into the transient expression vector pCDNA3.1 (Invitrogen, Carlsbad, CA). 
In addition, the gene segment encoding the Sol-Sopt portion of the S gene was cloned 
alone for control purposes (Fig. 3.2A).  Both of the gene constructs contained a 3XFL 
epitope tag inserted in-frame at the amino terminus of each protein. Expression of both 
gene constructs was detected using anti-FLAG monoclonal antibody following transient 
transfection into Vero cells. Multiple protein species were detected by western 
immunoblots in cellular extracts derived from Vero cells transfected with either gene 
construct. Specifically, the Sol-Sopt and Sopt-CD154 proteins were detected in both the 
cell culture supernatants and cell pellets of transfected cells (Fig. 4.2B: lanes, 1,2, 3, 4). 
The Sol-Sopt predominant protein species migrated with apparent molecular masses of 
150, 75 and 50 kDa. The slowest migrating protein species of 150 kDa corresponded to 
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the predicted molecular mass of the 1277 aa sequence after post-translational 
modification (i.e glycosylation). Similarly, the Sol-Sopt-CD154 fusion protein profile 
revealed a slowly migrating protein species with the apparent molecular mass of 
approximately 190 kDa, while other protein species with faster migrating mobilities were 
also detected. The 190 kDa protein species correlated well with the predicted molecular 
mass of the Sol-Sopt-CD154 protein (1512 aa), considering the effect of glycosylation of 
the Sol-Sopt portion of the molecule in Vero cells. Both proteins were detected in 
supernatants of transfected cells in substantial amounts considering that a small volume 
of supernatants were tested in comparison to cell pellets, which were concentrated in 
much smaller volumes. 
Construction of recombinant baculoviruses expressing Sol-Sopt and Sopt-
CD154 proteins in insect cells    
To enable the production of relatively large amounts of proteins suitable for vaccine 
testing, recombinant baculoviruses were constructed expressing the Sol-Sopt and Sopt-
CD154 gene constructs as described in Materials and Methods. Sf9 cellular extracts 
obtained after infection with a recombinant baculovirus expressing either Sol-Sopt or 
Sopt-CD154 were tested for the presence of the proteins in western immunoblots reacted 
with anti-3XFL antibody (Fig. 3.3). The slowest migrating protein species of 150 and 190 
kDa corresponding to the Sol-Sopt and Sopt-CD154 proteins (lanes 3-4 and 1-2, 
respectively) were readily detected in both supernatant (lanes 2 and 4) and cellular extract 
(lanes 1 and 3) samples, as was previously detected in transient expression in Vero cells 
(Fig. 4.2). A relatively large amount of each recombinant protein was detected in 
supernatant samples in comparison with samples obtained from cellular extracts,   
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Figure 3.2. Sol-Sopt and Sopt-CD154 constructs were cloned into the pcDNA3.1 mammalian 
expression vector and transiently transfected into Vero cells. A high level of expression of both 




suggesting that both proteins were efficiently secreted into extracellular spaces (Fig.3.3).  
Animal vaccination protocol   
Calves (n=129) were pre-screened for the presence of anti-BRCoV antibodies 
using an indirect ELISA developed for this purpose and animals were selected for the 
vaccination experiments, based on their apparent lack of anti-BRCoV antibody (see 
Materials and Methods).  The animals were allotted into two treatment groups based on 
sex. A prime-boost vaccination strategy involving priming with the pcDNA gene 
constructs followed by a booster vaccination with mixtures of purified proteins (Sol-Sopt 
or Sopt-CD154) mixed with pcDNA gene constructs expressing each protein, 
respectively was administered depending on animal treatment group (Figure 3.4).  All 
animals were infected intranasally with BRCoV at d 28 post vaccination and sacrificed at 
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day 42 post vaccination after bronchial and blood samples were obtained at different time 
intervals as described in Materials and Methods.  
Humoral immune responses of vaccinated animals.   
The relative amounts of anti-BRCoV antibodies were obtained for the different 
animal groups at different times post vaccination by an indirect ELISA. The highest 
amounts of circulating anti-BRCoV antibodies were detected on d 35 in the group of 
animals vaccinated with the Sopt-CD154 gene and purified protein mixture that were 
then challenged intranasally with BRCoV in comparison to animals that received either 
Mock-vaccination (p = 0.0184) or the Sol-Sopt gene and protein mixtures and challenged 
by BRCoV (p = 0.0663). In addition, on d 35 of the study antibody responses of animals 
immunized with either vaccine and challenged were higher than that of mock-vaccinated 
animals challenged with virus (p  0.0001). All other pairwise comparisons failed to 
show any statistically significant differences (Fig. 3.5). ELISA profiles of average 
relative circulating antibody concentrations within treatment group revealed a time-
dependent increase of antibody levels between day 0 and day 35 for animals vaccinated 
with either Sol-Sopt or Sopt-CD154 gene and protein mixtures. The greatest increase was 
observed for the Sopt-CD154 immunized animals from day 0 to day 35 (p< 0.0012; Fig. 
3.6A) in comparison to that of all other animals (Fig. 3.6). Antibody neutralization assays 
revealed that only animals vaccinated with the Sopt-CD154 gene and protein mixtures 
produced a significant increase in IC50 titers from day -7 to day 28 post vaccination. 
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Figure 3.3. Sol-Sopt and Sopt-CD154 constructs were cloned into the pFastBac Dual 
baculovirus shuttle vector and used to construct recombinant baculoviruses. A high level of 




Fusion proteins containing the soluble portion of CD154 have been extensively 
utilized for the augmentation of humoral and cellular immune responses against a variety 
of protein antigens. In this work, we constructed and tested fusion proteins consisting of 
the soluble portion of the bovine CD154 fused-in-frame to the extracellular domain of the 
BRCoV S glycoprotein. Vaccination and challenge experiments revealed that the bovine 
CD154 protein enhanced humoral immune responses of vaccinated animals, suggesting 
that it can be effectively utilized for the production of subunit vaccines capable of 
eliciting robust humoral responses against multiple antigens in cattle.  
Purified Sol-Sopt-CD154 protein was initially utilized to immunize rabbits (see chapter 
IV). These immunizations resulted in the production of high titer antibody that 
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specifically reacted with BRCoV S glycoprotein in western immunoblots (see chapter 
IV).  It is highly possible that the high degree of amino acid conservation observed 
between the rabbit and bovine CD154 proteins allowed for the bovine CD154 to function 
in rabbits as an adjuvant, suggesting that the bovine CD154 may be useful in generating 
monospecific antibodies against specific proteins in this species. It is important to note 
that the coronavirus S glycoprotein is known to form dimers and trimers, suggesting that 
multimeric forms of the Sopt-CD154 proteins are formed (Xiao et al., 2004), which may 
then very likely further potentiate the adjuvant properties of the CD154 moieties by 
enhanced development of the immunological synapse between APCs, T cells, and B 
cells.  
Efficient expression of the Sol-Sopt-CD154 protein was observed in both 
transient expression in Vero cells, as well as in insect cells after infection with 
recombinant baculoviruses. Of particular interest was the fact that this protein was readily  
secreted to extracellular spaces despite its high molecular mass. These results suggest that 
this rather large fusion protein may be readily purified and concentrated from 
supernatants of cell cultures, substantially lowering the costs associated with purification 
from cellular extracts. Furthermore, expression of these proteins in a mammalian 
expression system may result in post-translational modifications more similar to those 
observed within the native host, as the insect cell and mammalian post-translational 
pathways, especially those involved in glycosylation, differ considerably (Thomas et al., 
2009). Post translational modification of this fusion protein may result in an even more 
robust immune response and the production of higher-affinity neutralizing antibodies 
targeting conformational epitopes. 
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Figure 3.4. Timeline of animal vaccination and experimental protocol. 
Figure 3.5. ELISA detection of circulating serum anti-BRCoV S glycoprotein 
antibodies in calves vaccinate with either the mock, Sol-Sopt, or Sopt-CD154 
vaccines and infected or not infected with BRCoV.
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Figure 3.6. ELISA data expressed as group means by day. 
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Animal vaccination experiments strongly suggested that prior immunization with 
the Sopt-CD154 gene and protein mixtures generated the strongest immune response 
after challenge with the virus, suggesting that the presence of CD154 protein was 
responsible for the observed enhancement of humoral responses. The fact that this 
enhancement was observed only after challenge with the virus suggests that a strong 
memory immune response was present that was not detected in the absence of viral 
infection. This observation, in turn, then suggests that infection completes immunological 
stimulation initiated by the CD154 molecule. Additional experiments would be required 
to assess whether long-term immunological memory exists in animals immunized with 
the Sopt-CD40L fusion protein. 
Previous attempts to utilize the bovine CD154 for the production of subunit 
vaccines for bovine herpes virus type-1 showed strong humoral immune responses in 
sheep, but not in cattle (Manoj et al., 2003; 2004). Manoj and colleagues reported that 
fusion of the gene encoding bovine CD154 to that encoding a truncated version of BHV-
1 gD and inserted into a plasmid for use as a DNA vaccine elicited a significantly 
enhanced antibody response in sheep versus animals vaccinated with a DNA plasmid 
expressing only the truncated portion of BHV-1 gD (2003). However, when this study 
was performed in cattle the researchers failed to see the same response (Manoj et al., 
2004). It is possible that the positive results obtained with the Sopt-CD154 fusion 
proteins are due to the ability of the S protein to efficiently form multimeric complexes 
predicted to augment humoral immune responses.  
The experiments described here were not able to discern whether humoral 
immune responses against the BRCoV S glycoprotein may be protective against BRCoV 
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infection largely because there were minimal clinical signs and practically no disease 
symptoms observed in infected animals other than a transient temperature elevation and 
the recovery of infectious virus from fecal samples of one of three animals infected after 
being mock-vaccinated. The notable exception that one animal that relatively high titers 
of virus were detected in fecal samples of one-of-three mock-vaccinated animals, while 
no virus was detected in vaccinated animals. Additional experiments are needed using  
gnotobiotic calves to maximize disease parameters associated with BRCoV infection. 
Moreover, BRCoV virulent strains serially passaged in gnotobiotic calves may be needed 
to ensure preservation of their virulence characteristics, since it is known that only few 
passages of BRCoV strains in cell culture results in the generation of BRCoV 
quasispecies potentially significantly decreasing the virulence characteristics of viral 
stocks (Chouljenko and Kousoulas, unpublished). Given these results, it is highly likely 
that cocktails of fusion proteins and gene constructs expressing multiple BRCoV 
antigens, as well as antigens specified by other pathogens involved in shipping fever 
could be combined to produce efficacious vaccine approaches that can protect animals 
against multiple viral and bacterial pathogens involved in BRD. In this regard, both DNA 
immunogens and easily purified fusion proteins containing the bovine CD154 protein 
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DESIGN OF DIAGNOSTIC TOOLS AND APPLICATIONS 
Introduction 
The use of antibodies within the molecular biology laboratory is a particularly 
common one, as they have a plethora of applications, including immunohistochemistry, 
receptor-site blocking and binding, and western blotting. Antibodies can be created 
against virtually any protein molecule of sufficient size and relative antigenicity. Even 
those proteins not possessing adequate size may act as haptans when fused to or 
recombined with larger, more antigenic peptides. Antibody applications abound in the 
field of virology, where both polyclonal and monoclonal antibodies are used in receptor 
binding assays, virus detection and microscopy studies, protein-protein interaction assays, 
and fluorescence-assisted cell sorting, just to name a few. In fact, the argument could 
easily be made that a vast amount of what we in the field of virology understand about 
viruses has been a result of the use of antibody applications in the laboratory. 
Antibodies are generated by activated B cells and plasma cells of the immune 
system in response to exposure to foreign antigen. These immunoglobulins may be 
divided into 5 different classes: IgM, IgD, IgG, IgE, and IgA. Avians are an exception to 
this, as they express a variation of IgG called IgY (Warr et al., 1985). The class 
designation of antibody is based on its C region, a result of genetic rearrangement of the 
, , , , and  heavy chain genes, respectively, during B cell maturation as discussed 
previously.  The majority of Ig are monomers, with IgM and IgA being exceptions; these 
molecules are, in soluble form, pentamers and dimers, respectively, linked by co-
expressed J chain molecules. Antibodies are roughly Y-shaped in structure and may 
interact to form aggregates. The top of the Y-structure contains the V, or variable, region, 
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containing three hypervariable sequences that undergo affinity maturation during B cell 
maturation and are responsible for providing the extreme specificity usually associated 
with antibody, as it is these areas that recognize and interact with antigen. The bottom, or 
stem, of the Y contains the C, or constant, region, responsible for interacting with effector 
cells and molecules. This structure is composed of two heavy chains and two light chains 
linked both to each other as well as to one another via disulfide bonds (reviewed by Wang 
et al., 2007). 
The spike gp (S) of coronaviruses is arguably the most distinctive coronaviral 
protein, as it projects some 17 to 20 nm out from the surface of the viral envelope, giving 
the virus the appearance of a crown. The gp is large, ranging anywhere from 1160 amino 
acids in the IBV S to 1452 in FCV and contains numerous glycosylation sites, ranging in 
number anywhere from 21 to 35, all of which are exclusively N-linked (Holmes et al., 
1981; Rottier et al., 1981). Responsible for facilitating not only host receptor recognition 
and binding (Collins et al., 1982; Godet et al., 1994; Kubo et al., 1994) but also virus-host 
and host-host membrane fusion and viral entry (Gallagher et al., 1991; Qiu et al., 2006), S 
plays a vital role in promoting infection and has been implicated as a significant factor 
influencing virulence (Navas et al., 2001), as well as both tissue (Navas et al., 2001; 
Phillips et al., 2001; Navas and Weiss, 2003) and host tropism (Li et al, 2006). The 
protein exists on the virion surface as a trimer (Delmas and Laude, 1990), with the S1 
subunits, the approximately N-terminal one-half of the polypeptide, interacting to form 
the globular head and the S2 subunits, comprised of the approximately C-terminal one-
half of the polypeptide, interacting to form the transmembrane stalk (de Groot et al., 
1987). 
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The Coronavirus S can be divided into two approximately 90 kD subunits, the S1 
and S2 domains of the protein, which can be cleaved from one another in the presence of 
trypsin (Hogue and Brian, 1986), the latter of the two being acylated (Sturman et al., 
1985). Most of the MHV S proteins, with the exception of those belonging to MHV-2, 
are cleaved postranslationally by a cellular furan-like protease into the S1 and S2, which 
remain bound via a non-covalent linkage (Frana et al., 1985; Sturman et al., 1985). Being 
the primary viral protein involved in host cell binding, and, ultimately, the determinant of 
host cell infectivity, it is perhaps no surprise that the S gp is also the primary target of the 
host adaptive immune response (Collins et al. 1982; Stohlman et al., 1985; Williams et 
al., 1991; Compton et al., 1992), with antibodies developed against this protein generally 
associated with strong protection against viral infection (Buchmeier et al., 1984; 
Nakanaga, 1986). Studies performed with Mab produced against the S gp of IBV have 
shown that strongly neutralizing antibody formation was associated primarily with the S1 
subunit of S (Mockett et al., 1984), and, in fact, research utilizing IBV in which the S1 
portion of the S gp had been removed via treatment with urea, while the S2 portion was 
retained, failed to induce production of protective antibody (Cavanagh et al., 1986).  
There are few, if any, commercially available antibodies that specifically 
recognize the S gp of BRCoV. For this reason our laboratory undertook the process of 
designing, expressing, and purifying recombinant spike gps to be used in the 
development of anti-spike polyclonal antiserum. Our goal was to generate a robust 
antiserum for the recognition of the BRCoV, to be utilized in laboratory procedures 
commonly used in the study of viruses. 
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Materials and methods 
Cells 
African green monkey kidney (Vero) cells were obtained from the American 
Type Culture Collection (Rockville, MD) and were propagated and maintained in 
Dulbecco’s Modified Eagle Media (DMEM; Invitrogen, Carlsbad, CA) containing 
sodium bicarbonate, 25 mM HEPES (Invitrogen, Carlsbad, CA), and 10% heat-
inactivated fetal bovine serum (FBS). 
SF9 cells, derived from Spodoptera frugiperda (Fall Armyworm) IPLB-Sf21-AE 
cells, were obtained from Invitrogen (Carlsbad, CA). Cells were propagated and 
maintained in serum-free SF900-II SFM (Invitrogen, Carlsbad, CA) containing 1% 
penacillin-streptomyacin solution (Invitrogen, Carlsbad, CA), either as attached cells in a 
monolayer or as a suspension culture. Cells were maintained at 29° C in a 0% CO2 
atmosphere. 
Sopt plasmid 
The DNAworks program (Hoover and Lubkowski, 2002) was used to design 
synthetic oligonucleotides to be utilized in a PCR-based system for the generation of a 
codon-optimized BRCoV S glycoprotein (Sopt) corresponding to the S sequence of 
isolates obtained from a calf having succumbed to fatal pneumonia during a bovine 
shipping fever epizootic (Chouljenko et al., 2001). Since the S gps only differ between 
the pneumopathogenic and enteropathogenic strains by seven amino acids, the codon 
optimized enteropathic S gp was first constructed via PCR overlap extension (Aiyar, et 
al., 1996). The BCoV-Lun Sopt 3xF and BCoV-Ent Sopt 3xF plasmids were then 
generated by cloning the respective codon-optimized BCoV S gene, either BCoV-Lun 
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Sopt or BCoV-Ent Sopt, lacking the DNA sequence coding for the signal peptide, into the 
p3XFLAG-CMV-9 plasmid vector (Sigma, St. Louis, MO).  
Recombinant protein production 
The Bac-to-Bac Baculovirus protein expression system (Invitrogen, Carlsbad, 
CA) was used to produce two versions of the truncated, soluble portion of the Bovine 
Respiratory coronavirus (BRCoV) codon-optimized spike glycoprotein (Sopt): the 
soluble portion of Sopt, from amino acid 19 through amino acid 1296 (an EcoRV site; 
Sol-Sopt), and the second consisting of the same fragment fused after amino acid 1296 to 
the soluble portion of bovine CD154 (SoptCD154). These proteins were designed to 
contain a 5’ 3X Flag sequence and a 3’ 9-histadine tag for detection and purification 
purposes, respectively, and were over-expressed in SF9 insect cells infected with 
recombinant baculovirus carrying the appropriate expression cassette, either that of Sol-
Sopt or Sopt-CD154. Briefly, SF9 cells were seeded into SF900-II cell culture media 
(Invitrogen, Carlsbad, CA) at a density of 2x106 cells/ mL and infected with recombinant 
baculovirus carrying the expression cassette for either Sol-Sopt or SoptCD154 at an MOI 
of 5. Cell suspension cultures were maintained at 27°C in an orbital incubator. Cell 
supernatants were harvested approximately 72 h post-infection, and soluble protein 
present in the supernatant was isolated and purified via two rounds of cobalt-based 
immobilized metal affinity chromatography (IMAC) using the Talon Metal Affinity resin 
(ClonTech Laboratories, Inc., Mountainview, CA). Briefly, SF9 cell cultures were 
decanted into 50 mL centrifuge tubes and centrifuged at 3000 rpm for 10 min at 27°C. 
The resulting supernatant was then decanted into clean 50 mL centrifuge tubes and 
placed on ice, while the cell pellets were stored at -80°C. A 20% Igepal  CA-630 
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(Sigma, St. Louis, MO) solution was then added to each supernatant for a final 
concentration of 1% Igepal (v/v) and inverted to gently mix. Supernatants were then 
centrifuged for 30 min at 8,000 rpm at 4°C. The resulting supernatants were then 
decanted into new 50 mL centrifuge tubes and Talon Metal Affinity resin (ClonTech 
Laboratories, Inc., Mountainview, CA) was added 1:100 (v/v) to each aliquot. 
Supernatants were then rocked overnight at 4°C to allow binding of His-tagged proteins. 
Following overnight incubation, supernatants were centrifuged at 4,000 rpm at 4°C. The 
resulting supernatant was decanted from the pellet, which consisted of the affinity resin 
bound to His-tagged proteins. Beads were then washed 4 times with native wash buffer 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, pH 7.4). Bound proteins were then 
eluted twice with 0.5 mL each of native elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
250 mM Imidazole, pH 7.4) and stored at -80°C until further analysis. The purified 
proteins were verified via expected size using western blot analysis, using mouse anti-
flag antibody (Sigma, St. Louis, MO) as the primary detection antibody. The purified 
protein concentration was then determined using the Pierce BCA protein quantification 
assay (Thermo Fisher Scientific, Inc., Rockford, IL), according to manufacturer’s 
instructions. 
Polyclonal anti-BRCoV spike glycoprotein production 
Purified Sopt-CD154 protein was used to inoculate an immunologically naïve 
rabbit via IM injection, 50 μg in 0.5 mL phosphate buffered saline (PBS) emulsified with 
an equal volume TiterMax Gold (TiterMax, Norcross, GA) into each hind leg. Two 
weeks later the rabbit was administered a booster inoculation of 50 μg purified Sopt-
CD154 protein in the same manner as previously described. Following an additional two 
 137
weeks, the rabbit was placed under general anesthesia and exsanguinated via cardiac 
puncture. Blood was then allowed to clot at room temperature for 1 h, followed by 
centrifugation for 30 min at 4,000 rpm. The resulting serum was then aliquoted into to 
clean 1.5 mL centrifuge tubes and again centrifuged at 10,000 rpm for 20 min to remove 
any remaining solid or insoluble blood components. Serum was then stored at -80° C 
until analysis. 
Antiserum verification (Western immunoblot analysis) 
To verify the specificity of any antibodies against BRCoV-Sopt that may be 
present in the rabbit serum obtained as described previously, a western immunoblot was 
performed. To each the wells of a 4-20% Tris-HEPES denaturing protein electrophoresis 
gel (Thermo Scientific, Rockford, IL) was added 7.5 μL of one of the following: purified 
Sopt-CD154, purified Sopt-CD154, or BCoV-Lun virus culture, each prepared in 
Laemmli sample buffer (Bio-Rad, Hercules, CA) containing 5 % -mercaptoethanol 1:1 
and boiled at 100° C for 5 min, such that the total volume added to each well was 15 μL. 
The resulting nitrocellulose immunoblot was then incubated with rabbit serum diluted 
1:1000, and previously verified western-positive mouse anti-flag antibody (1:4000) was 
utilized as a positive control. Naïve rabbit serum obtained from the rabbit prior to the 
initial inoculation with Sopt-CD154 was used as a negative control. Following 1 h 
incubation, goat anti-rabbit or goat anti-mouse secondary antibody conjugated to HRP 
was added at a dilution of 1:10,000 to each immunoblot and incubated 1 h.  
Immunofluorescence assay 
In order to further determine the ability of the rabbit-derived anti-S gp antiserum 
to detect viral S gp, an IFA was performed. Briefly, HRT-18G cells were cultured 
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overnight in 6-well tissue culture plates to obtain a confluent monolayer. Serial 10-fold 
dilutions of virus from 10-2 to 10-6 were prepared in DMEM and 1 mL of these dilutions 
used to infect individual wells. Plates were then rocked at room temperature for 1h to 
permit virus adsorption onto monolayer. The cell culture medium was then removed from 
each well, and wells washed twice with PBS. Fresh cell culture medium was then added 
to each well and plates incubated at 37°C. After 12h culture medium was removed and 
cells washed with two volumes of PBS, followed by 1mL ice-cold methanol to fix cells. 
Cells were incubated in methanol for 15 minutes, followed by washing with ice-cold PBS 
containing 2% bovine serum albumin (BSA). Wells were then blocked for 1h with PBS 
containing 2% BSA. To each well was then added the anti-BCoV spike hyperimmune 
rabbit serum, obtained as discussed previously, diluted 1:2500 in PBS containing 2% 
BSA and incubated 2h at room temperature with rocking. Cells were then washed twice 
with PBS containing 2% BSA. Alexafluor 488-conjugated goat anti-rabbit secondary 
antibody (Invitrogen, Carlsbad, CA) diluted 1:500 in PBS containing 2% BSA was added 
to each well and incubated at room temperature for 1h with rocking. Infected cells were 
then visualized and counted via an Olympus fluorescence microscope at an excitation of 
488 nm.  
Sopt hydrophobicity and antigenicity analysis 
The Sopt nucleotide sequence corresponding to the S1 region was analyzed for its 
hydrophilicity as it related to potential antigenic sites, based on predicted amino acid 
sequence (Parker et al., 1986) utilizing the web-based analysis tool, IEDB analysis 
resource (http://tools.immuneepitope.org/tools/bcell/reference.jsp). The Sopt nucleotide 
sequence was also analyzed for predicted linear epitopes based on the predicted amino 
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acid sequence (Larsen et al., 2006) utilizing the same web-based analysis resource. As a 
result of these combined analyses, two regions within the S1 subunit, termed “region 1” 
(Sopt-R1; Sopt bases 60-1200) and “region 2” (Sopt-R2; Sopt bases 1200-2100) were 
selected for recombinant protein and antibody production based on their relative 
hydrophilicity, suggesting they were exposed surface peptides not hidden within 
secondary structure, and potential as linear epitopes, as these regions should be 
recognized by B-cell receptors as linear molecules not reliant on B-cell recognition of 
secondary structure, which could be significantly compromised in truncated versions of 
the proteins. 
Plasmid production 
Primers were designed for use in PCR to amplify each of the regions of interest 
corresponding to Sopt-R1 and Sopt-R2. Using overlap extension PCR, an EcoRI 
restriction site was added to the 5’ end of each PCR fragment, Sopt-R1 and Sopt-R2, 
respectively using the forward primers, 5’TATATAGAATTCAAATGCACCACAGTGAGC 
ATCAATGAC 3’ for R1 and 5’ TATATAGAATTCCGGAAGGTGGATCTGCAGC 
TGGGAAA 3’ for R2; additionally, an XhoI site was added to the 3’ end of each PCR 
fragment, Sopt-R1 and Sopt-R2, respectively using the primers 5’TATATACTCGAGGT 
TAGGGATTGCGAACTTATCAATTGT 3’ for amplification of Sopt-R1 and 5’TATATACT 
CGAGGGTTCGCTGCTGTTAGCGTGAAATGC 3’ for Sopt-R2. For purification 
purposes, the plasmid pGEX6.1 (Figure 4.1; GE LifeSciences, Picastaway, NJ) was 
chosen for insertion into and expression of the Sopt-R1 and Sopt-R2 PCR fragments, as 
this plasmid allows for the 5’ in-frame fusion of a cleavable GST molecule to the inserted 





Figure 4.1. The pGEX-6P-1 cloning vector (GE LifeSciences, Picastaway, NJ) for 




cloning the respective PCR fragments into the pGEX6.1 plasmid vector (GE 
LifeSciences, Picastaway, NJ), using the New England BioLabs Quick Ligation  Kit 
(New England BioLabs, Inc., Ipswitch, MA). The resulting plasmids, pGEX-R1 and 
pGEX-R2, were amplified in E. coli Max Efficiency  DH5 -T1R competent cells 
(Invitrogen, Carlsbad, CA), extracted, purified on Qiagen columns (QIAGEN, Inc., 
Mississauga, ON, Canada), quantified via spectrophotometry, and stored at -20°C until 
use. Plasmid sequences and correct insert orientation were then verified via sequencing 
on an ABI Prism 377 DNA sequencer (PE Applied Biosystems) using the forward PCR 
primers 5’ GTGTGGAATTGTGAGCGGATAAC 3’ and 5’ GGGCTGGCAAGCCACGT 
TTGGTG 3’ in conjunction with the reverse primer 5’CGGGAGCTGCATGTGTC 
 141
AGAGG 3’. 
Recombinant protein expression 
Purified pGEX-R1 and pGEX-R2 were used to transform E. coli One Shot  BL21 
competent cells (Invitrogen, Carlsbad, CA) for expression of the recombinant proteins 
Sopt-R1-GST and Sopt-R2-GST. Additionally, as a GST control, empty pGEX6.1 
plasmid expressing GST alone was also used to transform BL21 E. coli. Transformation-
positive colonies were inoculated into LB broth containing ampicillin (100 μg/mL) and 
incubated at 37°C with 225 rpm rotation. To determine when cell density was high 
enough to induce expression of the recombinant proteins, OD600 was measured at 1 h 
intervals until OD600 = 0.6-0.8, at which time expression of the recombinant protein was 
induced via addition of 1 mM isopropyl -D-1-thiogalactopyranoside (IPTG). The 
bacterial culture was then allowed to continue incubating for an additional 3 h post-
induction, with 1 mL samples taken at 0, 1.5, and 3 h post-induction. Following 3 h 
incubation, cultures were removed, cells pelleted at 4,000 rcf for 10 minutes, and frozen 
at -80°C until analysis. For comparison and optimization purposes, cultures were also 
induced at OD600 = 1.0, and with three different concentrations of IPTG: 1, 0.5, and 0.1 
mM IPTG. In addition, recombinant protein yield was also compared for cultures grown 
at 32°C and 37°C. 
Recombinant protein isolation and purification 
To isolate recombinant proteins, lysis conditions first required optimization. To 
this end, bacterial pellets were thawed on ice and lysis was first attempted using B-Per 
Lysis Buffer (Thermo Fisher Scientific, Rockford, IL) containing 1 mM 
phenylmethylsulfonyl fluoride (PMSF; Sigma, St. Louis, MO) and 10 mg/mL lysozyme 
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(Sigma, St. Louis, MO), according to manufacturer’s specifications. Briefly, 4 mL B-Per 
was added to each 1 g weight of wet cells and the pellet homogenized in B-per solution 
via pipetting action. Homogenization was then followed by incubation for 10 to 15 min at 
room temperature. The resulting lysate was then centrifuged at 15,000 rcf for 5 min in 
order to separate soluble from insoluble proteins. Cell lysate (soluble) and cell pellet 
(insoluble) fractions were then each prepared for Western immunoblot analysis under 
denaturing conditions in order to determine whether the Sopt-R1-GST and Sopt-R2-GST 
recombinant proteins were both adequately expressed and soluble. 
In an attempt to free the expressed Sopt-R1-GST and Sopt-R2-GST recombinant 
proteins from bacterial inclusion bodies and thus improve their solubility and yield, an 
alternative lysis buffer and method were utilized. The cell pellet was first thawed to room 
temperature and washed once with bacterial lysis buffer II (50 mM Tris-HCL, 300 mM 
NaCl). Following centrifugation and discard of resulting supernatant, 1 mL lysis buffer II 
was added to the pellet, followed by shearing via a 21 gauge needle in order to resuspend 
the entire pellet. Once the pellet was completely resuspended in lysis buffer II, an 
additional 5 mL lysis buffer II was added to the suspension, which was then vortexed 
thoroughly to mix. To the bacterial pellet suspended in lysis buffer II was added 500 mM 
EDTA for a final concentration of 5 mM EDTA; solution was again vortexed thoroughly 
to mix. To this suspension was then added 25 mg/mL lysozyme (Sigma, St. Louis, MO) 
for a final concentration of 1 mg/mL, followed by mixing via gentle inversion shaker for 
30 minutes at room temperature. Benzonase nuclease (Sigma, St. Louis, MO) was then 
added to the solution for a final concentration of 5 U/mL and pellet in solution returned to 
the inversion shaker for an additional 30 min at room temperature. Following mixing, 
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solution was centrifuged 16,000 rcf for 20 min at 4ºC and resulting supernatant discarded. 
To the remaining pellet was added 1 mL lysis buffer II and 50 L of 500 mM EDTA. 
Pellet was once again resuspended in solution via use of a 21” needle. Approximately 4 
mL lysis buffer II was then added to the resulting solution followed by mixing via brief 
vortexing. Once mixture was homogeneous, 1 M dithiothreitol (DTT; Sigma, St. Louis, 
MO) was added to a final concentration of 5 mM DTT and solution was again subjected 
to vortexing. A solution of 10% sarkosyl (v/v; Sigma, St. Louis, MO) was added to the 
bacterial pellet solution, 200 L per approximately 5 mL of bacterial pellet suspension, 
which was then mixed by gentle inversion on an inversion shaker for 30 min at room 
temperature. This was followed by overnight incubation with inversion at 4ºC. Following 
the lysis incubation period, bacterial suspension was subjected to sonication 3 to 4 times 
on ice in 12 to 15 s intervals using an output control of 7 and a 20% duty cycle. A 1 min 
rest period was used to allow sonicated suspension to cool between sonications. 
Sonicated suspension was then centrifuged at 16,000 rcf for 30 min at 4ºC and resulting 
supernatant decanted into new conical tubes, while the resulting pellets were returned to 
ice for later analysis. To the remaining supernatant was added 750 L of a 10% solution 
of Triton X (Sigma, St. Louis, MO) in ddH2O (v/v), followed by gentle inversion to 
ensure complete mixing of solutions. Samples were then either purified via Profinia (Bio-
Rad, Hercules, CA) according to manufacturer’s instructions using GST-binding columns 






Recombinant Sol-Sopt and Sopt-CD154 are expressed to high levels in an 
SF9 cell culture system 
 The recombinant Sopt protein was expressed using the baculovirus expression 
system in insect cells to allow for post-translational modification that may increase the 
immunogenicity of the protein. (Goffard and Dubuisson, 2003; Harrison and Jarvis, 
2006). The proteins were found to be expressed at high levels (Fig. 4.2) using this 
system, not only in the SF9 cells themselves (lanes 1 and 3), but also as soluble proteins 
secreted into the extracellular space and detectable in the cell culture supernatant (lanes 2 
and 4). 
Both in vitro expressed and wild type S gp are recognized by Sopt gp-specific 
antiserum 
In an attempt to create a stock of BRCoV S gp-specific antiserum for use in 
BRCoV studies, an immunologically naïve rabbit was inoculated with SF9-expressed 
Sopt-CD154 and boosted 14 days later. Serum was then harvested from this rabbit via 
exsanguination and tested for its ability to recognize both recombinant Sopt protein 
purified from SF9 cell supernatants, as well as S gp on the surface of wild-type BRCoV 
isolated from a calf that succumbed to fatal pneumonia during a shipping fever epizootic. 
To determine the ability of this antiserum to detect S gp, a western immunoblot was 
performed (Figure 4.3) using the serum as the primary antibody against recombinant Sol-
Sopt purified from SF9 cell supernatants, recombinant Sopt-CD154 purified from SF9 
cell supernatants, or whole virus particles (lanes 5, 4, and 6, respectively). For 





Figure 4.2. Sopt-CD154 (lanes 1 and 2) and Sol-Sopt (lanes 3 and 4) expressed in SF9 






Figure 4.3. Rabbit-derived anti-Sopt-CD154 antiserum detects both recombinant Sol-
Sopt and Sopt-CD154 expressed expressed from a baculovirus expression system, as well 
as wild-type S gp from the laboratory strain BCoV-Lun (lanes 5, 4, and 6, respectively), 
while naïve rabbit serum from the same rabbit pre-vaccination does not (lanes 8, 7, and 9, 
respectively).  
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 anti-3XFL antibody (Sigma, St. Louis, MO) as the primary detection antibody (lanes 2, 
1, and 3, respectively). As expected, an approximately 150 kDa band was observed in 
lanes corresponding to the recombinant Sol-Sopt in both anti-3XFL and rabbit antiserum-
treated immunoblots. Likewise, a slightly larger 190 kDa band was observed in lanes 
corresponding to the recombinant Sopt-CD154 in both anti-3X-FL and rabbit serum-
treated immunoblots. The ant 3XFL antibody did not, however, react with the S protein 
from the BRCoV-Lun virus located in lane 3, while rabbit-derived anti-serum was able to 
detect bands varying in size, predominantly those migrating as 150, 190, and possibly 
250 kDa species, in the lane corresponding to BRCoV-Lun virus (lane 6). Furthermore, 
naïve serum taken from the rabbit prior to the initial exposure to Sopt-CD154 antigen 
yielded no signal as compared with serum isolated from the same rabbit following a 
second exposure to antigen (lanes 7-9).  
To further evaluate its usefulness in BRCoV-related laboratory applications, the rabbit-
derived anti-S gp antiserum was tested for its ability to detect wild-type S gp expressed 
on the surface of fixed cells in an immunofluorescence assay system. The serum was 
used in the assay at a relatively low dilution, 1:2500, resulting in low amounts of 
background or non-specific staining. As predicted, the anti-S gp antiserum reacted with S 
gp expressed on the surface of fixed HRT-18G cells and was detectable by secondary 
goat anti-rabbit antibody conjugated to Alexafluor 488 (Invitrogen, Carlsbad,CA), 
resulting in easily observable infected cells that stained fluorescent green when viewed 
under a fluorescent light microscope (Figure 4.4). 
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The S1 portion of the S gp contains regions suggestive of hydrophilic, linear 
epitopes 
In order to determine the most hydrophilic regions of the S1 subunit of the S gp 
that may contain linear epitopes conducive to antibody response, the Sopt predicted 
amino acid sequence was analyzed using an available web-based analysis tool, IEDB 
analysis resource, which makes available a number of various prediction logarithms for 
nucleotide sequence analysis. Based on the results of the Emini Surface Accessibility 
(Emini et al., 1985; Figure 4.5) and Parker Hydrophilicity Prediction plots (Figure 4.6), 
the Bepipred Linear Epitope Prediction plot (Figure 4.7), two regions within the S1 
subunit of the BRCoV S gp were selected for recombinant protein production. These 
regions, termed Sopt-R1 and Sopt-R2, were found to be considerably hydrophilic with 
respect to the rest of the gp, and were areas predicted most likely to contain linear 
                  
 
 





epitopes, of particular interest for their ability to incite the production of antibody not 
dependent on protein secondary structure for recognition. This was deemed a vital feature 
since production of truncated and/or recombinant versions of the gp would likely not 
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share native conformation with wild-type S gp. For this reason, regions encompassing 
amino acids 20-400 and 400-700 within the S1 subunit were selected. In addition, the 
production of small recombinant proteins less than 450 amino acids was desirable since 
the Profinia system (Bio-Rad, Hercules, CA) would be used for purification. This system 
utilizes an automated two-step affinity chromatography procedure to immobilize 
recombinant GST or His-tagged proteins for protein purification. However, the system is 
restricted to purification of relatively small GST-tagged proteins. Thus, we restricted our 




Figure 4.5. Emini surface accessibility prediction plot of the S1 region of the BRCoV 
Sopt gp. Regions most likely to be accessible when the protein is folded in native 
conformation are shown as spikes above a surface probability value equal to 1; an 
increase in surface probability value is proportional to an increase in the likelihood that 






Figure 4.6. Parker hydrophilicity prediction plot. Regions of the BRCoV predicted to 
contain particularly large concentrations of hydrophilic residues are depicted as spikes 
above the threshold of 1.163. These regions are more likely to be exposed on the surface 






Figure 4.7. Bepipred linear epitope prediction plot. Regions of the BRCoV sopt gp more 
likely to contain potential linear epitopes are shown as spikes above the threshold value 
line, equal to 0.350, where an increase in spike distance from the threshold is 
proportional to the likelihood that the region my contain antigenic residues not reliant on 
native protein structure for recognition. 
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Recombinant Sopt-R1-GST and Sopt-R2 are expressed to high levels in BL21 
E. coli  
Because expression of recombinant proteins in bacterial systems generally 
generates large quantities of recombinant protein products, a BL21 E. coli (Invitrogen, 
Carlsbad, CA) expression system was selected for expression of the pGEX-R1 and pGEX-
R2 plasmid constructs. The multiple cloning site of this plasmid places the inserted 
cassette under control of the inducible expression promoter/operator tac, which is 
inducible by IPTG. Expression from the tac promoter/operator is IPTG concentration 
dependent and proportional to the concentration of IPTG added. Addition of IPTG at a 
concentration of 1 mM resulted in high level expression of the Sopt-R1-GST and Sopt-
R2-GST proteins, as shown by western immunoblot. As expected, bands representing the 
71.5 kDa Sopt-R1-GST and the 60.5 kDa R2 proteins were visible, primarily in lanes 
containing the resuspended bacterial pellet following lysis treatment. The immunoblot 
was treated with anti-GST antibody (Invitrogen, Carlsbad, CA) for detection of the fusion 
proteins. Based on results of the immunoblot, it was concluded that a large amount of the 
fusion protein remained insoluble following lysis of the bacterial cells, as considerably 
more protein was evident in lanes corresponding to the bacterial pellet following lysis 
than in lanes corresponding to the lysate, necessitating optimization of the expression 
protocol. 
Sopt-R1-GST and Sopt-R2-GST remain trapped within bacterial inclusion bodies 
following cell lysis 
In an attempt to increase the solubility of recombinant Sopt-R1-GST and Sopt-R2-
GST proteins expressed in E. coli, growth of E. coli cultures at two different temperatures 
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(Smith and Corcoran, 1990) in conjunction with induction via two different 
concentrations of IPTG were considered (Figure 4.8). Bacterial cell cultures were grown 
at either 32°C (lanes 3, 4, 7, and 8) or 37°C (lanes 1, 2, 5, and 6). Expression of the 
recombinant proteins was induced using concentrations of 0.1 mM IPTG (lanes 1-4) or 
0.5 mM IPTG (lanes 5-8). These cultures were sampled at 0 and 1.5 h post-induction, and 
again at 3 h post-induction, when cells were harvested, pelleted via centrifugation, and 
frozen until analysis. Western immunoblot analysis of Sopt-R1-GST (panel A) and Sopt-
R2-GST (panel B) cell lysates (lanes 1, 3, 5, and 7) and remaining pelleted cellular 
material (lanes 2, 4, 6, and 8) at 3 h post-induction revealed that both changing the 
culture incubation temperature and reducing the IPTG concentration failed to increase the 
amount of soluble protein that could be recovered from the cells. For that reason, 
adjustments were again made to the induction protocol. For this experiment, induction of 
Sopt-R1-GST expression was performed when at two different concentrations of bacteria 
in culture: when the OD600 = 0.6 and when the OD600 = 1.0 and two different 
concentrations of IPTG for induction, 0.5 mM and 1.0 mM. Again, samples were taken at 
0 h, 1.5 h, and 3 h post-induction. Western immunoblot analysis (Figure 4.9) of both the 
cell lysates (lanes 1, 3, 5, and 7) and remaining pelleted material (lanes 2, 4, 6, and 8) 
sampled at 3 h post-induction revealed that, once again, the majority of protein remained 
insoluble within the remaining cell pellet. No differences were observed in protein 
solubility between either samples taken from cultures induced at OD600 = 0.6 or 1.0, or 
between samples taken from cultures induced using 0.5 or 1.0 mM IPTG. Based on the 







Figure 4.8. R1-Sopt (panel A) and R2-Sopt (panel B) expressed in BL21 E. coli  




R1-GST and Sopt-R2-GST bacterial expression products were trapped within inclusion 
bodies within the bacteria. 
Therefore, in an attempt to free the expressed recombinant proteins trapped within 
bacterial inclusion bodies, a new lysis technique was attempted utilizing high salt  
solution coupled with the addition of both lysozyme and sarkosyl in conjunction with 
mechanical shearing of the bacterial pellet. When the resulting lysates from bacteria 
expressing the Sopt-R1-GSTrecombinant protein were GST column-purified via the 




Figure 4.9. Western immunoblot analysis of Sopt-R1-GST expressed in BL21 E. coli at 
two different concentrations of IPTG and two different culture concentrations (OD600) for 
induction. The 71 kDa band representing Sopt-R1-GST is denoted by an arrow.  
 
 
electrophoresis and coomassie blue staining (Figure 4.10), Profinia-purified and eluted 
Sopt-R1-GST could be visualized only as a very faint band (lane 6), corresponding to the 
relatively small quantity of protein, only 0.08 mg/mL, that could be recovered via this 
method. The same gel showed that, as before, a considerable amount of the protein 
seemed to remain associated with the pelleted fraction following bacterial lysis (lane 2). 
In addition, a considerable amount of the solubilized protein escaped the GST-column 
and could be observed as bands corresponding to lanes in which the Profinia flow-
through and wash were added (lanes 4 and 5). To corroborate these results, a western 
immunoblot was also performed (Figure 4.11), the results of which were in agreement 
with those from the Coomassie blue gel. When the new lysis procedures were performed  
on E. coli expressing the recombinant Sopt-R2-GST fusion protein followed by western 
immunoblot to check protein solubility (Figure 4.12), it was observed that, similar to the 
results obtained via the new lysis conditions of bacteria expressing the recombinant Sopt-
R1-GST protein, the majority of the recombinant Sopt-R2-GST protein remained 
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associated with the cell pellet following lysis (lane 1), suggesting that this protein, too, 
may be insoluble, trapped inextricably within bacterial inclusion bodies. 
Discussion 
Production of rabbit-derived anti-spike serum  
 Given the observation in our laboratory as well as others that BRCoV, especially 
virus isolated from clinical samples, fails to produce in vitro plaques even though CPE 
including swollen, granular, detached cells may be evident (Benfield and Saif, 1990; Cho 
et al., 2000), coupled with the fact that our laboratory currently did not possess antibody 
specific for the respiratory strain of BCoV, there was considerable need for the 
 
 
Figure 4.10. Coomassie stained 10% Polyacrylamide gel of Profinia purified Sopt-R1-




Figure 4.11. Western immunoblot confirmation of coomassie results of Sopt-R1-GST 





Figure 4.12. Sopt-R2-GST Profinia affinity chromatography protein purification. Sopt-
R2-GST pellet (lane 1) contains completely insoluble protein, while lanes 2-5 represent 
the clear bacterial lysate, wash, flow-through, and eluate, respectively. A GST (24 kDa) 
control was also performed using pGEX-6-P-1 plasmid DNA containing no insert (lanes 
6-10); this protein was also subjected to Profinia purification, with lanes set up in the 
same order as listed for Sopt-R2-GST. 
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development of a method with which to detect virus, for use in both 
immunohistochemical applications as well as western immunoblot detection. Production 
of the S gp via an insect cell culture system proved to be fairly robust, providing adequate 
protein for use in the vaccination of a naïve rabbit for the purpose of antibody production. 
The baculovirus/insect cell protein expression system is one of the most widely used 
systems for expression of heterologous proteins within a eukaryotic host, and previous 
studies have utilized the insect cell system for the production of recombinant proteins 
specifically for vaccine use. Thomas and associates used this system for the production of 
recombinant E2 protein from BVDV in a study comparing the efficacy of proteins 
derived from baculovirus/insect cell systems as vaccine candidates versus the same 
recombinant proteins expressed via a mammalian system. The group reported a 
considerably higher yield of the recombinant protein was obtained with the 
baculovirus/insect cell system as compared with expression in the mammalian MDBK 
cell line (Thomas et al., 2009). However, it was found that the insect cell-derived proteins 
were less effective as a vaccine when compared with the same recombinant proteins 
derived from mammalian protein expression, as evidenced by the observation that in 
order to obtain a comparable level of BVDV protection with the insect cell-derived 
protein, considerably higher concentrations were required than were needed when 
mammalian-derived proteins were used (Thomas et al., 2009). There are differences in 
the glycosylation pathways utilized by insect and mammalian cells, and these differences 
could potentially affect protein conformation and even biological function (Jarvis, 2003). 
Fortunately, we observed no difficulty in eliciting a robust antibody response against the 
recombinant S gp we used; the deficit in immune response to low concentrations of insect 
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cell-derived proteins described by Thomas et al (2009) may have been ameliorated in our 
study by the fact that, at 1 μg/mL total dose concentration, we used a relatively high 
concentration of protein for vaccination. Furthermore, we found that antibody present in 
the hyper immune antiserum from this rabbit was specific for the S gp, as evidenced by 
its ability to detect wild type virus S gp in both western immunoblot and IFA. Our results 
were in agreement with those reported by Shmaljohn and colleagues (1990), in which 
Hantaan virus proteins expressed in a baculovirus system were observed to be specific for 
Hantaan virus, effectively eliciting a functional antibody response. In addition, as in our 
study, antibody specific for the wild-type Hantaan virus proteins were able to effectively 
recognize the recombinant proteins resulting from expression in a baculovirus system.  
Interestingly, but perhaps somewhat expected, was the observation that, in 
response immunization with the recombinant Sopt fusion protein possessing a truncated 
version of bovine CD154 at its carboxyl terminus, the antiserum appears to also have 
some degree of reactivity to bovine CD154, as evidenced by the appearance of an 
additional 24 kDa band in the lane corresponding to recombinant Sopt-CD154 purified 
from SF9 cell culture supernatants. It is likely that some amount of soluble CD154 may 
have been expressed or may have been a consequence of protein degradation either 
during the course of cell culture or during the purification process, resulting in soluble 
CD154 available for recognition by anti-CD154 antibody within the serum. 
Production of recombinant Sopt-R1-GST and Sopt-R2-GST in E. coli  
 Based on our success in producing both the soluble portion of the S gp and a 
fusion protein containing bovine CD154 in a baculovirus protein production system 
followed by production of specific antibody against the S gp, we next wanted to design a 
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small subunit vaccine that could easily be purified via automated means using the 
Profinia purification system (Bio-Rad) for high-throughput, inexpensive production of 
proteins. Because of its ease, low cost, and high protein production capabilities, as well as 
the ready availability of a plasmid for production of GST-tagged proteins, we decided to 
use a bacterial system for production of these small recombinant proteins. The positive 
results obtained with the use of a recombinant S gp fusion protein in the production of 
anti-S antibodies in rabbit prompted us to again use the S gp for this purpose. As it is a 
vital structural protein of the coronavirus virion and the primary viral protein implicated 
in host cell binding and infectivity, the S gp is also the primary target of the host adaptive 
immune response (Collins et al. 1982; Stohlman, 1985; Williams et al., 1991; Compton et 
al., 1992). Accordingly, antibodies developed against this protein are associated with 
strong protection against viral infection (Buchmeier et al., 1984; Nakanaga, 1986). 
However, its considerable size presented a potential problem with regards to purification 
via the Profinia system. For this reason, the S gp was evaluated for small regions 
containing predicted linear epitopes, as well as for indication of regions that would not 
undergo extensive folding when solubilized, based on the hydrophilicity prediction plots 
of these regions. We chose to target the S1 subunit of the S gp, as this region has 
previously been shown to be a major target for the induction of neutralizing antibody 
(Gallagher et al., 1990).  
 The GST-tagged protein production system has previously been used for the 
production of protein subunit vaccines. The pGEX-6-p-1 expression plasmid was 
successfully used for the high output production of the recombinant S gp subunit proteins 
in E. coli. However, most of these proteins were trapped within cytoplasmic inclusion 
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bodies following expression, a phenomenon commonly observed in the production of 
heterologous eukaryotic proteins expressed to high levels in bacteria (Eaton et al., 1986). 
As a result, the recombinant proteins could not be extracted via typical bacterial lysis. 
Manoj et al reported that, in agreement with our experience using this system, the vast 
majority of the tagged proteins expressed were insoluble, preventing isolation and 
purification directly from cell lysates (2003). As a result, the recombinant proteins 
required denaturing of the protein via SDS-PAGE gel extraction and related purification 
techniques in order to be isolated for use as a subunit vaccine. Unfortunately, because use 
of the Profinia purification system was desired for high-throughput protein production, 
maintaining the native conformation of the GST tag was necessary, as it was possible that 
disrupting this conformation may interfere with its ability to bind the glutathione 
sepharose columns used by the Profinia system. Further attempts to increase protein 
solubility were made by adjusting culture incubation and induction conditions, but these 
changes made no difference in the availability of the recombinant proteins for 
purification directly from the cell lysate. As a result, it was decided that the use of GST-
tagged proteins in this specific case would not be possible since they could not be 
extracted from the bacteria while maintaining native conformation. 
Future directions 
 It would be interesting, and potentially informative, to utilize the Sopt-R1-GST 
and Sopt-R2-GST proteins, as well as other small subunit Sopt proteins, for delineation 
of immunogenic epitopes capable of generating BRCoV neutralizing antibodies. This 
work could lead to the efficient production of smaller immunogenic segments or 
synthetic peptides that can be incorporated into a “cocktail” vaccine containing multiple 
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proteins and peptides. In addition, a study of this nature may provide information on the 
effect, if any, of CD154 fusion on B and T cell recognition of conformational versus 
sequential epitopes. 
 The use of a bacterial expression system resulted in the entrapment of 
recombinant Sopt-R1-GST and Sopt-R2-GST within cytoplasmic inclusion bodies 
rendering difficult the further purification of these antigens by affinity chromatography.  
Typically, inclusion bodies contain more than 70% of the expressed protein. In this 
regard, inclusion bodies could be purified by simple centrifugation methods due to their 
high density and used as immunogens.  These antigens could serve as vaccines for animal 
vaccination, although they are not suitable for human vaccine production. Alternatively, 
expression of these antigens in insect cells enables their subsequent purification by 
affinity chromatography, although in significant lower amounts than those that can be 
achieved in E. coli.  Post-translational modification of the BRCoV S glycoprotein in 
insect cells may preserve conformational epitopes that generate neutralizing antibodies, 
In this regard; insect cell expression may provide a unique advantage in the generation of 
potentially protective humoral immune responses.   Additional work is needed to further 
clarify the differential abilities of S-CD154 fusion proteins expressed in E. coli versus 
insect cells to generate anti-BRCoV humoral and cellular immune responses.  
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TALON RESIN PURIFICATION OF NATIVE HIS-TAGGED PROTEINS FROM 
CELL SUPERNATANTS (IMAC PROCEDURE) 
 
1.  Centrifuge detached cells in 50 mL centrifuge tube, 10 min, 2500 rcf.  
2. Decant supernatant into new 50 mL centrifuge tube  
3. Add 20% Igepal solution to supernatant for a final Igepal concentration of 1% 
4. Mix well via inversion (avoid vortexing, as it will result in bubbles since Igepal is 
a detergent) 
5. Centrifuge at 10,000 rcf, 4°C for 30 min to remove any remaining cell debris 
6. Decant supernatant into new 50 mL centrifuge tube. Place on ice. 
7. Add Talon Metal Affinity resin to supernatant; beads to supernatant ratio should 
be 1:100 
8. Mix well, and incubate with rocking at 4°C overnight  
9. Centrifuge supernatant/resin solution 4,000 rcf, for 10 min at 4°C 
10. Decant and discard supernatant carefully, ensuring that the resin pellet is not 
disturbed 
11. Wash beads/resin 4 times: 
• Add 8 mL native wash buffer to each sample 
• Incubate with rocking 5 min 
• Centrifuge 4,000 rcf for 5 min, at room temperature 
• Carefully discard supernatant, ensuring that resin pellet at bottom of tube 
is not disturbed 
• Repeat 3 additional times 
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• On last wash, all remaining wash buffer must be removed; following inital 
decanting of liquid, centrifuge an additional 2-5 min at 4,000 rcf, room 
temperature 
• Pipette off remaining liquid 
12. Elute protein with native elution buffer, using at least an equal amount of elution 
buffer to resin (slightly more is better, ie, if using 200 uL beads, use 250 uL 
elution buffer) 
• Add elution buffer to resin carefully, tapping gently to mix. Incubate with 
gentle agitation (ie tapping) for 5 minutes 
13. Repeat elution step with same volume elution buffer as first elution 
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TALON RESIN PURIFICATION OF HIS-TAGGED PROTEINS FROM CELL 
PELLET (IMAC PROCEDURE) 
 
1. For attached cells, detach cells from culture flask via scraping; Decant detached 
cells and centrifuge cells in 50 mL centrifuge tube, 10 min, 2500 rcf  
2. Decant supernatant 
3. Prepare Native lysis buffer  
4. Resuspend pellet in lysis buffer (5mL lysis buffer/pellet from 25 mL culture) by 
gently pipetting up and down 5 to 10 times 
10. Incubate cells in lysis buffer on ice approximately 30 min with occasional 
agitation 
11. Centrifuge 20 min, 10,000 rcf @ 4°C 
12. Decant supernatant into new 15 mL corning tube 
• Aliquot 75 μL of sample into microcentrifuge tube for western analysis of 
lysate. 
13. Add Talon Metal Affinity Resin (ClonTech) beads to lyates; the minimal resin to 
lysate ratio is 1:50, often use 1:25 
14. Thoroughly mix lysate and resin by tapping tube; incubate with rocking 1 to 1.5 
h, or overnight for large samples 
15. Centrifuge samples at 4500 rcf for 5 min (18-20°C) 
16. Discard supernatant 
17. Wash beads in resin 4 times: 
• Add 8 mL wash buffer to each sample 
• Incubate with rocking 5 min 
• Centrifuge 4,000 rcf 5 min, at room temperature 
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• Carefully discard supernatant, ensuring that resin pellet at bottom of tube 
is not disturbed 
• Repeat 3 additional times 
• On last wash, all remaining wash buffer must be removed; following 
decanting of liquid, centrifuge an additional 2-5 min at 4,000 rcf, room 
temperature 
• Pipette off remaining liquid 
18. Elute protein with native elution buffer, using at least an equal amount of elution 
buffer to resin (slightly more is better, ie, if using 200 uL beads, use 250 uL 
elution buffer). 
• Add elution buffer to resin carefully, tapping gently to mix. Incubate with 
gentle agitation (ie tapping) for 5 minutes. 










SDS-PAGE GEL, NITROCELULOSE TRANFER, AND WESTERN IMMUNOBLOT 
PROCEDURE 
 
**Samples must be mixed with Lammeli Sample Buffer (1:1) that has had -
mecaptoethanol already added (50 μL BME, 950 μL lammeli sample buffer).  Sample 
should then be boiled at 100°C for 5 minutes for denaturing.  
Polyacrylamide Gel: 
1. Set gel (either 12% or 4-20% gradient, appropriate well number) into running cell, 
opening of lanes facing inward. Ensure that gel is centered and pushed down to 
bottom of cell, so as to both ensure the gel is straight in the assembly, and limit 
leaking of running buffer. If running only 1 gel, will need to add dummy to 
opposite side of the cell. 
2. Add running buffer to the top of the gel(s), between the gels. Add running buffer 
to the outside of the gel unit, but only until it covers the very bottom of the gels 
3. Flush all urea out of each lane using 200 μL pipette and running buffer. 
4. Load samples. Marker must also be added to a lane, and it is important NOT to 
add it to the middle of the lanes containing sample; add marker so that sample 
arrangement is asymmetrical (for identification/orientation purposes). Typically 
load 32 μL of sample in buffer, adding 16 μL at a time. Any volume over 20 μL 
should be added in two volumes. ** It is typically advisable to avoid loading the 
first and last. 
5. Run gel at 77 V (low voltage allows for increased resolution over time, especially 
for proteins close in MW) for approximately 1 h. Gel may be run longer (up to 1.5 
h), but only if protein MW is relatively high; otherwise bands may run off of gel. 
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6. Remove gel from cell; gently crack open protective casing and remove gel, 
cleaning up rough edges. Gently lift gel and place into container with small 
amount of transfer buffer. 
Nitrocellulose Transfer: 
** Will need to prepare ahead of time: 
• Small container containing transfer buffer 
• Pre-cut sheet(s) or nitrocellulose, labeled with name of antibody (Ab) and 
direction of lanes 
• 4 pre-cut sheets of immunoblotting paper, pre-soaked in transfer buffer 
1. Pre-soak 4 transfer sponges with ddH2O, ringing out excess. Place transfer 
sponges into container containing enough transfer buffer to saturate all four 
sponges.  
2. Place pre-soaked sponge into transfer assembly first. Use 1 sponge if performing 
transfer on two gels, or two sponges of only performing one transfer. 
3. Place pre-soaked immunoblotting paper (soaked in transfer buffer; cut to 
approximately sponge-size) down next. Again, if performing two gel transfers use 
one immunoblotting paper, but if performing only one transfer place two papers 
down. 
4. Pour small amount of transfer buffer onto immunoblotting paper. 
5. Place gel onto immunoblotting paper, in reverse orientation (so, numbered 
backwards from right to left, ie, 10 to 1 or 12 to 1). Ensure that no bubbles form 
between the gel and the immunoblotting paper. 
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6. Pour small amount of transfer buffer onto gel, just enough to dampen, to keep air 
bubbles from forming between gel and nitrocellulose. 
7. Place pre-soaked nitrocellulose paper onto gel (try to use forceps for this part; 
avoid touching nitrocellulose as much as possible), lining up edges and ensuring 
that no bubbles form between the gel and the paper. Protein bands will not 
transfer through bubbles! 
8. Place pre-soaked immunoblotting paper on top of nitrocellulose. Again, if running 
two gels place one sheet, if running one gel place two sheets. 
9. Place sponge(s) on top of assembly last. 
** If transferring two gels, repeat steps 1-9 on top of first gel “sandwich”. 
10. Place cover onto assembly. Lift gently over container with transfer buffer, and 
squeeze excess buffer from assembly. Place entire assembly into transfer cell. 
Tighten, again pouring off any excess running buffer. 
11. Add running buffer to top of white nodes in between the transfer assembly only. 
Ice-cold tap water will be added to the outside of the assembly. 
12. Add ice to the cell, outside of the transfer assembly. Pour cold tap water to almost 
the top of the assembly and place lid onto assembly in proper orientation. Run at 
30 V for 1 h. 
13. After running 1 h, remove transfer assembly from cell. Remove nitrocellulose 
membrane from assembly, ensuring that as little gel as possible remains 
associated with nitrocellulose. 
Western Immunoblotting: 
1. Block nitrocellulose membrane in 6 mL milk, rocking 1 hr.  
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2. 5 to 10 minutes before h is up (so after 50 to 55 minutes) prepare primary Ab 
treatment: 
3. After 1 h, discard blocking milk and add primary Ab preparation. Incubate on 
rocker 1 h. 
4. While waiting, prepare TBS wash buffer (~200 mL per immunoblot/membrane): 
5. After 1 h, wash membrane 4 times: 1 initial 2-3 min wash in 15 mL TBS, 
followed by 3 subsequent 10 min washes (on rocker) in 15 mL TBS. 
6. During final wash, prepare secondary Ab (anti-mouse Ab conjugated to HRP): 
7. After final wash, discard TBS and add secondary Ab preparation. Incubate on 
rocker 1 h. 
8. After 1 h, wash membrane 4 times: 1 initial 2-3 min wash in 15 mL TBS, 
followed by 3 subsequent 10 min washes (on rocker) in 15 mL TBS. 












QIAGEN DNA EXTRACTION PROTOCOL FOR MODERATE VOLUME DNA 
EXTRACTION 
 
1. Pour contents of culture into 50 mL centrifuge tube. Centrifuge for 10 to 15 min 
at max speed (4,000 to 6,000 rpm). 
2. Discard resulting supernatant. 
3. Resuspend pellet with 5 mL Qiagen Buffer P1 (stored at 4°C). Resuspend cells by 
vortexing vigorously. 
4. Add 5 mL Qiagen Buffer P2 (stored at room temp). Mix gently by inversion 
(vigorous mixing or shaking will shear genomic DNA). Proceed to next step 
within 5 minutes of adding Buffer P2! 
5. Add 5 mL Qiagen Buffer P3 (stored at 4°C). Mix well via gentle inversion. 
6. Place on ice for 10 to 15 minutes. Longer incubation time on ice will result in less 
genomic DNA, so increasing incubation time may be beneficial. 
7. Centrifuge for 15 min @ 4°C, 4,000 rpm. 
8. Using a coffee filter, filter resulting supernatant into new 50 mL centrifuge tube. 
9. Add an equal volume of isopropanol (or two volumes of EtOH) to filtered 
supernatant. 
10. Mix by gentle inversion, and allow to stand 10 to 15 minutes at room temperature 
(or, if working with EtOH, incubate on ice) to allow DNA to precipitate.  
11. After 10 to 15 minutes, centrifuge at 4°C, 4,000 rpm for 10 to 15 minutes. The 
DNA will be contained in the resulting pellet. 
12. Discard supernatant and place 50 mL tube containing pellet upside down on paper 
towel/chem wipe to drain. Watch to ensure that pellet does not slide onto paper 
towel. 
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13. Resuspend pellet in 0.5 mL TE buffer or DEPC-treated dH2O. Place on ice. 
14. Centrifuge DNA sample at 13,000 rpm for 5 minutes at 4°C. 
15. Equilibrate Qiagen-tip 100 by applying 4 mL Buffer QBT, and allow column to 
empty via gravity flow. Allow tip to drain completely. 
16. Apply 500 μL DNA sample supernatant from step 1 to 4 mL QBT buffer. Apply 
4.5 mL buffer+sample to Qiagen-tip and allow it to enter the resin by gravity-
flow. 
17. Wash the Qiagen-tip with 2  10 mL Buffer QC. Allow buffer QC to move 
through the Qiagen-tip by gravity-flow. The first wash is generally sufficient to 
remove all contaminants in the majority of plasmid DNA preps. The second wash 
is especially necessary when large culture volumes or bacterial strains producing 
large amounts of carbohydrates are used.  
18. Elute DNA with 5 mL buffer QF into a 15 mL conical tube. 
19. Precipitate DNA by adding 3.5 mL room-temperature isopropanol to the eluted 
DNA. Mix and centrifuge immediately at  15,000 x g for 30 min at 4°C. All 
solutions should be at room temperature to minimize salt precipitation, but 
centrifugation is carried out at 4°C to avoid overheating of the sample. Larger, 
conical-bottom centrifuge tubes may be used for centrifugation at 5,000 x g for 60 
min at 4°C. Carefully decant supernatant; isopropanol pellets are loosely 
associated with the centrifugation tube, so care should be taken during decanting 
not to lose the pellet. 
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20. Dry the pellet and resuspend in 500 μL DEPC-treated H2O. Transfer to a 
microcentrifuge tube and centrifuge at 13,000 rpm (or max speed) at 4°C for 10 to 
15 minutes. 
21. Pipette supernatant into new 1.5 mL microcentrifuge tube and reprecipitate with 
equal volume of isopropanol plus potassium acetate added at 1/10 volume (so 50 
μL KAc added to 500 μL DNA in DEPC-treated H2O).  
22. Centrifuge at maximum speed at 4°C for 10 to 15 minutes.  
23. Carefully decant the supernatant and add 1 to 1.5 mL room temperature 70% 
EtOH and centrifuge at max speed and 4°C for 20 minutes. Carefully decant the 
supernatant without disturbing the pellet. 
24. Air-dry the pellet for 5 to 10 min, and dissolve the DNA in 500 μL TE buffer or 
DEPC-treated H2O. Rinse walls with suspension liquid to recover all DNA, but 
avoid pipetting DNA up and down to facilitate resuspension, as this may result in 
shearing of the DNA. Overdrying the pellet will make it very difficult to 




CORONAVIRUS ISOLATION FROM FECAL SAMPLES 
** ideally, HRT-18G cells should have been plated and confluent 12 hours prior to 
infection** 
 
1. Collect samples in sterile specimen collection cups or 50 mL corning tubes 
2. Store on ice or at 4°C until prep 
3. Prepare 10-20% (w/v) suspension of fecal material in PBS containing 
antimicrobials (pen-strep and amphoceterin B). Store remaining undiluted sample 
at -70°C. 
4. Homogenize suspension by vortexing gently. 
5. Clarify suspension (~ 1 mL) via low-speed centrifugation at 1000 x g for 10 
minutes 
6. Dilute resulting supernatant 1:10 in DMEM containing appropriate antimicrobials 
(pen-strep and amphoceterin B) 
7. Prepare a 0.45 μm filter by wetting with 1 mL DMEM to keep virions from 
adsorbing onto the filter 
8. Filter resulting supernatant through a 0.45 μm filter into a clean microcentrifuge 
tube. 
9. At this point, sample may be stored overnight (or short-term) at 4°C or may be 
stored long-term at -70°C until analysis 
10. Wash HRT-18G cells twice in PBS containing antimicrobials  
11. Remove media, and add diluted fecal sample filtrate supernatant to HRT-18G 
cells (~ 500 μL diluted fecal sample filtrate supernatant per well of 6-well plate). 
Rock 1 h at 37° C to allow for adsorption. 
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12. Add DMEM containing antimicrobials and 2% -irradiated FBS to wells and 
return to incubator at 37° C. Observe daily for CPE. 
13. Perform a minimum of 3 blind passages before attempting to harvest virus from 
infected cells. 
14. After third passage, observe cells for CPE. Lyse cells via 3 cycles of freeze-thaw 
at -80°C.  
15. Free any remaining attached cells via pipetting. Aliquot 1.5 mL per well into pre-
















CORONAVIRUS ISOLATION FROM NASAL SWAB SAMPLES 
** ideally, HRT-18G cells should have been plated and confluent 12 hours prior to 
infection** 
1. Swabs should be placed in either DMEM or RPMI containing antibiotic and 
antimycotic 
2. If not using immediately, place on ice or at 4° C for transport 
3. Allow samples to incubate at room temperature for 30 min 
4. Homogenize swabs in DMEM/RPMI containing antimicrobials by vortexing 
vigorously for approximately10 seconds. 
5. Centrifuge low-speed (1000 x g) for 10 min. Remove and discard swabs 
following centrifugation. 
6.  Remove a small aliquot (~ 1 mL) and store at -70° C. 
7. Centrifuge 1500 x g, 15 minutes 
8. Filter resulting supernatant via 0.45 μm filter into clean 15 mL corning tube (at 
this point, sample may be stored short-term at 4° C or frozen at -70° C). 
9. Wash HRT-18G cells twice in PBS containing antimicrobials  
10. Remove media, and add nasal swab supernatant to HRT-18G cells (~ 500 μL 
swab supernatant per well of 6-well plate). Rock 1 h at 37° C to allow for 
adsorption. 
11. Add DMEM containing antimicrobials and 2% -irradiated FBS to wells and 
return to incubator at 37° C. Observe daily for CPE. 
12. Perform a minimum of 3 blind passages before attempting to harvest virus from 
infected cells. 
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13. After third passage, observe cells for CPE. Lyse cells via 3 cycles of freeze-thaw 
at -80°C.  
14. Free any remaining attached cells via pipetting. Aliquot 1.5 mL per well into pre-
labeled microcentrifuge tubes and store at -80°C until analysis. 
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INDIRECT ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTION OF 
ANTI-CORONAVIRUS ANTIBODIES 
 
1. Prepare antigen for coating by diluting appropriately in coating buffer, pH 9.6. 
2. Coat well of a PVC microtiterplate by pipetting 100 μL of diluted antigen into 
each well. 
3. Cover the plate with adhesive plastic or wrap in foil and incubate for 2 h at room 
temperature or 4°C overnight. 
4. Remove the coating solution and wash wells 4 times with 1X TBS solution.  
Solution between washes is removed by flicking the plate over a sink; residual 
solution in wells may be removed by firmly patting plate onto a clean paper towel 
between washes. 
5. Block remaining protein binding sites in coated wells by adding 200 μL blocking 
solution (PBS containing 5% goat serum) to each well. Cover plate with adhesive 
plastic or wrap in foil. Incubate with rocking for 2 h at room temperature. 
Alternatively, plate may be blocked at 4°C overnight. 
6. Wash the plate twice with 1X TBS solution. 
7.  Add 100 μL primary antibody in blocking solution to each well.  
8. Cover the plate with adhesive plastic or wrap in foil and incubate 1 h with rocking 
at room temperature. Alternatively, if a stronger signal is desired, plate may be 
incubated at 4°C overnight. 
9. Wash the plate 4 times with 1X TBS. 
10. Add conjugated secondary antibody diluted appropriately in blocking 
solution,100 μL per well.  
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11. Cover plate with adhesive plastic or wrap with foil and incubate with rocking 1 to 
2 h at room temperature. 
12. Wash the plate 4 times with 1 X TBS. 





















CORONAVIRUS NEUTRALIZATION ASSAY 
1. Seed wells of a 24-well plate with HRT-18G cells to be confluent the following 
morning. 
2. Prepare 5-fold serial dilution of sample and control sera, 4 dilutions (1:5, 1:25, 
1:125, and 1:625) per sample. 
• 1:5  70 μL undiluted serum + 280 μL DMEM containing 0.2% 
Primocin but no FBS 
• 1:25  70 μL 1:5 diluted serum + 280 μL DMEM containing 0.2% 
Primocin but no FBS 
•  1:125  70 μL 1:25 diluted serum + 280 μL DMEM containing 0.2% 
Primocin but no FBS 
• 1:625  70 μL 1:125 diluted serum + 280 μL DMEM containing 0.2% 
Primocin but no FBS 
3. For each dilution, combine 250 μL BCoV-Lun p8 stock virus with 250 μL dilute 
serum for a final volume of 500 μL. Incubate for 30 min at room temperature on 
nutator. 
4.  Infect tightly confluent HRT-18G cells in 24-well culture plate with 150 μL per 
well of serum-treated BCoV-Lun, infecting wells in triplicate per dilution. Rock 
cells with serum-treated virus at room temperature for 1 h to allow virus 
adsorption onto the monolayer. 
5. Remove supernatant from each well and wash once with 1 mL PBS per well. 
6. Add 0.5 mL fresh DMEM containing 0.2% Primocin but no FBS to each washed 
well. Return plate to 37°C incubator with 5% atmospheric CO2. Incubate 16 h. 
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7. After 16 h incubation, wash wells once with 1 mL PBS per well. Add 200 μL 
TrypLE to each well and incubate at 37°C for 10 to 15 min, or until majority of 
cells have detached from bottom of each well.  
8. Add 50 μL goat serum to each well to quench TrypLE. 
9. Dislodge remaining attached cells via gentle pipetting and transfer the entire 250 
μL volume to well of a 96-well U-bottom plate.  
10. Centrifuge 96-well plate containing transferred cells at 400 rcf, 4°C, for 7 min. 
11. Flick plate over sink to remove resulting supernatant from wells, being careful not 
to dislodge cell pellet.  
12. Wash cells with 100 μL cold FACS wash buffer, gently pipetting each well to 
resuspend cells. Centrifuge 96-well plate at 400 rcf, 4°C, for 7 min. 
13.  Add primary antibody diluted appropriately in PBS containing 5% goat serum, 
100 μL per well. Incubate with rocking for 30 min at 4°C. 
14. Centrifuge 96-well plate at 400 rcf, 4°C, for 7 min. Flick plate over sink to 
remove resulting supernatant from wells, being careful not to dislodge cell pellet. 
15. Wash cells once with 200 μL cold FACS wash buffer, pipetting to completely 
resuspend cells. Centrifuge 96-well plate at 400 rcf, 4°C, for 7 min. Flick plate 
over sink to remove resulting supernatant from wells, being careful not to 
dislodge cell pellet. 
16. Add secondary, fluorophore-conjugated antibody diluted appropriately in PBS 
containing 5% goat serum to each well, 100 μL per well. Incubate with rocking 
for 30 min at 4°C.  
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17.  Centrifuge 96-well plate at 400 rcf, 4°C, for 7 min. Flick plate over sink to 
remove resulting supernatant from wells, being careful not to dislodge cell pellet. 
18. Wash cells once with 200 μL cold FACS wash buffer, pipetting to completely 
resuspend cells. Centrifuge 96-well plate at 400 rcf, 4°C, for 7 min. Flick plate 
over sink to remove resulting supernatant from wells, being careful not to 
dislodge cell pellet. 
19. Resuspend cell pellet in 150 μL cold FACS wash buffer.  
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OVERNIGHT BACTERIAL LYSIS/RELEASE OF FUSION PROTEINS 
FROM INCLUSION BODIES 
1. Thaw bacterial pellet to room temperature. 
 
2. Wash pellet with 1 mL Lysis Buffer, completely resuspending pellet. 
3. Transfer contents to 2 mL microcentrifuge tube. 
4. Centrifuge at 18,000 rcf (~14,000 rpm) for 5 min at 4° C 
5. Discard supernatant; tap tube onto a paper towel to remove remaining liquid from 
pellet 
 
6. Resuspend with 1 mL Lysis Buffer 
7. Using a 21 gauge needle, resuspend pellet completely in Lysis Buffer 
8. Transfer solution to 15 mL conical tube using syringe and needle 
9. Bring volume in tube to 5 mL with Lysis Buffer and vortex briefly to mix 
10. Add 50 μL of 500 mM EDTA to each 5 mL solution (cells in buffer) for a final 
concentration of 5 mM EDTA 
11. Vortex solution briefly to mix 
 
12. Add 200 μL of 25 mg/mL Lysozyme to each 15 mL tube for a final concentration 
of 1 mg/mL lysozyme 
13. Place tube onto gentle inversion shaker for 30 minutes 
14. Add Benzonase at 5 units/mL (so, 25 μL for 5 mL) 
15. Return tube to shaker for an additional 30 min 
16. Pipette 1.75 mL into each of three 2 mL microcentrifuge tubes 
17. Centrifuge at 18,000 rcf for 20 min at 4° C 
18. Discard supernatant 
19. Add 1 mL Lysis Buffer to resulting pellet 
20. Add 50 μL EDTA to each tube 
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21. Using a 21 gauge needle, resuspend pellet and transfer resulting solution to a 15 
mL conical tube 
22. Bring volume in 15 mL tube to 5 mL with Lysis Buffer. Vortex briefly. 
23. Add 25 μL of 1M DTT for a final concentration of 5 mM DTT. Vortex briefly 
24. Add 200 μL of 10% Sarkosyl solution to tube. Vortex briefly. 
25. Place tube onto shaker, incubate with gentle inversion shaking at room 
temperature for 30 min. 
26. Place tubes at 4° C and incubate overnight with gentle inversion shaking. 
27. If original cell pellet was large, add an additional 3 mL of lysis buffer to sample 
mid-lysis. 
28. At the end of lysis-incubation period, sonicate samples 3 to 4 times (or as many as 
10 times) on ice, 12 to 15 seconds each time, with a 1 min rest period between 
each sonication: 
a. Pulse 
b. Output control = 7 
c. 20% duty cycle 
29. Pipette ~1.7 to 1.75 mL of sample into each of five 2 mL microcentrifuge tubes 
 
30. Centrifuge samples @ 18,000 rcf, 4° C for 25 to 30 min 
31. Decant supernatant into a new 15 mL conical tube. Return remaining pellets to 
ice. 
32. Add 750 μL 10% Triton X in ddH2O to supernatant. Keep at room temp if 
planning to purify via Profinia. Otherwise, clear lysate should be stored at 4° C 
for no longer than 1 d. 
33. Resuspend pellets in 1.5 mL lysis buffer (total, for all pellets. Combine pellets.) 
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